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ABSTRACT OF THESIS 
The development of the hiSti.dJflaT1i-C (his/his) mouse has been examined as a model 
of a human ajninoacidopathy. The concentrations of histidine and its derivatives have 
been measured in tissues and body fluids in utero and during the first five weeks 
after birth. The placental transfer of raised maternal histidine concentrations to 
developing his/his embryos results in a twenty-fold increase in foetal histidine 
concentrations. After birth, histidine concentrations are also increased between 
four and twenty-three fold in the his/his offspring of his/his mothers. 
Developmental changes in histidine catabolizing enzymes have been compared in 
wild-type (+/±) and his/his mice. The histidase defect in the liver does not appear 
till after birth, although in the skin it is present earlier. Liver histidine amino-
transferase activity is two to three times higher shortly after birth than in the 
adult in both genotypes. 
Parallel studies of brain growth and development have been carried out in +/-f 
and his/his mice. Changes in cell number, cell growth and myelination have been 
estimated from measurements of DNA, RNA, water, cholesterol and protein content. 
Although some small differences emerge, the two genotypes show near identical brain 
growth profiles despite large metabolic differences before and after birth. 
The biochemical genetic nature of histidase deficiency has been examined in 
his/his mice. Structural and kinetic studies show that the residual mutant activity 
has markedly different properties from the wild-type in crude extracts. Partial 
purification experiments show that there are two distinguishable components with 
histidase activity in wild-type liver, only one of which is found in the mutant. 
Th his allele may be a null allele at a histidase structural or regulatory locus, 




(i) Inborn errors of amino acid metabolism in man 
Since A.E. Garrod (1908) introduced the concept of a genetically 
determined metabolic block, some 200 - 250 further inborn errors of 
metabolism have been described in man (Eidjaim et al., 1 975). The 
expression "inborn error of metabolism" refers to those conditions 
in which a congenital deficiency of a specific protein occurs as 
a result of an alteration in a single gene. The deficient protein 
may be involved in catalysis, transport, structure or any other 
function (Brock, 1978), although Garrod originally envisaged only 
the first of these. Most known inborn errors show recessive 
inheritance which is almost the rule with enzyme deficiencies. 
Deficiencies of non-enzymic proteins may account for many of the 
dominant conditions whose aetiology is at present unknown. Only 
500 out of the 1000 - 2000 single gene disorders known in man show 
recessive inheritance and of these a specific enzyme deficiency 
has only been demonstrated in about 20.0 (McKusick, 1975: Stanbury 
et al., 1978). 
The inborn errors of amino acid metabolism are clinically 
important despite their individual rarity. This is because while 
a few are wholly or relatively benign (e.g. c— aniinoisobutyric 
aciduria,albinism) many give rise to severe disability. Sometimes 
death occurs in infancy (e.g. urea cycle disorders), but permanent 
disability, such as mental handicap (e.g. phenylketonuria), cardio-
vascular anomalies (e.g. homocystinuria) or renal impairment (e.g. 
hyperoxaluria) is a more common outcome. 
At the biochemical level, inborn errors of amino acid metabolism 
generally show typical Garrodian blocks with build up of proximal 
metabolites. The latter often "overflow" into the urine, so that 
the term Itaminoaciduriatl is used as a synonym, although it includes 
conditions with aminoaciduria secondary to severe renal or hepatic 
disease. A better term is hereditary 'Tairinoacidopathy't which can 
be classified into four types according to mechanism (Rosenberg and 
Scriver, 1974). 
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Primary defect in catabolism. The tissue concentration 
of one or more amino acids increases as a result of the block. The 
amino acid may have a low renal clearance so that it accumulates in 
the plasma and renal tubules until the tubular reabsorption mechanisms 
are saturated, leading to "overflow" aininoaciduria (e.g. phenylketonuria, 
histidinaemia). Alternatively the amino acid may have a high renal 
clearance which results in relatively low plasma concentrations but 
a marked ("no threshold") aminoaciduria (e.g.o-aininoisobutyric 
aciduria). 
Primary defect in catabolism with a secondary defect in 
transport. Accumulation of one amino acid in the plasma and renal 
tubules saturates the renal transport system shared by other amino 
acids, so that the latter are reabsorbed at a reduced rate and 
increase in the urine (e.g. hyperprolinaemia). 
Primary defect in membrane transport site. An amino acid 
carrier protein is defective in the kidney and often other sites, so 
that there is no plasma increase, but an increased renal loss (e0g0 
cystinuria, histidinuria). 
Generalized inhibition of transport processes. Tubular 
reabsorption of amino acids is impaired at the level of ion-dependent 
or energy-requiring steps, so that a generalized aiminoaciduria 
results, often with excessive loss of other solutes (e.g. oculo-
cerebrorenal syndrome). 
Inborn errors rarely occur with a frequency greater than 1 in 
102000 live births in outbreeding populations. Those few that show 
higher frequencies in certain populations (2 - 30 per 10,000 live 
births) may well be genetically heterogeneous (Brock, 1972). The 
majority of inborn errors are far less frequent. The incidence of 
some amainoacidopathies is shown in Table 1:1. 
It could be argued that the extensive research into the inborn 
errors of metabolism has far outweighed their importance; that they 
are rare causes of clinical disability and that their study is 
unlikely now to contribute further to our understanding of genetics 
or metabolism. However, collectively they remain important causes 
of severe disability. The inborn errors are said to account for 
almost 10% of mentally retarded individuals in economically advanced 
TABLE 1:1 
Incidence of certain inborn errors of amino acid metabolism 
among newborn infants in Massachusetts. 
(Data from Levy, 1973;  from Harris, 1 975). 
Disorder Incidence Number  
Screened 
Phenylketonuria 1:15,000 1,012,017 
Cystinuria 1:15,000 350,176 
Hartnup disease 1:16,000 350,176 
Histidinaemia 1:17,500 350,176 
Arginin osuccinic acidoemia 1:705000 350,1 76 
Cystathioninaemia 1:117,000 350,176 
Honiocystinuria 1:160,000 480,271 
Branched-chain ketoaciduria 1:175,000 872,660 
Hyperglycinaemia (non-ketotic) 1:175,000 350,176 
Propionic acidaemia <1 :350.000 350,1 76 
I- 
 
Iyperlysinaeniia <1:350,000 350,176 
3 
populations (W.H.O. Report, 1969). With the decline in importance 
of infectious and nutritional disease, genetically determined 
diseases have become more important. The causes of most of these 
conditions are still largely obscure. But as Garrod himself 
realised the inborn errors "are merely extreme examples of 
variations of chemical behaviour which are probably everywhere 
present in minor degrees and .... far more subtle than those of 
form" (Garrod, 1902), so that the principles of biochemical aialysis 
and treatment which are developing from their study are likely to 
underly further advances in those more subtle or common variations 
still to be elucidated. Three main areas of research into inborn 
errors are of outstanding importance in this respect. (1) Increased 
understanding of the molecular nature of the enzymic lesion and its 
clinical consequences. This is being facilitated by advances in 
cell culture and by the use of animal models. (2) Improved means 
of treatment, which is now shifting in emphasis from dietary means 
towards enzyme replacement, stabilisation or enhancement. (3) Improved 
and extended methods of antenatal diagnosis, so that the opportunity 
to selectively abort those with severe, incurable disease is open 
to parents. This thesis will be largely concerned with the first of 
these areas. 
(ii) Human histidinaeinia 
Biochemistry. Histidinaemia was first described in 1961 
(Ghaftimi et al., 1961a, b) when a phenylketone-like substance in 
the urine of a speech-retarded child turned out to be a breakdown 
product of histidine. The condition was shown to be characterised 
by abnormal accumulations of histidine or its derivatives in blood, 
urine and cerebrospinal fluid (Auerbach et hi., 1962; Ghadimi et al., 
1962; Shaw et al., 1963; La Du et hi., 1963). The reported 
concentrations of histidine and its metabolites in histidinaernic 
and control subjects are shown in Table 1:2. In contrast, the 
products of histidine degradation such as urocanic acid in skin 
or sweat (La Du et hi., 1962; Whitfield and Shepherd, 1970;  Neville 
et al., 1972) and foriiiiminoglutamic acid (FIGLU) in urine (La Du et hi., 
1963) were found to be deficient, even after loading the subjects 
with histidine. These findings suggest a defect in the major pathway 
TABLE 1:2 Concentrations of histidine and its metabolites in skin, liver and body fluids from human histidinaemic 
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Im pyruvate - 	- - 647 - 	- - 	- - - - 	- 
Ln lactate - - 9•6 	2676 - - - - - 	- - - 
Im acetate - 	- 3.14 	106.7 - 	- - 	- - - - 	- 
N-ac histidine - - 8.14 	50.8 - - - - - 	- - - 
tJrocanate - 	- - - - 	- 1.9 	0.06 - - 612 	69 
1 	Control data from Auerbach et al (1962), Stein and Moore (19514) and Baldridge and Greenberg (1963). Histidinaemic data 
from Appendix 	(mean of 68 histidinaemics). 
2 	Mean urinary imidazoles in 7 histidinaeimic and 224 controls (Wadman et al 1971). 
3 Data of Wadman et al (1967) and Analcura et al (197) on 3 histidinaemics. Shaw et al (1963) also found a raised 
CSF histidine in another patient: however. Ghadimi et al (1962) found only a marginal increase and Berlow et al (1965) 
no definite increase. 
24 	Data from Auerbach et di (1967) on 7 histidinaemics and 17 controls. 
5 Data from Auerbach et al (1967) on liver biopsies from 1 histidinaernic and 2 controls. 
6 	Data from Whitfield and Shepherd (1970) on 5 histidinaemics and 53 controls. 
of histidine degradation, namely deamination to form urocanic 
acid and ultimately glutaimic acid (See Fig. 1:1). The presence 
of large accumulations of iinidazolepyruvic, imidazolelactic and 
iimidazoleacetic acids in the urine of histidinaemics implied an 
increased flux through the alternative transamination pathway. 
An oral histidine load in these subjects produced further prolonged 
accumulations of histidine and its imidazole acid derivatives in 
urine, but still no demonstrable urocanic acid, imidazolone 
propionic acid or FIGLU (Auerbach et al., 1962; Ghadind et al., 
1962; La Du et al., 1963, Holton, 1964)0 When an intravenous 
urocanic acid load was administered, it was metabolised normally 
to imidazolone propionic acid and FIGLU, suggesting a normal 
pathway from urocanic acid to glutamic acid. These findings 
provided strong but indirect evidence of a specific defect in the 
first enzyme of the pathway, histidase (histidine ammonia-lyase 
EC1..3.1.3.). Final confirmation came with the finding of a 
greatly reduced or absent histidase activity in the epidermal 
layer of skin in histidinaemics (La Du et al., 1962; Zannoni and 
La Du, 1963). Histidase activity in liver biopsies taken from 
two patients with histidinaemia also showed greatly reduced activity 
compared with controls (Auerbach et al., 1967). The diagnosis 
of histidinaemia is therefore suggested by a sustained increase 
in the plasma and urinary histidine and in its urinary transaimination 
products and confirmed by a reduced or absent skin histidase activity. 
A reduced or absent excretion of urinary FIGLU or urocanic acid after 
a histidine load and reduced sweat urocanic acid also help to confirm 
the diagnosis. 136 presumed cases of histidinaemia have been rorted 
in the literature since 1961 (Appendix )° Skin histidase activity 
has been reported in 53 of them. All but three of these show reduced 
or absent skin histidase activity. The three siblings reported by 
Woody et al., (196) had slightly raised plasma and urinary histidine 
concentrations, increased urinary imidazolepyruvic acid concentrations 
but normal skin histidase activity. The authors suggested that their 
subjects had a defective liver histidase and normal skin histidase. 
This seems unlikely because of the fact that all other histidinaemics 
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FIG.1:1 The metabolism of histidine and its derivatives. 
at least in the rat, the two enzymes are identical by several 
criteria [(see Section (iv)J. The family described by Woody 
et al. is however the best documented example of genetic hetero-
geneity in histidinaemia. Levy et al. (1974)  also report two 
siblings with slightly elevated plasma and urinary histidine con-
centrations and skin urocanic acid concentrations only reduced 
to about one-quarter of normal, which may be another example of 
"atypicaltt histidinaemia. Finally, Kothari et al. (1970)  have 
described an atypical histidinaemic with an increase in skin 
urocanic acid concentration, although the skin histidase activity 
was not examined. 
Other metabolic abnormalities have been reported intermittently. 
An increased alanine concentration in blood and urine has been 
reported (Ghadimi et al., 1961; Auerbach et alL., 1962, 1967;  Ghadimi 
and Zischka, 1967; Corner et al., 1968; Rosenblatt et al., 1 970; 
Carton et alL., 1970;  Popkin et al., 1974; Armstrong,  1975). It is 
not clear whether this represents increased liver transanination of 
pyruvate with histidine or some other effect of the metabolic error 
(Ghadimi and Zischka, 1967). Only one of the 26 cases described by 
Levy et al. (1974) had an increased alanine concentration, so it is 
a relatively uncommon finding. The concentration of 5-hydroxy-
tryptamine in platelet-rich plasma was found to be reduced by about 
40% in one histidinaeinic child compared with age matched controls 
(Auerbach et al., 1962). This was confirmed in some studies (Holton 
et al., 1964; Corner et al., 1968) but not others (Ghadimi and 
Zischka, 1967). Holton et al. (1964) reported that platelet 5-
hydroxytryptamine returned to normal with a low-histidine diet. 
A reduction in the glutamic acid concentrations of blood and 
cerebrospinal fluid (CSF) has been reported (Ghadimi et al., 1962; 
Auerbach et al.., 1967;  Carton et al., 1970).  The CSF glutaniine 
concentration has also been found to be low (Ghadimi et al., 1962), 
a finding that was confirmed by Berlow et alL., (1 965)  but not by 
Holton et al. (1964). 
Genetics. Human histidinaemia is inherited in a manner 
consistent with an autosomal recessive character (La Du, 1972; 
Ghadimi, 1974).  Popkin et al. (1974) examined the frequency of 
histidinaemia in 63 siblings of 21 histidinaemic probands and found 
it to be 0°238 compared with an expected 0°25 with an autosomal 
recessive character. Levy et al. (1974) also found that, excluding 
their propositi, 7 out of 26 siblings were affected in 20 families 
with histidinaemia identified by routine newborn screening. Their 
parents all had normal blood and urinary histidine concentrations. 
The ratio of male to female patients identified was 12:14. Hetero-
zygosity in the parents and sibs of histidinaemics has been supported 
by the demonstration of skin histidase activity at or below the lower 
limit of normal (La Du et al., 1963; Holton et al., 1964; Cain and 
Holton, 1968; Gatfield et al., 1969; Neville et al., 1972). La Du 
(1972) reviewed the reported histidase activities in histidinaemics 
and their parents and found that the mean parental activity is well 
below control values. This finding is consistent with the parents 
being heterozygous carriers of the mutant gene with codorrtinant 
inheritance of the enzyme defect. Histidine loading has been used 
to identify heterozygotes (Ghadimi and Partington, 1967) although 
it is not possible to unequivocally distinguish heterozygotes from 
normal controls in this way (Hague and Holton, 1971; Neville et al., 
1972). La Du (1972) has suggested that a more sensitive method of 
detecting heterozygotes may be to monitor the urinary excretion of 
histidine and FIGLU or urocanic acid after a histidine load. Con-
sanguinity in the parents of histidinaemics has been reported in three 
families with histidinaemia (Woody et al., 1965; Rostenberg et al., 
1974; Ran et al., 197)4). A family with histidinaemia in two successive 
generations has been reported by Bruckman et al. (1970). The authors 
suggested an autosomal dominant mode of inheritance in this instance. 
However, they assumed that the father of three affected children was 
not a heterozygote since he showed no increase in serum or urinary 
histidine and a FIGLU test was normal. However his skin histidase 
activity was relatively low at 1.4 piol/hr./g. (lower limit of normal 
15). Since most authors have not been able to unequivocally distinguish 
heterozygotes from normals, it seems more likely that this man was 
heterozygous for histidinaemia, especially since his mother's sister, 
who was histidinaemic, had seven unaffected children. The hypothesis 
of dominant inheritance is therefore implausible. All other reported 
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cases of histidinaemia affect only one generation, with approximately 
equal numbers of males and females (La Du, 1972) 
Incidence. Since many known histidinaemics show no clinical 
abnormality, an unknown number are likely to remain undetected in 
the community. Random or total population screening of blood histidine 
concentrations must therefore be employed to determine the incidence 
of histidinaemia. Guthrie's bacterial inhibition test is now routinely 
used in some centres to screen for raised blood concentrations of 
several amino acids including histidine (Guthrie, 1968; Guthrie and 
Murphy, 1971). A positive result from screening with the bacterial 
inhibition or paper chromatographic methods must then be confirmed 
by a quantitative method, usually ion-exchange chromatography. A 
diagnosis of histidinaemia is likely if the plasma concentration is 
consistently raised above 0o3 - 024 pmol/ml. (5-6 mg./lOOinl.). Since 
transient states of histidinaemia have been described in infants 
(Thalhamnier et al., 1 971), the diagnosis is normally confirmed by 
low or absent histidase activity in skin and a reduction in skin 
urocanic acid. Newborn populations have been screened for histidin-
aemia in at least 13 different countries (Table 1:3) In all cases 
the diagnosis has been confirmed by quantitative amino acid analysis, 
although in many cases a definitive diagnosis by skin histidase assay 
was not made. The overall incidence is in the region of 1 in 19,000 
live births. Histidinaemia is therefore one of the more common amino-
acidopathies (see Table 1:1) with a frequency similar to that of 
phenylketonuri a. 
Clinical features. Although many histidinaemics show no overt 
clinical abnormality, others show varying degrees of mental or neuro-
logical impairment (La Du, 1 971; Ghadimi, 19714). However the relation-
ship between any clinical abnormality and the metabolic condition is 
by no means clear.The Appendix contains a summary of the 136 reported 
cases to date. Intelligence has been assessed with varying degreas 
of accuracy in 113 of them (excluding 5 atypical cases). About one-
quarter (27/113) of this sample of histidinaemics is mentally retarded 
(IQ 70) compared with 2% in the general population (Penrose, 1963; 
Clarke and Clarke, 1 9714). However this difference can in part be 
attributed to ascertainment bias. Those histidinaemics with clinical 
TABLE 1:3 
The incidence of histidinaemia in different populations 







Australia Berry 230,000 3 1:77000 2,5 
Austria GBIA (His) 11,137 9 1:16000 
Denmark GB 	(His) 30,000 0 0 	5 
Great Britain GB 	(His) 110,000 10 1:11000 
Scver 87,982 4 1:22000 
Woolf 6.565 0 0 
New Zealand GB 	(His) 81,77 7 1:12000 
Poland Berry 72057 0 0 
United States Efron 25,379 th 1:18000 
GB 	(His) 70118 2 1 :35000 
7 countries 215,503 18 1:12000
4  
TOTAL 1,2901818 67 1:19000 
1 GBIA (His) is the Guthrie Bacterial Inhibition Assay, as applied 
to histidine screening. The methods of Scriver, Berry and Efron 
are paper chromatographic methods using blood (Scrir) or dried 
urinary (Berry, Efron) samples. 
2 It is virtually certain that several additional infants with 
histidinaemia are present in this screened population. The 
authors were unable to obtain blood specimens from several 
infants with persistent histidinaemia, to confirm the diagnosis. 
3 Neville and Lilly. 1 973. 
L Schmid-Ruter. 1972. Survey of newborn in Belgium, France, W. Germany, 
Ireland, Netherlands, Switzerland and the United Kingdom. 
5 Sources quoted in Levy, 1973. 
LS 
disability are more likely to reach the attention of the medical 
profession and those with severe disability are more likely to be 
reported in the literature. Levy et al. (1974) examined the mental 
status of 59 reported histidinaemics according to the reason for 
ascertainment. Out of 25 children reported to be mentally retarded 
(IQ 85), 19 were ascertained because of an already recognized mental 
subnormality, 3 because of a speech problem and only 3 for some reason 
unrelated to their mental function. On the other hand, out of 33 
histidinaemic children ascertained in routine newborn surveys or 
because of a medical problem unrelated to mentality, only 3 were 
mentally subnormal (2 also had speech defects). 85% of histidinaemics, 
whose ascertainment wcs not biased towards the detection of mental 
subnormality, were therefore found to be normal. Popkin et al. (1974) 
also tried to exclude the ascertainment bias in a survey of the 
siblings of 21 late-diagnosed histidinaemic probands. 91% of the 
probands were retarded compared with only 40% of their histidinaemic 
siblings whose abnormality only came to light as a result of the 
index sibling. The 60% normality figure of these workers may be 
lower than that of Levy et al. (1974) because of stricter clinical 
criteria which excluded at least one family with normal histidinaemic 
siblings. Levy et al. (1974) also tested the IQs of 12 histidinaemics 
identified in newborn surveys and 14 unaffected siblings. The tests 
were carried out at an average age of 7 and 8 years in the two groups 
and without a knowledge of the diagnosis or nature of the study. The 
mean (± S.D.) IQ scores were 107 + 12 and 108 ± 11 for histidinaemic 
and non-histidinaemic groups respectively. Further prospective studies 
of subjects identified in random or total population surveys should 
help to confirm the above findings which suggest a relatively small 
(5 - 10 fold) increase in the risk of intellectual impairment in 
histidinaeinia. 
Other signs of neurological damage, such as electroencephalogram 
(E0E0G.) abnormalities, epileptic seizures, poor co-ordination, tremor, 
ataxia and dysarthria have been reported in some histidinaemics (see 
Appendix ). These signs tend to be worse in the more severely retarded. 
Again it is not clear if there is a relationship with the metabolic 
defect. One of the first clinical abnormalities reported in association 
with histidinaemia was a speech defect (La Du et al., 1963; 
Witkop and Hendry, 1963; Gerritsen, 1964, Ghadiini and Partington, 
1967; Bakwin, 1968). Witkop and Hendry (1963) suggested that 
defective speech, particularly impaired articulation and auditory 
memory, may be a specific consequence of the metabolic defect. 
Lott et al. (1970) studied the speech of four histidinaemic children 
and found that all had normal speech, although some had poor auditory 
memory which was related either to low intelligence, cultural deprivation 
or a conductive hearing loss. They then examined the relationship 
between reported IQ and speech in 36 histidinaemics. 92% of those 
with IQs less than 85 had abnormal speech compared with 38% of those 
with IQs greater than 85. They concluded that the speech and language 
abnormalities noted in histidinaemia are not specific to the disorder 
but are mainly related to concomitant subnormality of intelligence. 
Other investigators have reached a similar conclusion (Gordon, 1970; 
Kibel and Levy, 1970; Neville et al., 1972). However some cases with 
speech defect and apparently normal overall development have been 
described (Massengill and Smith, 1967). Neville et al. (1972) pointed 
out the association between seizures, low IQ and speech problems in 
some histidinaemics. They also noted the occurence of neurological 
deterioration at times of frequent seizures. Other clinical abnormalities 
have been intermittently and probably fortuitously associated with 
histidinaemia (Appendix ). 
Since at least three-quarters of all histidinaemics are likely 
to be clinically normal, any causal association between histidinaemia 
and intellectual impairment is certainly very much weaker than in the 
biochemically comparable condition of phenylketonuria (PElT). Possible 
reasons for this difference have been suggested. Firstly, the molar 
concentration of amino acid is two to three times higher in PKU than 
in histidinaemia. Possible reasons for this include differences in 
the flux through alternative pathways (e.g. trarisauiination: see 
Ghadimi and Partington, 1967), differences in the dietary content of 
histidine and phenylalanine (Seakins and Holton, 1969) and the higher 
renal clearance of histidine compared with phenylalanine (Rosenberg and 
Scriver, 1971). However the occurence of intellectual damage may not 
simply be a function of the plasma amino acid concentration. Neville 
et al. (1972) reporting on L severely retarded and 3 intellectually 
normal histidinaemics found no difference in plasma or urinary histidine 
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or its metabolites between the retarded and normal patients. 
Anakura et al. (1975) did find such a difference in two siblings, 
only one of whom was retarded and showed a higher plasma and 
urinary histidine concentration. Retarded subjects have been 
reported with plasma histidine concentrations as low as 2 - 4 mg% 
(Woody et al., 1965; Whitfield and Shepherd, 1970; Rostenberg et al., 
197)) and normal subjects with 10 - 13 mg% (Armstrong, 1975; Stevens 
et al., 1975). Experience in PKU suggests that tissue concentrations 
correlate more appropriately with intellectual development than plasma 
concentrations (Andrews et al., 1973). Since the net uptake of 
phenylalanine from blood into brain is higher than for histidine 
(Pratt, 1976), it may be that a combination of lower plasma concentrations 
and restricted brain uptake in histidinaemia is less damaging to the 
developing brain than in PKU. The importance of the amino acid 
concentration is supported by the finding of a lower incidence of 
mental retardation in atypical PKU where the phenylalinine concentration 
is about half of that in classical PKU brian and Sidbury, 19) and that partial 
phenylalanine restriction in PKU., allowing a 5 - 10 fold plasma 
increase, is not associated with a drop in intelligence (Koch et ale, 
1973). A second possible reason for the difference between histidinaemia 
and PKU is in the toxicity of the amino acid metabolites (see Chapter 
6 ). 
Intellectual function is influenced by numerous interacting factors, 
some of which are likely to be particularly important in an aminoacid-
opathy. These include the occurence of intercurrent infection, injury 
or debilitation, diet, fluid intake, renal function, concomitant 
epilepsy and, perhaps above all, the effect of known illness or handi-
cap on parental attitudes, educational and social opportunities. These 
and other environmental factors are most likely to be important in the 
mildly subnormal group who are probably overepresented in histidinaemics 
compared with the general population. Considerable caution must there-
fore be used before attributing the occurence of intellectual impairment 
to a direct effect of altered metabolites. 
In 1971 Neville et al. reported a case of maternal histidinaemia, 
analogous to the condition of maternal phenylketonuria (Stevenson and 
Huntly, 1 967; Allan and Brown, 1968). The case described was that of 
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a histidinaemic woman with random plasma histidine concentrations 
in the region 7 - 10 mg./100 ml., giving birth to a boy who was 
normal in all respects, at least until aged L- years. Lyon et 
al. (1974) found another family of five children all born to a 
histidinaemic mother. Four of the children were old enough to 
undergo precise intellectual assessment. The IQs were closely 
grouped, with mean full scale IQ (86°5 - 96°5) about 20 points 
less than the mid-parent value (1065 - 116'5). Since the mean 
IQ of children is expected to approximate the mid-parent value, 
the authors suggested a possible causal relation with the maternal 
histidinaemnia. Such a relation has yet to be confirmed by others. 
Again these findings are in striking contrast with classical 
phenylketonuria, where mental retardation is almost invariable 
in the non-PKU offspring. However, Levy and ShTh (1974) have 
suggested that foetal brain damage does not occur in mild 0 - 6 ing%) 
or moderate (6 - 12 mg%)  hyperphenylalaninaemia, occurs to a small 
extent in atypical PKU ( 12 - 15 mng%) and to a major extent in 
classical PKU (20 - 40 nig%).  In maternal PKU other abnormalities 
such as growth retardation, nticrocephaly and abnormalities of skeleton, 
heart and eyes have also been reported (Stevenson and Huntly, 1 967; 
Allan and Brown, 1968; Mabry, 1 963,   1966; MacCready and Levy, 1972). 
Dietary treatment of PKU mothers during pregnancy may help to prevent 
abnormality in the offspring and has led to the birth of a number of 
normal children (Allan and Brown, 1968). The case for dietary treat-
ment of histidinaemic mothers remains to be demonstrated, especially 
in view of the hazards of such diets (Cain and Holton, 1968; Neville 
et al., 1972). 
Treatment. Tbodiscovery that a reduced dietary intake of phenyl-
alinine, starting in early infancy, reduces the incidence or severity 
of mental deficiency in PKU (reviewed by Knox, 1972) opened the way 
to dietary treatment of other aminoacidopathies. Such treatment is 
mainly applicable to the dietary-essential amino acids. There is 
some controversy as to the need for dietary histidine in man. Ackroyd 
and Hopkins (1916) first reported the need for dietary histidine in 
the young, growing rat. Since then it has been shown that histidine 
is an essential amino acid during the growing phase of all animal 
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species investigated including the human infant (Strecker, 1 970). 
Omission of histidine from the diet of human infants results in 
failure to gain weight, decreased nitrogen retention and the 
appearance of a rash, all of which disappear on reintroduction of 
histidine to the diet (Snyderinan et al., 1963; Snyderman, 196). 
These workers conclude that the dietary requirement for histidine 
is rather less than 35 mg/Kg/day. In contrast, pre-adolescent 
children and adults can maintain their weight and nitrogen balance 
on a histidine-free diet for periods up 'to four weeks (Rose et al., 
191; Nakagawa et al., 1963; Wixon et al., 1977). Histidine is 
therefore regarded as semi-essential in man, but in all other animals 
it is indispensible for growth or maintenance of nitrogen balance 
(Strecker, 1970; Stifel and Herman, 1972). 
There are several reports of the effect of a reduction in the 
dietary histidine intake in histidinaemia (Table 1:4). These reports 
show that it is possible to lower the plasma histidine concentration 
to near normal values with a histidine intake of 20 - LtO mg/Kg/day in 
infants and young children. Older children (roughly over five years) 
may require a lower histidine intake and control takes longer and is 
more difficult to regulate. The need for dietary control in these 
older children is not established even in PKtJ (Lancet, 1974). The 
clinical response to introduction of a low-histidine diet has in the 
majority of cases been disappointing. Only two patients showed some 
clear-cut improvement (Thalhanmer et al., 1971; Neville et al., 1972). 
Three patients showed impairment of growth on the diet (Van Sprang 
and Wadmara, 1967; Corner et aL, 1968; Cain and Holton, 1968). In 
view of the dangers and inconvenience of such diets and the evidence 
that intellectual impairment is much less likely to occur in histidin-
aemia than in PK[J, their routine introduction would seem unjustified. 
If there are indications for introducing the diet, this should be 
done as early as possible, preferably within the first four weeks of 
life, and continued for about two years, provided that growth is 
adequate (see Griffiths, 1973). 
(iii) Nurine histidinaernia 
Biochemistry. In 1973 Kacser et al. reported the discovery of 
a mouse mutant with a twenty to thirty-fold increase in the plasma 
TABLE 1:)4 Summary of the reports on the use of a low-histidine diet in the treatment of histidinaenda. 
Age when diet Duration of Histidine content Control of plasma Clinical change or progress Authors U introduced diet of 	diet histidine on diet 
Ghad.iimi et 3 years 3 days 24 mg/Kg/day Slight reduction No change 
al., 	1962 4 years 3 days 374 mgper day Slight reduction No change 
La Du et 5 years 4 days 4 mg/Kg/day No change No change 1963 
Holton, 1964 6 months Not specified 32-38mg/Kg/day Good Not specified 
Waisman, 26 months 1 month Not specified Halved No change 
1967 31, years 1 month Not specified Not specified No change 
11* months 3 weeks Not specified Halved No change 
Auerbach et 91 years 5 weeks Histidine free Good No change di., 	1967 
Van Sprang 1 year 2 years 1 5-28 mg/Kg/day Satisfactory Favourable progress in speech 
and Wadin.an, and motor development. 
1967 Inadequate growth. 
Corner et 7 months 2 	years 30-35 mg/Kg/day Good for 18nmths Cessation of growth from 20 
al., 	1968 then poor months till death at 41  months. 
Cain and 11 years 11 months 40  mg/Kg/day Poor Slowing of growth Holton, 1968 
Gatfield et 5 years 4 months 1 5-40 mg/Kg/day Good No change 
al., 1969 6 years 3 months 20-30 mg/Kg/day Good No change 
Thal-hammer et S -  months 6-9 months 30-40 mg/Kg/day Good Ataxia improved on diet. 
al., 	1971  5 months 9 months 30-40 mg/Kg/day Good No change 
4 -  months 8 months 30-40 mg/Kg/day Good No change 
TABLE 1:4 continued 
Authors 
Age when diet 
introduced 
Duration of Histidine content Control of plasma Clinical change or progress 
diet of diet histidmne on diet 
Neville et 3 years Not specified Not specified Adequate Improved 
al., 	1972 12 years Not specified Not specified Adequate No change 
years Not specified Not specified Adequate No change 
Wadman et 1 year 10-15 days 20 jag/Kg/day Good 
al., 	1973 3yrs 5 months 10 days 20 mg/Kg/day Good 
lOyrs 11 months 12 days 19.5 mg/Kg/day Moderate reduction Diet stopped after plasma 
21 days 7 mg/Kg/day Good; takes 1ar histidine normalized. 
to achieve than in 
younger subjects 
Griffiths, 12 weeks 1 	years Not specified Good Developing normally 
1973 17 weeks 7 months Not specified Good Developing normally 
8 weeks lye 10 months Not specified Good Developing normally 
8 weeks lye 10 months Not specified Good Developing normally 
Popkin et hi., 10 weeks 	> 6 months 	25 mg/Kg/day 	Good 	 Developing normally 
19714 
Duffner and 1 year 	13 months 	314 mg/Kg/day 	Good 	 No change Cohen, 1 975 
Kotsopoulos 
and Kutty, 	10 years 	3 weeks 	Histidine free 	Moderate 	 No change 
1979 	 reduction 
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histidine concentration and an enzyme abnormality strikingly 
similar to human histidinaemia (Table 1:5). The discovery was 
made in the course of an amino acid screening survey of mutant 
mice. The mutant was found in a stock of mice derived from 
animals caught in the wild in Peru in 1962 (Wallace, 1971 ). Some 
of the stock showed a "balance defect" consisting of abnormal 
circling and head tilting behaviour (Wallace, 1970, 1971). Elevated 
histidine concentrations were found in the animals, some of which 
were behaviourally normal, others of which were balance defective. 
The histidine concentration was also found to be increased in the 
urine, liver, brain and skin. 
Increased concentrations of several histidine metabolites 
were found in the mutant (Kacser et al., 1 973; Bulfield and Kacser, 
1974, 197). In the urine, concentrations of imidazolelactc acid 
(ILA) and imidazoleacetic acid (IAA) were increased seventeen and 
twentysix-fold respectively. It was not possible to separate N- 
acetyl histidine from imidazole pyruvic acid (IPA) chromatographically 
but the combined peak was increased thirty-fold in urine. In the 
plasma, these compounds were again increased at least ten to twenty- 
fold, although none were detectable in the wild-type. The concentrat- 
ions in liver and brain were also increased (Table 1:6). The 
histamine concentration was measured in whole brain and found to 
be two-fold higher in histidinaemics, compared with a twelve-fold 
increase in brain histidine (Bulfield and Kacser, 1975). When 
histidinaemic mice were put on a 6% histidine supplemented diet, 
brain histamine was only increased by a further 40%. 
Histidine accumulations of this magnitude, coupled with the 
increased concentration of its transamination products, suggested 
a block in the major catabolic pathway, namely deamination to urocanic 
acid. The activity of the first enzyme in the pathway, histidase, 
was measured in the livers of histidinaemic and non-histidinaemic 
mice. The former all had drastically reduced histidase activity 
(less than % of normal; Kacser et al., 1973). Skin histidase was 
also found to be about one-third of normal in 7-day old histidinaemic 
mice. The mutation therefore appeared to result in defective histidase 
activity with accumulation of metabolites prior to this step. The 
TABLE 1 :5 
Comparison of mouse and human histidinaemia (Balfield and Kacser, 1974) 
Mouse Man 
Gene Autosomal recessive Autosornal recessive 
Enzyme activity in liver Histidase 45% of normal Histidase absent 
Histidinaemic/normal ratio Histidinaemic/norinal ratio 
Plasma 
Histidine 287 5 to 25 
Urine 
Histidine 21.5 2 to 20 
Im lactate 17.3 15 to 125 
Im acetate 25.8 46 to 66 
Acetylbistidine 290 16 to 22 
Skin 
Urocanate O•)5 0.05 to 0.11 
Histidae 029 002 to 0.5 
Test for heterozygotes 
Not distinguishable Not distinguishable Plasma histidine 
Histidase Distinguishable (sex difference) Possibly distinguishable 
Histidine loading Distinguishable Distinguishable 
TABLE 1 :6 
Biochemical characterization of histidinaemic mice (Bulfield and Kacser, 1 974, 1 975) 
Tissue Histidinaemia Normal R = H/N 
Liver 
Histidase 0.013 0-280 oo46 
Histidine 209 0-880 23°7 
Ac histidine 	1 
+ liii pyruvate 0•111 00082 13o5 
liii lactate 0-102 0-0069 148 
Im acetate 0-017 <o-ooL± >3-7 
Urine 
Histidine 0-86 O-OL 21.5 
Ac histidine 
+ Im pyruvate 3.19 0011 29•0 
Im lactate 1-21 0-07 17.3 
Lii acetate 1.29 0.05 25•8 
Plasma 
Histidine 3•30 0.115 28.7 
Ac histidine 
+ Im pyruvate 0.016 <0-0008 >20.0 
Jim lactate 0•012 0•001 >12.0 
Lii acetate 0.008 (0.001 >8.0 
Brain 
Histidine 2-16 0.169 12•8 
Ac histidine 
+ Im pyruvate 0-0044 <0.0006 )7•3 
liii lactate 00204 (0-0007 >29-1 
Im acetate <0-004 40-0006 - 
Histamine 1-02 0548 1-9 
Note: All values are the means of between 5 - 10 animals. Liver and brain 
metabolites: jimol/g. wet tissue. Plasma and urine metabolites: pmol/nul. 
All determinations by column chromatography and ninhydrin or Pauly 
reaction respectively. 
1 	In the buffer system used, these two substances were not completely 
resolved. The values reported are the sum of both. 
liii, imidazole. 
Ac histidine, N-acetyl histidine. 
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urocanic acid concentration in skin was measured in 7-day old 
histidinaerhic and control mice (Bulfield and Kacser, 197)4). It 
was found to be reduced from 12 pmol/g. to 054 puol/g. This 
gives a crude estimate of the flux from histidine to urocanic 
acid as the next enzyme in the pathway, urocanase, is absent in 
skin. No attempt was made to check the patency of the pathway 
distal to the histidase step either by urocanic acid or FIGLU 
loading. Bulfield, Whitehouse and Kacser (in press) measured the 
flux from histidine to glutamate using tracer methods and found 
it to be about 40% of normal. The finding of a more than 95% 
reduction in histidase activity coupled with a 60% reduction in 
the flux is perhaps reconciled by a substantial mass action effect 
on the flux as a result of the twenty-fold increase in steady state 
histidine concentration (Kacser et al., 197).  There is a sex 
difference in wild-type hepatic histidase activity with a female/ 
male activity ratio of about 3/2, but this was not apparent in 
histidinaemic mice (Bulfield and Kacser, 197)4). 
Genetics. The inheritance of histidinaemia was investigated 
by crossing a stock of true-breeding "high histidine" mice to 
biochemically normal mice from an inbred strain (C57BL/6J) (Kacser 
et al., 1973). The F1 progeny showed normal histidine concentrations. 
The intercross (F2) progeny segregated for high and low histidine 
concentrations to give a ratio not significantly different from 3:1. 
These results suggested the presence of an autosomal recessive 
character with complete penetrance. The mutant allele was designated 
his. The recessive hypothesis was tested further by examining 
histidase activities in heterozygous matings (his/+ x his/+). By 
this means it should be possible to identify heterozygotes since 
codominant expression is the rule at the level of enzyme activity 
even if recessive expression occurs at the metabolic or clinical 
levels (Paigen, 1971).  Hepatic histidase activities in the off-
spring of heterozygous matings showed segregation into three classes. 
The numbers in each class did not differ significantly from 1:2:1 
(Kacser et al., 1973). The mean histidase activity of the intermediate 
group was 45% of the high group mean. Histidase activity was then 
examined in animals true breeding for "high histidine" (presumed his/ 
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his), wild-type animals (+/±) and the intercross offspring of 
these two genotypes (presumed his/+). Again three classes of 
activity were found, corresponding to those seen in the segregating 
litters. These findings support the hypothesis that the his 
allele is an autosomal recessive character. 
Behaviour. After the discovery of histidinaenda in some of the 
Peru strain mice, it became clear that the balance defect did not 
segregate with the metabolic defect. In fact, only the offspring of 
histidinaendc mothers were balance defective, regardless of their own 
or their fathers' genotype. This strongly suggested a maternal 
effect (Kacser et al., 1973). The balance defect showed variable 
expressivity and consisted of some or all of the following features; 
circling behaviour, head tilting, deafness, inability to swim, lack 
of disorientation after spinning and poor maze learning (Kacser et 
al., 1973). The penetrance of the defect varied in the offspring of 
histidinaeimic mothers. A colony of Peru mice had been established in 
Cambridge with 80% penetrance of the balance defect. This was maintain-
ed by selection, but on relaxation of selection the penetrance dropped 
to 37% in 1974 and  7% in 1977 (Nya Mya, 1978). Outcrossing to other 
strains of mice such as AG/Cam or C57BL/6J also resulted in a reduction 
of the penetrance. The plasma histidine concentrations of the stocks 
showing different penetrance were not found to be significantly 
different (Kacser et al., 1977). Penetrance was therefore strongly 
influenced by the genetic background, but apparently not via differences 
in plasma histidine concentration. 
The lesion underlying this balance defect has been shown to be 
a series of inner ear abnormalities (Kacser et al., 1 973, 1 977; 
BuJiield and Kacser, 1974, Nya Nya, 1978). These abnormalities include 
distorted semi-circular canals, shortened. crus commune, reduced pig-
mentation, absent or abnormal otoliths, enlarged or distorted cochlea 
and enlarged ampullae. These changes were present in varying degrees 
in one or both ears. The inner ears of litters taken from (1) his/ 
his x his/his and (2) his/+ x his/+ crosses, were examined by Dr Mary 
Lyon without a knowledge of the behavioural or metabolic assessments 
made on the same animals. It was found that all the balance defective 
offspring from cross (1) showed severe vestibular damage and two-thirds 
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of the behaviourally normal offspring of this cross also showed 
mild damage. All the offspring of cross (2) were behaviourally 
and histologically normal, whether they were biochemically histidin-
aemic or normal (Bulfield and Kacser, 197)4). A histological 
examination of balance defective histidinaemic brains and spinal 
cords was carried out by Dr H. Eraser. There was no evidence of 
histological abnormality in overall cellular morphology and the 
nerve fibres and myelin sheaths were intact (Kacser et al., 1 973). 
It therefore appears that the behavioural abnormality segregating 
within the histidinaemic stock is due to a maternal teratogenic 
effect on the structural development of the inner ear. 
The timing of this maternal effect was investigated further 
by administering a high-histidine diet to his/+ animals during the 
second week of pregnancy. Fourteen out of 130 offspring born to 
heterozygotes on 8% histidine-supplemented diets were balance 
defective compared with none out of 209 on a normal diet. The diet 
raised blood histidine concentrations to near histidinaemic values. 
(Kacser et al., 1977). Administration of the high-histidine diet 
during the first or third weeks of pregnancy produced no abnormal 
offspring. When a low-histidine diet was administered to histidin-
aemics during the second week of pregnancy, the plasma histidine 
was reduced by a factor of six and the proportion of balance defective 
offspring declined from 26% to 3% (Kacser et al., 1977). Similarly, 
changing the diet of histidinaemics during the second week of pregnancy 
to a 2% histidine-supplemented diet did not change the proportion of 
balance defective offspring. Loading -1-/± mice with 5 or 10% phenyl-
alalanine or lysine-supplemented diets during the middle week of 
pregnancy did not produce balance defective offspring so that the 
phenomenon is probably histidine-specific. Mutant mice with prolin-
aemia were also found to produce non-balance defective litters. 
Finally, to try and reproduce the balance defect in ±/± mice, ±/+ 
embryos were transplanted into pregnant his/his mice (Kacser et al., 
1977). Coat colour markers distinguished the transferred eggs. No 
balance defective transplant +/-i- offspring were found, but eight out 
of 15 had structural abnormalities in the canals or otoliths of the 
inner ear, similar to those found in balance defective animals. 
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Additional maternal effects of the his/his genotype were found 
on litter size and growth. The mean litter size was reduced in 
histidinaeimic mothers to about 67% of the normal at birth, and a 
further reduction occurred up to weaning (Bulfield and Kacser, 1974). 
The three-week and seven-week weights of histidinaemics born to his/ 
his mothers were reduced compared with those born to his/ -1- mothers. 
Preliminary experiments (Bulfield and Kascer, unpublished) showed 
impaired maze learning in his/his mice. However, a subsequent study 
was unable to confirm this (MacKenzie and Kacser, unpublished). The 
occurrence of severe degrees of mental defect in the offspring of 
human PKIJ mothers suggested that brain damage may also be occurring 
in the offspring of histidinaemic mice (probably independent of the 
balance defect). This seemed to be an interesting possibility since 
the plasma histidine concentration in his/his mice is about thirty 
times normal, which is comparable to the difference in phenylalanine 
concentration in PKLJ. In human histidinaemia, the difference is only 
ten-fold. Also, the effect on brain development could be expected to 
be greater where there is prenatal and postnatal exposure to increased 
histidine concentrations. For this reason, the experiments on brain 
development (Chapter 4 ) were carried out on the his/his offspring of 
his/his mothers. Any changes found would therefore be associated with 
a combination of genotypic and maternal effects. 
(iv) The metabolism of histidine and its derivatives (see Figure 1:1) 
Dietary requirement [see section (ii)] 
Protein metabolism. Radioactively labelled histidine has been 
fed to rats, mice and guinea pigs and was incorporated into body proteins 
(Tesar and Rittenburg, 1947; Borsook et al., 1950, 1952). A number of 
amino acids have relatively specific roles in determining the con-
figuration or binding properties of polypeptides. 1-Listidine, with 
its lone electron pair in the ring nitrogen, may serve as a potential 
metal ligand as in the iron-binding proteins haemoglobin and cytochrome 
C. The release of histidine from body protein during periods of 
increased net catabolism (e.g. fever, trauma) could perhaps exacerbate 
the metabolic abnormality in histidinaem!a. When this was investigated 
by Holton et al. (1968) in a histidinaeiwic child during febrile illnesses, 
no significant increase in urinary or plasma histidine was found. The 
experience with PKtJ has been different, since Woolf et al. ( j958) 
have reported the return of clinical signs and loss of dietary 
control during infectious illnesses in patients otherwise well 
controlled on low-phenylalanine diets. However this deterioration 
was not shown to be specifically related to increased protein 
catabolism. 
Nethylation. The 1- and 3-methyl derivatives of histidine 
were originally thought to be derived only from dietary or bacterial 
sources. Urinary 1-rnethylhistidine is derived from the breakdown 
of the endogenous dipeptides, anserine (-alanyl i-methylhistidine) 
and homoanserine (-y-aminobutyryl 1-methyihistidine) (Meister, 1965). 
Urinary excretion of 3-methylhistidine, which is largely derived 
from skeletal muscle, has been used as an index of muscle breakdown 
(Ward and Buttery, 1978). There is evidence that histidine is 
methylated in the N (N-3) position of the imidazole ring after its 
incorporation into muscle proteins and that this compound is not 
recycled into protein after its release (Munro., 197)4). There is 
also evidence for ring N 	(N-i) methylation of histidine when it 
is in the dipeptide carnosine (McManus, 1956). The ring methylated 
derivatives of histidine are not incorporated directly into body 
proteins. The 2-methylated derivative of histidine has been reported 
in a dipeptide with p-alanine (Ophidine), but this has only been 
found in snake muscle (Meister. 1 965). 
Dipeptides. There are three histidine-containing dipeptides 
known. Carnosine is a dipeptide of histidine and .-alanine and is 
found mainly in the skeletal muscle of vertebrates (Cantarow and 
Schepartz, 1967) Along with creatinine and anserine, carnosine is 
one of the three most abundant compounds in the non-protein nitrogen 
fraction of vertebrate muscle (Martignoni and Winnick, 195)4). Margolis 
(1974) noted that very high concentrations of carnosine are present in 
the mouse olfactory epithelium and the olfactory bulb which may be 
acting as a neurotransmitter in the primary olfactory pathway. A 
rare disorder called carnosinaemia has been described in which there 
are neurological symptoms, a raised concentration of carnosine in body 
fluids and carnosinase deficiency (Perry et al., 1 967). 
Homocarnosine is the dipeptide of y-azninobutyric acid (GABA) and 
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histidine. It has been reported in the CNS of mice and several 
other animal species (Quinn and Fisher, 1977).  Both carnosine 
and homocarnosine can be methylated by an enzyme found in a variety 
of rat tissues (Pisano et al., 1961; Nakajiina et al., 1967)  to form 
anserine and homo anserine respectively. 
-aspartyl histidine is another histidine-containing dipeptide, 
which has been found in human urine (Kakimoto and Armstrong, 1961), 
but whose significance remains unknown. Three families with a 
combination of cerebromacular degeneration and histidine peptiduria 
(increased carnosine and anserine excretion) have been reported 
(Levenson et al., 1964; Tocci and Bessman, 1967). 
Thiol derivatives. Ergothioneine is the betaine of thiol 
histidine and was first isolated from the fungus ergot (Tanret, 1909). 
It is not known to be formed in mammals and is regarded as "strictly 
exogenous" (Cantarow and Schepartz, 1967). 
Acetylation. N-acetyl histidine has been reported in the urine 
of niainnials (Baidridge and Tourtellotte, 1958; Brown et al., 1960). 
It has been shown to be excreted in increased quantities in both human 
(Neville et al., 1972) and mouse (Kacser et al., 1973)  histidinaemia. 
The function of N-acetyl histidine is not known, although it has been 
suggested that it acts as an acetyl donor (Anastasi et al., 1964; 
Hanson, 1966). It was not found to be synthesised in the mouse brain 
after intracerebral injection of 1C_histidine  (van Balgooy et al., 
1972) although this does occur in frog brain (Baslow, 1 967). 
Transamination. Transamination reactions are important both for 
the synthesis and breakdown of many amino acids. In mammals histidine 
has not been found to undergo transamination with the amino-acceptors 
o-ketoglutarate or oxaloacetate to a significant extent (Lin et al., 
1958; Albers et al., 1962; Haavaldsen, 1962; Meister, 1965). Trans-
amination of histidine with-ketosuccinarnic acid has been demonstrated 
in rat liver preparations to yield inddazolepyruvic acid and asparagine 
(Meister and Fraser, 1954). An active histidine-pyruvate amino-
transferase has been found in the liver of rats, mice and humans (Lin 
et al., 1958;  Spolter and Baidridge, 1963;  Auerbach et al., 1967; 
Budillon et al., 1971;  Norris et al., 1973;  Noguchi et al., 1976a, 
b,; Ninatogawa et al., 1977;  Bulfield, 1978). This is thought to be 
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the main enzyme catalysing the transamination of histidine. There 
is disagreement in the literature over the number and intracellular 
distribution of the histidine aminotransferase isozymes. The existence 
of cytosolic and mitochondrial forms of the enzyme, differing in Km, 
heat stability and pH profile, was first reported by Spolter and 
Baidridge (1963). These two forms of the enzyme were also shown to 
differ in their response to glucagon (Morris et al., 1973).  Recently two 
isozyis have been purified to homogeneity from rat and mouse liver by 
Japanese workers (Noguchi et al., 1976a, b,; Minato.gawa et al., 1977), 
who found that both isozymes appear in the cytosolic and the mito-
chondrial fractions. The isozymes were found to differ in their 
isoelectric points. Only one of the isozymes was inducible by glucagon. 
Bulfield (1978) helped to clarify the situation by reporting a variant 
form of the cytosolic enzyme which occurred independently of the mito-
chondrial enzyme. This result tends to support the original suggest-
ion of a cytosol isozyne and a mitochondrial one, rather than both 
isozymes being present in the two locations. 
Substrate specificity and affinity studies were carried out by 
Noguchi et al. (1976a, b) on the purified histidine aminotransferase 
isozymes. Both isozymes were found to show greater activity with 
phenylalariine or tyrosine as substrates than with histidine, although 
the Km for histidine was lower than for phenylalanine in one of the 
isozymes. Isozyme I was found to occur only in the liver while 
Isozyme II was present in all rat tissues examined. 
The development of mouse liver histidine aminotransferase 
activity has not been described. Changes in the developing rat liver 
phenylalanine-pyruvate transaminase, which may be identical to histidine-
pyruvate aminotransferase, have been reported (Auerbach and Waisman, 
1959). The activity was low until the day before birth when it 
increased dramatically until two days after birth, remaining high 
(about three times adult activity) until about two weeks, then gradually 
falling to adult levels over the next fortnight. A similar sharp 
increase in the activity of tyrosine transaminase occurs after birth, 
reaching levels two to four times those of the adult, in several 
species (Sereni et al., 1959; Litwack and Nemeth, 1965;  Moog,  1971). 
The premature development of tyrosine transaininase can be reproduced 
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by glucagon administration (Moog, 1971). The liver isozynie of 
histidine arninotransferase is also inducible by glucagon (Lee and 
Harper, 1971;  Morris et al., 1972;  Noguchi et al., 1976 a). The 
products of histidine transamination with pyruvate are imidazole 
pyruvic acid and alanine. The former is either reduced to iinidazole-
lactic acid or decarboxolated to irnidazoleacetic acid. linidazole-
acetic acid is also a product of histamine metabolism in some 
organisms, by the action of histazninase (or diamine oxidase) via 
ijuidazole acetaldehyde (Schayer, 1966). 
Deamination. Non-oxidative deamination of histidine to urocanic 
acid is thought to be the major route of histidine catabolism in 
mammals (Meister, 1965).  This route was first described by Edibacher 
(1926) who found that the mammalian liver decomposes histidine with 
with the liberation of ammonia. The degradation of histidine to 
urocanic acid has since been reported in the livers of rat, mouse, 
rabbit, dog, cat, guinea pig and man (Hall, 1952; Borek and Wae]sth, 
1953; Mehier and Tabor, 1953; Coltorti et al., 1966). The enzyme 
responsible has been called histidase (Edibacher, 1926) or histidine 
ammonia-lyase (EC )4.3.1.3.). Although the liver is thought to be the 
main site of histidine degradation, histidase is also present in the 
epidermal layer (stratum coimeum) of mammalian skin (Schwartz, 1961; 
Zannoni and La Du, 1963). The histidase activity of the skin appears 
to be located in the epithelial cells and is not present in fibro-
blasts (Barrthisel et al., 1970; Melancon et al., 1971). There are few 
reported systematic studies of histidase distribution in mammalian 
tissues. Zannoni and La Du (1963) were unable to detect histidase 
activity in guinea pig kidney or muscle but found very low activity 
in intestine, testis, spleen and heart. Bulfield and Kacser (1975) 
were unable to detect histidase activity in mouse brain. Histidase 
activity has also been studied in fish, where it occurs in liver 
and muscle (Sakaguchi et al... 1970). Several bacteria are rich in 
histidase activity and one of the best sources of the enzyme is the 
bacterium Pseudonionas (Tabor and Mehler, 1955). 
Histidase reaction mechanisms. The reaction involves a trans-
elimination of the cC -amino group and p -proton of L-histidine to form 
trans-urocanic acid (Tabor, 1954;  Kuroguchi et al., 1957;  Peterkofsky, 
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1962; Givot et al., 1969; Retey et al., 1970; Hanson and Havir, 
1972). Peterkofsky (1962) suggested that this reaction takes place 
in two steps. He found that in addition to the irreversible de-
arnination of histidine, histidase catalyses two partial reactions: 
(1) a p-hydrogen exchange into histidine; (2) a urocanic acid ex-
change into histidine. Since solvent tritium and 14C_urocanic acid 
were incorporated into histidine in contrast to 15 NH he suggested 
that an amino-enzyme complex is formed, which either reversibly 
reforms histidine or is irreversibly degraded to ammonia and free 
enzyme. Givot et al. (1969) and Wiclaaer (1969) later suggested 
that the . -amino group of histidine may bind covalently to a dehydro-
alanyl residue in the active site of histidase. Removal of the 
p -proton and rupture of the C-N bond would then result in formation 
of urocanic acid and the amino-enzyme complex. The two steps envisaged 
are therefore:- 
histidine + enzyme ± NH2-enzyme + H + urocanic acid 
NH2-enzyme + H 
2 
 0 ± enzyme + NH3  
Reaction (1) is freely reversible and reaction (2), although thought 
to be irreversible by Peterkofsky, can be reversed under certain 
conditions, at a very slow rate (Williams and Hiroms, 1967). The 
equilibrium constant of the overall reaction is about five (Klee et di., 
1 975). Further support for amino-enzyme formation comes from the non-
competitive inhibition of the reaction by urocanate with respect to 
histidine, suggesting that inhibition occurs by reversal of reaction 
(1) (Givot et al., 1969). Specificity studies show that only histidine 
echanges with tritium and only urocanic acid accepts the amino group 
in reaction (1) (Givot et al., 1969). 
The stimulating effect of metal ions and inhibitory effect of 
metal chelators on the elimination reaction (Nehler and Tabor, 1953; 
Tabor, 1954; Peterkofsky and Nehler, 1963; Cornell and Viflee, 1968; 
Rechier, 1969; Givot et al., 1970; flee, 1972) suggests that metal ions 
operate at the rate-detQnnining step which mabe the rupture of C-H 
and/or C-N bonds in thed,p -elimination (flee et ml., 1975). Givot 
et al. (1970) suggest that a divalent metal ion forms part of an 
enzyme-metal-substrate bridge complex, which would facilitate the 
removal of the p -proton from histidine in the elimination reaction. 
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 ) have been shown to stimulate histidase activity although it 
is unclear which is the cofactor in vivo (Klee, 1972; Okamura et al., 
197)4). It is likely that the metal is bound to free -SF1 groups at 
the active site (Peterkofsky and MehJ.er, 1963; Klee, 1 972; Okamura 
et al., 197)4). Oxidation of active site sulphydryl groups, which 
occurs during ageing or purification of the enzyme, results in a 
marked loss of activity (to 10 - 20% of normal), which can be restored 
by addition of sulphydryl reagents (Tabor and Mebler, 1955; Peterkofsky 
and Mehler, 1963;  Givot et al., 1 969; Soutar and Hassall, 1969; Klee, 
1970; Frankfater and Fridovich, 1970; Okamura et al., 197)4). Oxidation 
of free sulphydryl groups is associated with a loss of affinity for 
metal ions (Klee, 1972) and the activating effect of sulphydryl 
reagents is lost in the presence of the metal chelator EDTA (Okamura 
et al., 197)4). The loss of histidase activity that occurs with 
ageing, prolonged dialyis or purification (Tabor and Mehier, 1955) 
is also-associated with polymerization of enzyme monomers (Soutar 
and Hassall, 1969; Klee, 1970; Okamura et al., 197)4). This polymer-
ization can be reversed by addition of thiol reagents. There is also 
evidence from sequencing the SF1-containing peptides isolated from 
the depolymerized enzyme, that disulphide bonds are formed between 
cysteine residues at the active site of different enzyme monomers 
(Hassall and Soutar, 197)4). Finally, in addition to the divalent 
cation and sulphydryl groups which are required for optimal activity, 
an as yet unidentified prosthetic group, which may form part of the 
active site,is also thought to be present (Smith et al., 1967;  Givot 
et aL, 1969; Klee, 1970;  flee et al., 1979) 
The enzyme shows a high degree of specificity for L-histidine 
(Brand and Harper, 1976) although 2-fluorohistidine and 4-nitro-L-- 
histidine also act as substrates for the bacterial enzyme (flee et al., 
1975; Klee etaL,199). Studies with inhibitors suggest that the enzyme 
interacts with the substrate specifically through the carboxyl, 
c -amino and imidazole moieties (Givot et al., 1969; Brand and Harper, 
1976). The imidazole ring of the substrate may bind to the divalent 
metal ion, which in turn is attached to an enzyme-bound - SH group 
(flee, 1972). The &-amino group is thought to bind to a highly- 
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reactive electrophilic dehydroalanine residue on the enzyme 
(Givot et al., 1969; Givot and Abeles, 1970). The nature of the 
carboxyl binding site is unknown. 
Studies on purified mammalian histidase. Purified mammalian 
histidase has been less thoroughly studied than the bacterial enzyme. 
The latter appears to be a tetramer with a molecular weight in the 
region of 213,000 daltons, which exists in two (?oxidised" and 
"reduced") forms depending on its state of suiphydryl oxidation 
(flee, 1970), as discussed above. Cornfl and Villee (1968) purified 
rat liver histidase about 200-fold, to about 70% purity. Their 
preparation had an estimated molecular weight of 2262000 daltons 
by ultracentrifugal analysis. Okamura et al. (1974) purified rat 
liver histidase 390-fold and showed it to be homogeneous by ultra-
centrifugal, electrophoretic and immunoelectrophoretic analyses. 
They estimated the molecular weight to be 190,000 daltons. On 
electrophoresis there were two minor and one major band with histidase 
activity, which converted to a single, most anodal band after treatment 
with thiol reagents. These findings were interpreted as showing a 
tendency of the enzyme to aggregate by the formation of disulphide 
bridges,which are dissociated by thiol reagents. No attempt was 
made to dissociate the 190,000 dalton species into its subunits. 
Brand and Harper (1976) purified rat liver histidase more than 250-
fold to near homogeneity. The molecular weight was estimated to be 
in the region of 200,000 daltons. Lamartiniere and Feigelson (1977) 
purified rat liver histidase 319-fold to homogeneity by electrophoretic 
and ultracentrifugal analyses. The native enzyme had an estimated 
molecular weight in the region of 230,000 daltons and could be dis-
sociated into 77,000 dalton subunits. This would suggest three sub- 
units, which is uncommon (Harris, 1 975). In contrast, Brand and 
Harper (1 975) suggested that the rat liver enzyme is composed of six 
subunits. Since the bacterial enzyme can be inadvertently hydrolysed 
to a smaller species during purification, yielding subunits of 35000 
daltons instead of 55,000 daltons, Brand and Harper (1976) later 
suggested that there may be a similarly labile peptide bond in the 
mammalian enzyme. A tetrameric structure still remains a strong 
possibility therefore, although this remains to be established. 
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Mouse liver histidase has been purified in two inbred strains 
to 55% and 70% purity respectively (Hanford and Arfin, 1977). Electra-
phoretic analysis showed a single band with histidase activity. 
The rat liver enzyme has a minimum Km for L-histidine of 0°5 mM 
at pH 9°0, increasing progressively at higher or lower pH (Brand and 
Harper, 1976). The Km value of 0°5 mM, approximately twice the fasting 
liver histidine concentration (Herbert et al., 1966), increases to 
more than 20 mM in the physiological pH range of 7°2 - 7°4. The 
optimal pH for activity is in the regioli 8•5 - 9°0 (Okaxnura et al., 
1974; Brand and Harper, 1976). The purified enzyme is activated 
three or more fold by prior incubation with thiol reagents. These 
reagents have little or no effect at earlier purification stages. 
The response to thiol reagents and metal chelators is similar in 
bacterial and mammalian histidase preparations. Rat liver histidase 
is, like the Pseudomonas enzyme, irreversibly inhibited both in vitro 
and in vivo by the carbonyl reagent nitrornethane (Givot and Abeles, 
1970). Hydrolysis of the 1C_nitromethane  inactivated enzyme gives 
identical products with rat liver and bacterial preparations, support-
ing the existence of a similar electrophilic centre in both enzymes 
(Givot and Abeles, 1970). Identification of these products suggested 
the presence of a dehydroalan.ine residue in the active site of both 
enzymes. 
The properties of partially purified mouse liver histidase 
(Hanford and Arfin, 1977) have not been studied in detail. The Km 
for histidine was found to be 0°9 mM at pH 93 and pH optimum was 
9°0 - 905. The enzyme was relatively heat stable with a ti of 13 - 
14 minutes at 530C. Baden and Gavioli (197) reported that at 75°C, 
partially purified rat liver histidase had a tl. of 10 minutes. The 
bacterial enzyme is even more heat stable, retaining its activity 
after heating at 78 - 83°C for 15 minutes (Tabor and Mehler, 1 955). 
Developmental changes in mammalian histidase. The development 
and regulation of rat liver and skin histidase has been extensively 
investigated (Auerbach and Waisnian, 1959; Baden et al., 1968; Makoff 
and Baidridge, 1969; Sahib and Krishna Murti, 1969; Feigelson, 1968, 
1971 a, b, c, 1972, 1973 a, b, c, 1974; Bhargava and Feigelson 1976 a, 
b,; Lamartiniere and Feigelson 1977; Lainartiniere and Lucier, 1978). 
The pattern of developmental changes in histidase activity is 
quite different in liver and skin. The liver enzyme appears at 
or shortly after birth, rises during the first week, plateaus and 
increases further at puberty. In females, the increase at puberty 
is more rapid and to higher levels than in males (Auerbach and 
Waisman, 1959; Feigelson, 1968; Makoff and Baidridge, 1969; Feigelson, 
1973 b)0 The skin enzyme is detectable at or a few days before birth, 
increases in the next week then falls to a low level in the adult, 
although in the male the activity drops further at puberty (Baden 
et al., 1968; Sahib and Krishna Murti, 1969; Feigelson, 1972, 197)4). 
In the liver, several hormones have been shown to modify the 
expression of histidase, each influencing activity at a particular 
stage of development and in a characteristic manner. Glucagon (acting 
via cyclic AMP) and glucocorticoid have been implicated in the induction 
of the neonatal rise in activity (Feigelson,1973 a, b). Glucocorticoids 
may also be involved in the adolescent increase in the male (Feigelson, 
1973 a, b) and oestrogen in producing the markedly enhanced activity 
in females (Feigelson, 1968, 1973 b). Glucagon can increase histidase 
activity at all postnatal stages; glucocorticoids only during the first 
two postnatal months but not in mature animals; oestrogen only after 
the first postnatal month (Feigelson, 1973 b). The hormonal regulation 
of skin histidase has not been extensively studies, although gluco-
corticoids (Bhargava and Feigelson, 1976 a) and androgens (Feigelson, 
197)4) may be involved. 
Feigelson and coworkers purified histidase to homogeneity and 
prepared a monospecific antibody to examine the nature of these 
developmental changes in activity. Bhargava and Feigelson (1976 b) 
showed that all changes in histidase activity during development are 
accompanied by parallel changes in the amount of iminunoprecipitable 
enzyme protein, in liver and skin. The rates of in vivo incorporation 
of (3H)  leucine into histidase irnmunoprecipitates were examined in 
skin and liver during development. Changes in histidase activity in 
both tissues were paralleled by corresponding changes in the rates of 
histidase synthesis (Bhargava and Feigelson, 1976 b). More recently, 
Larnartiniere and Feigelson (1977)  have shown that oestrogen, gluco-
corticoid, glucagon and cyclic AMP induced changes in rat liver 
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histidase activity, are each paralleled by equivalent changes in 
immunoprecipitable histidase protein and in vivo rates of (1 0 
leucine incorporation into iiurnunoprecipitated histidase. It was 
therefore inferred that the effect of these hormones on liver 
histidase development is mediated by a change in histidase synthesis. 
Hormonal agents capable of supressing hepatic histidase activity 
(including androgen, ACTH, growth hormone and thyroxine) have been 
described, but their modes of action remain unclear. The complex 
interplay of hormones, diet, tissue responsiveness and other factors 
influencing histidase activity at each stage of development is still 
being elucidated (Schirmer and Harper, 1970; Lee and Harper, 1971; 
Norris et al., 1972, 1973; Noda and Nakagawa, 1972; Feigelson, 1973 b, 
Lanartiniere and Lucier, 1978). Developmental changes in histidase 
activity have not been investigated in the mouse. 
Iso zymes. The differing developmental patterns and regulatory 
properties of skin and liver histidase suggested the possibility of 
different molecular forms of the enzyme (isozymes) in these tissues. 
This was investigated by Bhargava and Feigelson (1976 a). They found 
that purified rat liver and partially (fifty-fold) purified skin 
histidase were identical by three criteria: isoelectric point, Km 
and immunological properties. In contrast, crude preparations of 
rat liver and skin histidase show slight differences in electrophoretic 
mobility on polyacrylamide gels (Baden and Gavioli., 1974; Bhargava 
and Feigelson, 1976 a), which are not removed by partial purification. 
It is not yet clear whether this difference is due to absorption of 
contaminant protein or to molecular differences, since it was not 
possible to completely purify the skin enzyme. Baden and Gavioli (1974) 
also reported heat stability differences between 10 to 20-fold purified 
skin and liver histidase. The liver enzyme had a t1  of 10 minutes at 
° 75C, compared with a tj. of 20 minutes for the skin enzyme. On the 
basis of the differing heat stability, electrophoretic mobility and 
sensitivity to EDTA inhibition, Baden and Gavioli postulated the 
existence of distinct skin and liver isozymes of histidase. The 
results of Bhargava and Feigelson (1976 a) using more highly purified 
enzyme however make this conclusion rather doubtful. 
Pathway from urocanate to glutamate. Urocanic acid is thought by 
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some authors to have a protective action in the skin against 
ultraviolet light (Zenisek et al., 1955;  Hais and Zenisek, 1959; 
Everett et al., 1961). Urocanate is found in high concentrations 
in human sweat (Zenisek and Kral, 1953) and is thought to diffuse 
into the sweat from skin epithelial cells rather than being produced 
by sweat glands (Brusilow and Ikai, 1968). Histidinaemics have a 
deficiency of urocanate in the skin, but there is no evidence of 
unusual skin sensitivity to light (Ghaftimi, 1974)  although dietary 
deprivation of histidine in human infants results in a skin rash 
which disappears on introduction of histidine to the diet (Snyderman, 
1965). Urocanate is hydrblysed to 4-inlidazolone-5--propionic acid 
by the action of the enzyme urocanase. This enzyme is found in the 
soluble cytoplasmic fraction of liver, but is not present in skin 
(Zannoni and La Du, 1963). linidazolone propionic acid is converted 
by imidazolone hydrolase to N-formiininoglutamic acid (FIGLU) (Snyder 
et al., 1961). Some imidazolone propionic acid is transformed by a 
liver oxidase to hydantoin-5-propionic acid, which has been found in 
the urine of the rat, monkey and man (Brown and Kies, 1959; Hassall 
and Greenberg, 1963).  Tetrahydrofolic acid (THFA) combines with 
FIGLU to form L-glutarriic acid and 5-formyl-tetrahydrofolic acid. 
The latter is converted further to yield "active formaldehyde?' (10-
formyl tetrahydrofolic acid) and free ammonia. The conversion of 
FIGLU to L-glutaniic acid is catalysed by three separate enzymes 
(Meister, 1965). Histidine therefore contributes indirectly as a 
source (along with glycine and tryptophan) of formyl THFA which can 
be used directly in purine synthesis or converted to hydroxymethyl-
TRFA for use in transmethylation and pyriniidine synthesis. A genetic 
defect in the metabolism of FIGLU has been demonstrated in man 
as a result of a formiiminotransferase deficiency (Arakawa et al., 
1966; Arakawa, 1970).  The syndrome includes mental and physical 
retardation, neurological abnormalities and increased urinary 
excretion of FIGLU after an oral histidine load, in the presence 
of abnormally high serum folate levels. 
Decarboxylation. Histidine is converted to the physiologically 
active metabolite histamine by enzymatic decarboxylation0 In adult 
animals, only an estimated 1% of ingested histidine is metabolised 
to histamine (Van Arsdel and Beau, 1960). However, in certain 
physiological and pathological states (Kahison and Rosengren, 
1968), this percentage is likely to be considerably higher. The 
role of histamine in physiological processes has recently been 
reviewed (Schwartz, 1977; Beaven, 1978). 
Histidine decarboxylase catalyses the specific formation of 
histamine from histidine (Schayer, 1966). L-aromatic amino acid 
decarboxylase can utilise histidine as a substrate together with 
DOPA or 5-hydroxytryptophan, but is thought to play a minor role 
in histamine formation in most tissues (Aures et al., 1972; Schayer 
and Reilly, 1974 a, b). The latter enzyme has a low affinity for 
histidine and is distinguished from histidine decarboxylase by its 
pH optimum and response to inhibitors or activators (Weissbach et 
al., 1961; Ganrot et al., 1961; Lovenberg et al., 1962). Histidine 
decarboxylase (HDC) requires pyridoxal phosphate as a coenzyme both 
in vitro and in vivo (Ono and Hagen, 1959; Kahlson et al., 1963). 
Schayer has shown that the activity of EDO can be induced by a 
number of non-specific agents. On the basis of these findings, he 
suggested that histamine is important in the regulation of micro-
circulatory blood flow. H]JC activity can also be regulated by hormones 
such as oestrogen and catecholamines which enhance activity and 
glucocorticoids which depress activity (Kahlson and Rosengren, 1968). 
EDO is the only enzyme that is known to metabolise histidine 
to any extent in the mammalian brain. It has been studied in rat 
brain (Schwartz et al., 1970, 1971, 1972) and mouse brain (Taylor and 
Snyder, 1972; Schayer and Reilly, 19714 a, 1975). The development 
of mouse brain KDC has not been studied. Intraperitoneal injection 
of histidine in the mouse increases whole brain histidine and 
histamine concentrations about three-fold, with increases evident 
in all brain regions except the medulla oblongata-pons (Taylor and 
Snyder, 1972). Bulfield and Kacser (1975) found a two-fold increase 
in whole brain histamine in histidinaemic mice, which increased to 
three-fold with a 6% histidine-supplemented diet. These findings 
suggest that mouse brain I-}DC is not saturated with histidine under 
physiological conditions. 
Histamine formation by B])C shows some unusual features during 
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pregnancy in some species. In the pregnant mouse, urinary histamine 
excretion rises dramatically soon after fetilisation, reaching a 
peak at about the eighth day of gestation and remaining high until 
term, when it falls precipitously to near normal values (Rosengren, 
1963) Similar increases in urinary histamine excretion are found 
in the pregnant rat and hamster (Figure 1:2). The increased histamine 
excretion has been shown to be largely due to high foetal HDC activity, 
although maternal tissues also show higher than normal NBC activity 
(Kahlson et al., 1958; Rosengren, 1963; Maudsley and West, 196)4). The 
physiological significance of these changes in histamine formation 
during gestation are obscure. In the pregnant his/his mouse, 
exposure of foetal NBC to increased histidine concentrations might 
lead to even higher rates of histamine formation than occur normally 
in pregnancy. To speculate further, enhanced gestational histamine 
formation could be related to the inner ear teratogenic effect of 
maternal histidinaemia. Schnieder (1975) has suggested that, because 
of the topography of the perilymphatic vascular network, the inner 
ear niicrocirculation is especially sensitive to vasoactive substances 
such as histamine. Intracochlear administration of histamine is 
associated with a significant reduction in Inicrocirculatory flow. 
Increased circulating histamine could perhaps cause prolonged 
labyrinthine ischaeinia, leading to permanent damage to the developing 
inner ear. A mechanism of this sort is given further credence by 
the successful use of a histamine analogue (betahistine) to increase 
the Inicrocirculation in the inner ear in a human condition (Mnire's 
Disease) characterised by damage to otoliths which may also be the 
result of labyrinthine ischaeniia (Martinez, 1972; Wilmot and Menon, 1976; 
Frew and Menon, 1976). 
There are two major pathways of histamine degredation in mammals 
(Schayer, 1959). The first is by direct oxidative deamination by 
histamines (Buffoni, 1966) to imidazoleacetaldehyde, which is rapidly 
converted to iinidazoleacetic acid by the action of aldehyde dehydro-
genase (Tabor, 1 951 ). Imidazoleacetic acid is a neuroactive compound 
which exerts a powerful inhibitory effect on cortical neurons in some 
species (Green, 1 970; Tunnicliff et al., 1972). It is conjugated with 
5-phosphoribosyl-1 -pyrophosphate to form iniidazoleacetic acid ribotide, 
500 
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FIG. 1:2 Daily urinary excretion of free histamine in the mouse, 
rat and hamster. Periods of gestation were 19, 24 and 
16 days, respectively (Kahlson and Rosengren, 1968). 
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which is then dephosphorylated to the riboside (Crowley, 1964). In 
the mouse, there is an active liver histaininase which oxidises a 
large proportion of an oral or injected histamine load (Karjala et 
al., 1956, Schayer, 1956), but in this species, as in man, methylation 
is the major route for histamine degradation under most circumstances 
(Schayer 1959). 
Methylation of the imidazole nitrogen (Ni) of histamine is 
catalysed by the specific enzyme imidazole-N-methyltransferase (INMT) 
(Brown et al., 1959). S-adenosyl methidnine acts as a methyl donor. 
The immediate product is N'-or 1, Lt-methyl histamine, which is oxidised 
to inethyliinidazoleacetic acid (Schayer and Karjala, 1956). 1, 4-methyl 
hitamine is oxidatively deairiinated by monoamine oxidase to form 
riethyliinidazoleacetaldehyde (Rothschild and Schayer, 1958; Waldmeier 
et al., 1977). This is oxidised by aldehyde dehydrogenase to methyl- 
imidazoleacetic acid, which is the major urinary degradation product 
of histamine in the mouse (Karjala et al., 1956; Schayer, 1959). Some 
other histamine derivatives have been reported, including acetyl- 
histamine (. tJrbach, 1949)   N-methylhistamine, N,N-diinethylhistamine 
(Kapeller-Adler and Iggo, 1957) N'Lor 1, 5-methylhistainine and 1, 5- 
niethyliniidazoleacetic acid (Karjala and Thrnquest, 1955),  y-glutamyl- 
histamine (Konishi and Kakimoto, 1976). Histamine also forms amides 
with certain fatty acids (Bachar and tJdenfriend, 1966) andeptido- 
amines in the nervous system (Reichelt et al., 1975). All these 
compounds are quantitatively minor derivatives of histamine. 
(v) Genetic variation in histidase activity between inbred strains 
of mice. 
Arfin and coworkers (Hanford et al., 1974; Hanford and Arfin, 
1977) measured hepatic histidase activity in 26 inbred strains of 
mouse. The inbred strains fell into two groups, showing either a 
"high" activity (20 - 25 )niiol/hour/g. wet weight) or "low" activity 
(10 - 15 jimol/houi-/g. wet weight). A high activity strain (C57BL/6J) 
was crossed to a low activity strain (C3H/HeJ) and the histidase activity 
measured in the F1 , F2 and backcross generations. The results of these 
crosses and reciprocal backcrosses suggested the presence of a single 
autosomal genetic difference which could account for the major part of 
the observed differences in activity. Liver histidase was then 
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partially purified from the livers of the high and low strains. 
No difference was found between the two sources of enzyme during 
purification or on polyacrylamide gel electrophoresis. The final 
preparations were 55 - 70% pure, but specific staining for histidase 
activity on the gels revealed a single, identical band in both strains. 
Comparison of pH optimum. Km for histidine, heat stability, electro-
phoretic mobility, elution after gel filtration on Sephadex G_200 
and inhibition by histidine analogs revealed no difference between 
the strains. Antibodies to the partially purified enzyme were 
raised in rabbits and used in immunotitration experiments to determine 
the quantity of histidase enzyme present in liver supernatants from 
the two strains. The amount of enzyme antigen was found to be 
proportional to the level of enzyme activity in both strains, 
suggesting a difference either in the rates of histidase synthesis 
or degradation. Rates of enzyme degradation were measured in vivo 
from the recovery of activity after irreversible inhibition by 
nitromethane. There was no difference in the rate of histidase 
degradation. The rate of histidase synthesis, as measured by the 
incorporation of (3H)-leucine into immunoprecipitated histidase, 
was about 25 times greater for the high activity strain. The 
authors concluded that the activity difference could be completely 
accounted for by a higher rate of histidase synthesis in the high 
strain. These investigations raise the possibility of a regulatory 
locus influencing histidase synthesis but distinct from the structural 
locus. The electrophoretic analysis, however, cannot be regarded as 
definitive and should include comparison at different pH's and gel 
concentrations or isoelectric focusing. A subtle change in the 
enzyme structure could have been missed. The presence of intermediate 
histidase activity in the F1 generation after crossing high and low 
activity strains would be equally consistent with a cis-active 
regulatory gene or codondnant expression of structural genes. 
Definitive evidence for a regulatory mutation requires that the 
mutant map to a separate site from the structural locus. Identification 
of the his locus with the structural locus for histidase and its 
genetic mapping are therefore important steps in the elucidation of 
this strain difference in histidase activity. 
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(vi) Outline of investigations undertaken. 
The investigations undertaken fall into three parts. Firstly, 
the biochemical characterisation of the developing his/his mouse. 
The his/his mice used were all the offspring of his/his mothers, so 
combining the effects of maternal histidinaemia and histidase deficiency. 
+/+ Nice on the same genetic background were used for comparison. While 
the metabolic status of the adult mutant is well documented, the 
possibility of metabolically induced damage to the developing brain 
requires that a similar documentation be made during the period of 
brain development. The relationship between changes in the histidine 
metabolising enzymes and their precursor and product metabolites has 
therefore been examined during development. 
Secondly, biochemical indices of brain growth and cell prolif-
eration have been examined during postnatal development in the his/his 
offspring of his/his mothers. in comparison with +/i- mice. Although 
neuronal multiplication and morphogenesis occur largely before birth 
(except in the cerebellum), the indices of brain growth were only 
examined during the first five weeks after birth. This was done 
because of the greater technical difficulties of ageing and dis-
secting the animals before birth, while any interference with pre-
natal brain development is likely to leave a permanent deficit (mainly 
of cell numbers; Altman et al., 1970), which would therefore still be 
evident after birth. Also, the effect of histidinaemia on neuronal 
multiplication has been examined directly in the cerebellum, which 
is almost wholly formed after birth. The postnatal phase of brain 
development is characterised by an important "growth spurt". During 
this growth spurt the brain is particularly vulnerable to metabolic 
or toxic interference. It is during this phase of development that 
the brain damage in phenylketonuria occurs. 
Thirdly, the nature of the enzyme defect in his/his mice has 
been investigated. This provides an indirect but important indication 
of its genetic basis. The residual histidase activity has been 
scrutinised for evidence of a change in those physim-chemical properties 
(e.g. heat stability, electrophoretic mobility) suggestive of an 
alteration in the primary structure. If found, this suggestsa mutation 
at the structural locus for the enzyme. Alternatively, it could be 
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the result of a mutant gene concerned with the post-translational 
processing of the enzyme (e.g. attachment of carbohydrate or other 
conjugant groups). If there is no change in one of these physico-
chemical properties, the mutation could be at a regulatory locus 
controlling only the amount of enzyme protein, provided simple 
inhibition has been excluded. The properties of the residual mutant 




MATERIALS AND METHODS 
(i) Animals and breeding methods. 
The mice used in these experiments were derived from a stock of 
wild mice trapped in Peru in 1962 (Wallace. 1971) and maintained in 
the Department of Genetics. Edinburgh University since 1971 . After 
the discovery of histidinaemia segregating in the stock, selection 
for the his allele was carried out. After seven crosses a stock of 
true breeding his/his mice was obtained. Wild type (+/+) and hetero- 
zygous (his/+) mice on the same genetic background were also maintained. 
This stock (5EV) was routinely maintained as follows. Three crosses 
were made:- 	(1) his/his x his/his 
his/+ 22  x his/hisd 
+/+ 	x 
The offspring genotypes of the second cross were distinguished on 
the basis of urinary "Phenistix" (Ames Co.) testing. This is a dip 
test based on the ferric chloride reaction which gives a grey-green 
colour in the presence of high urinary imidazole pyruvic acid, which 
is only found in his/his mice. The stock was maintained in this 
manner until 1976, with avoidance of brother-sister matings which 
were found to reduce litter size. During the course of experiments 
in which histidase activity was measured, it was found that some 
putative ±/+ animals had histidase activity about half of that expected 
in this genotype. Definitive evidence that animals thought to be 
were in fact his/+ came when the offspring of one tt+/+tt  x 
mating was found to include an unequivocally histidinaemic mouse. 
A programme to select unequivocal +/+ and his/his mice was carried 
out by Dr G. Bacon. Six male and six female parent -i-/-- mice were 
crossed to known biochemically histidinaemic (his/his) mice of the 
opposite sex. At least ten offspring of each cross were then bled 
from the tail vein after reaching seven weeks of age. The bloods 
were analysed for the total imidazole concentration by the Pauly 
reaction without prior chromatographic separation of individual compounds. 
This technique was shown to give a clear distinction between histidin- 
aemic and non- histidinaemic bloods. Where female "+/+tt mice were 
being crossed to male his/his mice, the male was removed as soon 
as the female became pregnant. Where the test animal was a male 
being crossed to a his/his female, the male was left in the cage. 
In all cases, the offspring were removed at weaning 0 weeks) and 
the sexes separated. An animal was only identified as unequivocally 
+/+ if no his/his mice were found, out of at least ten test cross 
offspring. Some apparent +/+ animals tested were shown to be his/+ 
in this way and the procedure was continued until enough true +/+ 
males and females were obtained to set up new breeding stocks. There- 
after, only crosses (1) and (3) were routinely maintained, in view 
of the danger of his/ -I- being mistaken for +/+. Selection of animals 
for breeding stocks was routinely accompanied by blood iinidazole or 
histidine analysis, rather than relying on Phenistix urine testing. 
His/his were only selected for mating if their balance defect was 
relatively mild or absent (especially in the case of females), since 
otherwise the survival of litters was reduced, owing to a tendency 
to trample on the young. Some. selection against the balance defect 
was therefore occurring in the stock (see Kacser et al., 1979 b). 
Breeding stocks were checked every morning and late. afternoon for 
the presence of new litters. The day on which a new litter was found, 
was taken to be "day 01?, the following day "day 111 and so on. Weaning 
was routinely carried out at three weeks after birth, when the sexes 
were also separated. "Adult" mice were taken to be at least seven weeks old. 
Statistical methods. 
The statistical tests used were described by Snedecor and Cochran 
(1967) and calculated on a Sumlock 325 digital computer (Compucorp). 
Chemicals. 
All chemicals were Analar grade obtained either from British 
Drug Houses, Koch-Light or Sigma Chemical Company unless otherwise 
specified. (3H)-S-adenosyl-niethionine was obtained from the Radio-
chemical Centre, Aniersham. 
Dissection of tissues. 
Mice were killed by stunning, followed by cervical dislocation. 
Guinea pigs used in the extraction of imidazole-N-methyltransferase 
were killed by carbon dioxide inhalation and decapitation. 
The liver was extracted from mice by opening the abdominal wall 
with sharp scissors, removing the liver and placing it on a square of 
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aluminium foil on crushed ice. The gall bladder was then removed. 
Skin was dissected from the dorsal surface of the mouse with 
scissors. In older animals the moistened hair was first shaved off 
with a scalpel. 
In the case of brain dissections, mice were first anaesthetised 
with ether and then decapitated on a chilled metal plate cooled to 40C 
and lying on an ice-salt mixture. The skull was opened with scissors 
and the brain carefully removed, blotted with filter paper and placed 
on the chilled plate. It was dissected by mid-collicular section 
which separated the forebrain (cerebrum) from the rest of the brain. 
The cerebellum was then separated from the pons medulla and the latter 
was discarded. The cerebrum consist mainly of the cerebral hemispheres 
but includes the corpus striatum, hypothalamus and other parts of the 
diencephalon and midbrain. The dissection procedure, based on that of 
Glowinski and Iversen (1968), is shown in Figure 2:1. The cerebral and 
cerebellar portions were separately wrapped in aluminium foil and 
immediately dropped into liquid nitrogen, where they were stored until 
use. 
Blood was removed from animals either from the tail vein or at 
the time of death by decapitation. It was collected into 20 ji] heparin-
ised capillary tubes. 
Urine was collected first thing in the morning by picking up the 
mouse and collecting the urine into a watch glass or capillary tube. 
(v) Extraction of tissues. 
(a) Liver. In preliminary experiments, the liver was extracted 
for histidase assay using the method of Kacser et al. (1973). This 
involved homogenisation in 3 x W/V 0.25 M sucrose/lmN EDTA/ lmN dithio-
threitol/ 50 niN Tris HC1 pH 7-4, using 5 up and down strokes of a Tn-
R glass-Teflon homogeniser (Cariilab), at speed setting 10. The homogenate 
was then centrifuged in an MSE Superspeed 50 centrifuge at 60,00t in an 
angle rotor for 30 minutes at 40C. The clear supernatant was used for 
histidase assays. In initial experiments it was found that EDTA was 
inhibiting histidase activity, as reported by others (Tabor and Mehler, 
1955; Okamura et al., 1974), so it was omitted from the homogenisation 
medium. Dithiothreitol was also omitted from the extraction medium 
since it did not enhance the activity of crude extracts. 





Figure 2:1 	Diagram showing dissection procedure for mouse brain. 
The portion containing the cerebral hemispheres and 
diencephalic structures (cerebrum). 
The portion containing pons and medulla oblongata, 
not used in the experiments cited. 
The portion containing the cerebellum is labelled. 
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In experiments on the development of histidase and histidine 
transaminase activity in mouse liver, the extraction method of Spolter 
and Baidridge (1963) was adopted. By using this, both enzymes could 
be assayed in the same sample. The liver was homogenised in 3 x W/V 
KC 0 1 14 N/NaOH 0°005 N, as described above. The homogenate was then 
centrifuged in an MSE Superspeed 50 centrifuge at 105,000 g for 60 
minutes at 14°C, using an angle rotor. The clear supernatant was 
aspirated and used for enzyme assays. Using this method, however, 
the mutant histidase activity was diminished or lost altogether. 
The method was retained for histidine transaminase assays but histidase 
was assayed separately after extraction in sucrose 0.25 N/Tris HCL 
20 mM pH 714. Addition of the protease inhibitor phenylmethylsuiphonyl-
fluoride (FNSF, Sigma) (Lumsden and Goggins, 1977) to the homogenisation 
medium at a concentration of 1-2 mM did not affect histidiase activity 
in +/-- or his/his mice. 
Skin. Skin histidase activity was extracted as follows. 
The shin was first minced with scissors, weighed and added to a fixed 
volume (5 - 10 x W/V) of ice-cold sucrose 025 M/Tris HC1 50 mM DH 7•14. 
Five 10 second applications of a Polytron tissue disrupter were used, 
followed by 12 up-and-down strokes with a glass-Teflon homogeniser, 
cooling the tube in melting ice. The homogenate was then centrifuged 
at 60,000 g for 30 minutes at 140C in an MSE Superspeed 50 centrifuge. 
The clear supernatant was used for assays. 
Brain. For histamine assays, the mice were killed by 
immersion in liquid nitrogen for five seconds followed by decapitation 
on to a plate chilled to 140C. The skull was opened and the brain 
rapidly removed and dissected as described above. The samples were 
weighed and homogenised in 5 x W/V sodium phosphate 0•01 N pH 7•9 / 
Triton X-100 0°1% with five strokes of a glass-Teflon homogeniser at 
speed 10. The homogenate was then boiled in a 100°C waterbath for 
ten minutes in a capped conical glass centrifuge tube, in order to 
destroy endogenous S-adenosyl methionine. The tubes were cooled and 
centrifuged in an MSE bench centrifuge (speed 10) for five minutes 
and the supernatant was frozen at -20°C until use. For histidine 
decarboxylase assays, brains were extracted as above except that the 
boiling step was omitted. 
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Brain samples stored in liquid nitrogen were extracted for 
assay of nucleic acid, protein and lipid fractions as follows. 
Samples were removed from the liquid nitrogen store, quickly 
weighed (frozen) and put into glass homogenisation tubes in 
melting ice containing 5 - 10 x W/V perchloric acid 0°2 N/ - 
aminoguanidinopropionic acid (AGFA) 1mM. They were homogenised with 
five strokes of a glass-Teflon homogeniser at speed 8. Samples 
were then left for 15 minutes on ice for the protein to precipitate 
out. They were transferred to 10 ml. conical glass centrifuge tubes 
and the homogenisation tubes washed with a known volume of perchloric 
acid 0°2 N/AGFA 1 inN. The tubes were centrifuged in an NSE Highspeed 
18 centrifuge at 2,500 g for 15 minutes at Lt°C (angle rotor). The 
supernatant was removed and the pellet washed in 1-2 volumes of 
perchloric acid 0°2 N/AGFA 1 mM and centrifuged at 2,500 g for 10 
minutes. The supernatants were combined and used for amino acid 
analysis alter removal of perchiorate. A second wash was then 
carried out with 15 - 20 volumes perchloric acid / AGFA which was 
discarded since it only contributed a further 2 - 3% to the amino 
acid concentration of the combined supernatant and first wash. The 
pellet was used for DNA, RNA, lipid and protein extraction. 
Blood. Blood samples from a heparinised capillary tube 
were expelled into a plastic test tube and mixed with distilled water 
and a known volume of internal standard, AGFA mM. The sample was 
vortexed in order to haemolyse the cells. An aliquot of 30% sulpho-
salicylic acid was added and the tube vortexed to precipitate protein. 
The sample was then stored at -20°C prior to amino acid analysis. 
The final mixture was therefore as follows:- 
0°02 ml. heparinised whole blood 
0°08 nil, distilled water 
0°05 ml. AGPA 1mM. Vortex to lyse cells. 
0005 ml. suiphosalicylic acid 30%. Vortex and store at -20 
0
C. 
Urine. Urine collected from a watch glass or capillary tube 
was put into a plastic test tube on ice. Protein was precipitated by 
adding one volume of 30% suiphosalicylic acid to two volumes of urine. 
The sample was vortexed and stored at -20 0C for analysis of urinary 
inildazoles and creatinine. 
110 
(vi) Enzyme assays. 
(a) Histidase. The assay method used initially was that of 
Kacser et al. (1973). This contained sodium phosphate buffer, 
0065M pH 9°4, reduced glutathione 5 inN, L-histidine HC1 0.13 N and 
0.05 - 010 ml. enzyme extract in a final volume of 1 ml. This was 
a discontinuous assay at 3000  over 15 minutes, which was stopped by 
addition of 1 ml. ice-cold trichloroacetic acid 10%.  A number of 
alterations were made. First, the assay buffer was changed to Tris 
HC1 (pK 8°08) 50mN pH 9°0 since the phosphate buffer (pK 7.2) was 
outwith its effective buffering range. Second, the histidine 
concentration used by Kacser et al. (1973) (133 inN) was considerably 
higher than that recommended by Tabor and I"Iehler (1953) (3rnN) or 
Spolter and Baldridge (1963) (33 inN). The high histidine concentration 
may have been necessary to overcome histidase inhibition by EDTA 
which was present in the original homogenisation medium. After 
omission of EDTA, a histidine concentration of 30 inN was used, which 
was about 50 times the Km for histidine. Third, the assay was changed 
to a continuous one, followed on a Beckman DB spectrophotometer at 
277 nm. This had the advantage over a discontinuous assay of ensuring 
that linear initial rates were being measured under all circumstances. 
Boiled homogenate blanks were found to be associated with a slight, 
but steady, decrease in absorbance at 277 nra., so blanks containing 
+/-i- liver extract without added histidine were used routinely. In 
the case of his/his liver extract without added histidine, a small 
but perceptable increase in absorbance was found, presumably because 
of the higher endogenous histidine concentration (0.16 - 0•33 inN in 
the assay mixture) since it disappeared after gel filtration. 
The assay method is based on the spectrophotometric assay of 
Tabor and Nehler (1955)  which makes use of the strong ultraviolet 
absorbance of urocanic acid. A molar extinction coefficient of 
18,600 M Cm was used to calculate the amount of urocanic acid 
formed. Activity was expressed as jimol urocanic acid/min. per g. wet 
weight or per mg. protein. The assay is dependent on a low or negligible 
rate of urocanic acid degradation by the next enzyme in the pathway, 
urocanase. This is achieved by assaying at a pH (ca.9) where urocanase 
is inactive. 
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Initial rates of histidase activity were found to be proportional 
to enzyme concentration in the range used (50 - 200 pl supernatant 
from a 25% homogenate). Assays were performed with and without 5 niN 
reduced glutathione and no difference in activity was found using 
crude liver or skin extracts. Glutathione was therefore not included 
routinely in the assay mixture. Addition of a divalent metal ion 
at 10 M was also without effect on the activity of crude extracts. 
Histidine aminotrarisferase. The assay method described by 
Spolter and Baldridge (1963) was used with one modification. It was 
found to be impossible to use the high concentration (0.57 M) of 
alkaline borate solution recommended by these authors, because the 
borate came out of solution at the temperature of the assay. A borate 
concentration of 038 M was therefore used. This solution was first 
warmed to about 50 0C to get it into solution, mixed with the assay 
constituents and allowed to equilibrate at 30°C before starting the 
reaction by addition of histicLine. The final reaction volume was 
3 ml. and contained 50 - 200 p1 enzyme extract, in which range the 
rate was proportional to enzyme concentration. The method depends on 
the ultraviolet absorbance of enol-borate complexes with aromatic 
ketoacids such as imidazole pyruvate. The reaction was followed 
continuously at 293 ma on a Beckman DB spectrophotometer at 300C. 
Blanith containing water instead of histidine'  were used in both 
genotypes. The reaction rate was linear for about 5 minutes only. 
A molar extinction coefficient of 12,000 M 1 Cm 1 for the enol-borate 
complex of iinidazole pyruvate was used. 
Histidine decarboxylase. This was assayed in brain samples 
using the method of Taylor and Snyder (1972). Aliquots of homogenate 
(12.5 - 50 p1) were added to 0005 M-sodium phosphate buffer, pH 6.5/ 
0o1% Tritoh X-100 in a 705  ml glass test tube on ice. Samples of 
homogenate containing two concentrations of added authentic histamine 
(2°5 and 500  ng) were also analysed routinely. The tubes were pre-
incubated at 37°C for five minutes and the assay started by addition 
of 12°5 il 0°1M L-histidine HC1/01 MM pyridoxal-5-phosphate. The 
final reaction volume was 125 i1. The samples were capped and incubated 
in a shaker bath at 37°C for various times up to 90 minutes. The 
incubation was stopped by immersion in a boiling water bath for 10 
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minutes. The tubes were then cooled and 25 pl 01N-Na0H was added 
to bring the pH to 709. The samples were then centrifuged in an 
MSE bench centrifuge (speed 10) for 15 minutes. An aliquot of the 
supernatant was frozen at -50°C before being assayed for histamine. 
All pipetting was carried out with Gilson automatic pipettes (P20 
or P200). 
(vii) Quantitative separation of acid-soluble, protein, lipid and 
nucleic acid fractions from brain samples. 
The method used was a modification of the Schmidt and Thannhauser 
(1915) 'procedure, based on the recommendations of Hutchison and Munro 
(1961) and Munro and Fleck (1966). Each assay contained equal numbers 
of -'-1± and his/his samples at the same developmental stage and brain 
region to minimise the effect of methodological variation. 
Samples were removed from storage in liquid nitrogen, weighed 
and extracted in 0°2N-perchloric acid/AGPA 1mM as described above. 
The acid soluble supernatant and first wash were combined and neutral-
ised by addition of potassium hydroxide, which resulted in precipitation 
of potassium perchiorate. The samples were left overnight at 40c to 
complete the precipitation and then centrifuged on an MSE bench 
centrifuge for three minutes (speed 10) and quickly returned to ice. 
The supernatant was removed and acidified with a small volume of HC1 
before being stored at -20°C for amino acid analysis. 
Lipids were extracted from the acid-insoluble pellet first by 
suspension with ice-cold 90% ethanol containing 2% sodium acetate. 
Sodium acetate was added to prevent losses of nucleic acid and protein 
during ethanol extraction following acid precipitation (Steele et al., 
196)4). The suspension was then centrifuged at 2,500g for 10 minutes at 
40C. The supernatant was removed and the pellet re-extracted with 
chlorofom:methanol (2:1 V/V). This was centrifuged as above and the 
sup ernat ant was combined with the ethanol extract. A third extraction 
with ether was carried out as above and the ether, chloroform and etharibi 
extracts combined. This "lipid fraction" was stored at -20°C prior to 
cholesterol assay. 
Alkaline hydrolysis of the lipid-free pellet was carried out to 
separate the RNA. from DNA and protein fractions. The white powder 
remaining after ether extraction was suspended in 0-3N-potassium 
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hydroxide (after first mixing the pellet with 50 - 100 p1 03N-
perchioric acid to aid solubilization). The sample was then 
incubated at 37°C for one hour, stirring frequently with a glass 
rod. A small aliquot (100 pl)  was removed at the end of the incubation 
for protein estimation and the remaining sample was put into an 
ice bath for 10 minutes. This was then acidified with 1°2N-. 
perchioric acid and left standing in ice for 15 minutes to precipitate 
DNA and protein, which are resistant to alkaline hydrolysis under 
these conditions. Samples were centrifuged on an MSE bench centrifuge 
(speed 6) for five minutes at room temperature and returned to ice. 
The supernatant was removed and the pellet washed with cold perchioric 
acid to give a final perchiorate concentration of 0°3N. The wash was 
combined with the previous supernatant as the "RNA fraction" and the 
volume of this fraction recorded. RNA analysis was carried out on 
the same day. 
The acid-insoluble residue from the previous step was then 
extracted in hot perchioric acid to quantitatively hydrolyse the 
DNA to acid-soluble nucleotides, thus separating DNA from protein. 
The pellet was suspended in 1N-perchloric acid and heated in a water-
bath at 70°C for twenty minutes with frequent stirring. The samples 
were then removed from the bath, allbwed to stand at room temperature 
for one minute and put into ice for 10 minutes. They were centrifuged 
on an MSE bench centrifuge (speed 10) at room temperature for five 
minutes. The supernatant was removed. This procedure was repeated 
and the supernatants combined to form the "DNA fraction". The volume 
of this fraction was recorded. DNA assays were set up on the day of 
extraction and read the following morning. 
In preliminary experiments, the RNA concentration of brain samples 
was estimated after varying periods of alkaline hydrolysis. RNA was 
estimated both by the orcinol reaction and by measuring the absorption 
at 260 nM. The RNA concentration was found to reach a plateau within 
30 minutes of alkaline hydrolysis, thereafter remaining constant for 
up to two hours. In another experiment, acid hydrolysis in 1N-perchioric 
acid was carried out either once for 20 minutes at 700C,followed by a 
wash, or twice for 20 minutes at 70°C, as described above. Samples 
extracted twice at 70°C had DNA concentrations 1 5% higher than those 
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extracted once, so this procedure was adopted. 
(viii) Determination of creatinine, amino and imidazole acids. 
These compounds were separated on a modified Techriicon automated 
amino acid analyser. Amino acids were determined after reaction with 
ninhydrin on the basis of the amino acid peak area relative to that 
of the internal standard AGPA, added to samples during extraction. 
The relative peak sizes of equimolar amounts of amino acid and AGFA 
at 570 nN were determined to give a "colour value" for each amino 
acid (Table 2:1). The amino acid concentration was calculated as 
follows:- 
amino ino acid peak area x ilmol AGFA added to sample x colour value 
AGFA peak area x sample weight or volume 
Samples were routinely deproteinized before chromatography using 30% 
sulphosalicylic acid, in the case of blood and urine samples, or 
perchioric acid for brain samples. The perchlorate was later 
precipitated out as described above prior to ion-exchange chromatography. 
The internal standard method helped to reduce errors due to variation 
in sample loading and sensitivity. 
Imidazole acids (histidine:  N-acetyl histidine, imidazole lactate, 
imidazole pyruvate imidazole acetate) were determined by the Pauly 
(Diazo) reaction using diazotized suiphanilic acid (MacPherson, 19)42) 
and the same elution programme as for amino acids. Creatiriine was 
measured simultaneously with imidazole acids by time-switching the 
column effluent into a line carrying alkaline picrate reagent 
(Faulkner and King, 1970) for long enough to measure the creatinine 
peak at 520 n. The effluent was then switched back to the Pauly 
reagents. Creatinine chromatographed just after histidine. Standard 
curves were constructed by loading different concentrations of the 
authentic compounds. The urinary amino and imidazole acid concentrations 
were expressed in terms of the creatinine concentration. It was 
necessary to assay creatinine after ion-exchange chromatography rather 
than directly on deproteinized samples, because a number of compounds, 
including histidine, present in tissue or urine extracts were found 
to react with the creatinine chromogen (see also Polar and Metcoff, 
1965). Histidine has been reported by Cook (1975) to interfere with 
the determination of creatinine in unchromatographed samples. Initially, 
TABLE 2:1 
Relative peak sizes of equimolar 
amounts of amino acids and AGPA 
at 570 nra. after reaction with ninhydrin 





glutamic acid 0•77OL 
'-aininobutyric acid 09245 
* AGPA area (ipmol) 
AA 	area (i jmiol) 
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an attempt was made to express urine concentrations in terms 
of the 24-hour urinary creatinine excretion, to correct for 
variation in urinary dilution. This was abandoned because of 
the difficulty in obtaining uncontaminated 24 hour urine collections 
in mice. Two reports have showed that little or no variation in 
creatinine excretion occurs throughout the day in humans (Gitlow et 
al., 1965; O'Gorman, 1968). This supports the notion that creatinine 
is produced at a virtually constant rate from muscle creatinine. 
Creatinine estimation in random urine samples (as used in the experiments) 
should therefore be a useful measure of urinary dilution. 
(ix) Determination of histamine. 
There have been considerable problems in finding a specific 
and sensitive method for estimating histamine, which has led to 
the relative neglect of this amine in comparison with other biogenic 
amines (Green, 1970; Taylor,  1975).  The recently introduced radio- 
enzymatic assay of histamine is reported to be simple, specific and 
sensitive (Taylor, 1975; Beaven,  1975).  Although a double-isotope 
method was used initially, a single-isotope modification has been 
widely adopted (Taylor and Snyder, 1972;  Kobayashi and Maudsley, 
1972; Brownstein et al., 1974;  Beaven, 1975; Orr and Quay,1975; 
Thomisto, 1977). The principle of the assay is to methylate histamine 
with a radioactively-labelled methyl donor (S-adenosyl methionine, 
SAM) by means of a highly specific enzyme (iniidazole-N-methyltransferase, 
iN1IT). An organic extraction is then used to separate histamine and 
SAM from the radiolabelled product, 1,4-methylhistamine. 
The method described by Brownstein et al. (1974) was adopted. 
Glasswear was cleaned with detergent, soaked overnight in acid, rinsed 
twice in distilled water and dried before use. Stock solutions of 
hitamine dihydrochloride were made up in distilled water at 1 mg/mi. 
and stored in aliquots for one month at -200C. S-adenosyl-L- (methyl- 
3H) methionine (7°5 - 122 Ci/mmol) was stored in liquid nitrogen in 
suitable aliquots which were only thawed once. A 10 jil tissue sample 
was mixed with 10 ill  005N-sodium phosphate buffer pH 79 in a 7•5 ml 
glass screw-cap test tube on melting ice. The reaction was started 
by adding 10 }11 of a mixture containing 005 il 05N-sodium phosphate 
pH 801 2 pl (i iCi) [3H2-SAM and 705 Ill INMT which was partially 
purified from guinea pig brain as described below. The buffer and 
enzyme were mixed together before addition of [3H2 SAM. The tubes 
were incubated at 37°C in a shaker bath for varying periods of time. 
The method of Brownstein et al. (1974) used a 30 minute incubation 
routinely, but this was changed to 60 minutes since a time course 
experiment showed that methylation was not quite complete by 30 
minutes but was completed by 60 minutes, remaining the same at 90 
minutes. The reaction was stopped by addition of 25 jil 01N-
perchioric acid containing 1,4-methyl-histamine 1 mg/ml (Calbiocheni) 
as a carrier. The sample was vortexed and put onto ice. 3N-sodium 
hydroxide (0°5 ml) was then added to each tube followed by 5 ml 
chloroform. The original method used 6 ml chloroform but 5 ml gave 
better mixing and did not alter the recovery of labelled products. 
Tubes were capped and shaken mechanically for five minutes in a 
commercial flask shaker. Samples were then centrifuged in an MSE 
bench centrifuge (speed 10) for five minutes. This gave a clear 
separation into two phases, with the precipitated protein at the 
interface. Strong alkali is used in the extraction to increase 
the partition of methylhitamine into the organic phase. The upper 
aqueous phase was aspirated and discarded. 3N-sodium hydroxide 
(1 ml) was then added to each tube, which was shaken mechanically 
for a further five minutes and centrifuged as above. The aqueous 
phase was discarded and 4 ml of chloroform was transfered to a glass 
scintillation counting vial. This was evaporated to dryness at room 
temperature under a stream of air. A manifold acconiodating ten tubes 
was cohstructed for this purpose. Scintillant containing ethanol 
(1 ml) and toluene based PPO 0°4% and POPOP 0.01% (10 ml) was added 
to each vial after reaching dryness. Evaporation was complete within 
about 30 minutes. Samples were then counted in a Packard Scintillation 
Counter. 
The number of counts per minute was found to be proportional to 
the amount of authentic histamine added in the range 0°02 ng to 2 ng. 
Sensitivity (twice blank) was about 01 ng. Buffer blank counts were 
in the region of 2,000 CPM and 2 ng histamine gave about 60,000 CPM 
above the blank. Addition of internal histamine standards to brain 
extracts gave a recovery of 80 - 100% of counts obtained in the 
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absence of tissue extracts. 
A time course experiment, measuring histidine decarboxylase 
(HDC) activity in brain samples was carried out using the above 
method for assaying histamine. It became apparent that the HDC 
reaction product (histamine) was not being formed linearly with 
time. Instead, it reached a plateau within five minutes of adding 
the substrate (histidine) and remained relatively constant there-
after. The plateau counts exceeded the amount of endogenous 
histamine in the sample by up to 60-fold; When the product of the 
histamine assay was chroinatographed with ethyl acetate-butanol-
glacial acetic acid-water (1:1:1:1), two radioactive peaks were 
found, instead of the expected single peak corresponding to 1,4-
methylhistamine. One of these products corresponded to authentic 
1,1-methylhistainine with an Rf value of 077.  The other more 
rapidly migrating product (IIXI!)  (Rf = 0.92) had about ten times the 
number of counts found in the rnethylhistamine peak. Similarly, 
when authentic histamine was assayed by the above method in the 
absence of tissue extract, the organic extract was chromatographed 
and the same two radioactive peaks were found. Chromatography of 
the radioactive substrate (3H) SAM in the above solvent system 
showed that 86% of the total counts corresponded to authentic SAM 
(compared with 95 - 98% radiochemical purity on dispatch from the 
suppliers). The remaining counts were in a peak with an Rf value 
similar to the unidentified radioactive product "X" of the histamine 
assay (Rf = 0.90). However this radioactive impurity was not simply 
extracted into the organic phase and carried through the assay. 
Firstly, buffer blank counts were considerably lower than sample 
or standard counts (see above). Secondly, histamine standards were 
assayed in the presence and absence of the lIMP enzyme: in the 
presence of IN11T 1 ng histamine gave 61,187 CPM compared with 550 
CPM without INNT. The corresponding buffer blanks gave 996 CPM 
(+ INMT) and 508 CPM (- INNI). The radioactive product !!xt? was 
therefore dependent on the presence in the assay mixture of authentic 
histamine or brain tissue,(311) SAM and lIMP extract. SAM is reported 
to be rather unstable, particularly at alkaline pH (Beaven, 1 975 
Product Information, Radiochemical Centre, Arnersham). Several (3H) 
IN 
containing derivatives are possible. SAN is readily cleaved between 
the sulphur atom and the carbon chain of the amino acid residue to 
form thiomethyladenosine and homoserine (Baddiley et al., 1953). 
Thiomethyladenosine (Sigma), homoserine, 1,1v-methylhistanhine, 1,5-
methylhistamine, methionine and histidine were all chromatographed 
in ethyl acetate-butaflol-glacial acetic acid-water (1:1:1:1) (Table 
2:2). The chromatographic methods are described below. Two products 
were identified on chroriatographing thiomethyladenosifle, with Rf 
values of 067 and 0.88. Both had spectral maxima at 260 nN, 
suggesting that they could be adenine and thioniethyladenosine, 
although this was not verified. 
Two possible sources of the unidentified, enzymatically formed 
product X" were examined. First, it was possible that the other 
(3H) labelled reaction product, 1,4-methylhistamine, was being 
metabolised further by the next enzyme in the pathway, monoamine 
oxidase, which could also be present in the IN1'fl extract. The 
assay was therefore carried out in the presence and absence of a 
monoamine oxidase inhibitor, iproniazid", at a concentration of 
5 inN. When the reaction product was chromatographed, the same two 
radioactive peaks were found and the relative counts in the two 
peaks was unaltered by iproniazid. Secondly, the possibility that 
the decarboxylated derivative of (3H) SAM(S_(5_adenosyl)_3_(3H)methYl_ 
xnercaptopropyla.mineJ was acting as a propylamine donor to histamine, 
methyihistainine or a polyamine (e.g. putrescine, spermidine) present 
in brain extracts, was investigated. A propylamine transferase 
enzyme is present in brain tissue and could have been present in the 
IN-PIT extract. Although polyainines are known to be propylamine 
acceptors the possibility that inethyihistamine can also be an 
acceptor has not been reported. The expected radioactive products 
would include (3H) thiome±hyladenosine, which appeared to chromato- 
graph in the same region as the unidentified product flXt, (See Table 2:2). 
* This compound was synthesized and donated by Dr J.C. Emmett of 
Smith, Kline and French Laboratories Limited, Welwyn Garden City. 
3-ii- Donated by Dr R.N. Smith of Roche Products Limited, Welwyn Garden 
City. 
TABLE 2:2 
R  values of substances chroinatographed in ethyl 








1,4-methylhistamine 077 0•04 7 
1,5-inethylhistaznine 0•79 - 1 
histamine assay products (1) 0o75 0o05 9 
(2) 	"XI! 0o92 0•02 
histamine 073 - 1 
histidine 0•49 - 1 
niethionine 0o83 0o02 2 
hoinoserine 067 - 
S-adenosyl niethionine 0•42 0•01 3 
S-adenosyl (methyl 3H) methionine (1) 0•41 - 1 
(2) O•90 - 
thiomethyladenosine (i) 0o67 - 1 
(2) 0.88 - 
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Putrescine (2 mM), sperinidine (2 inN) and methylhistaniine (30 JIM) 
were incubated instead of histamine and carried through the assay 
procedure. The number of counts in the final assay products were 
63 cpni with putrescine, 1383 cpm with sperniidine and 1080 cpxn with 
methylhistamine after subtraction of buffer blank counts. None of 
these counts were high enough to account for the previous findings. 
The histamine assay was being developed to measure histidine 
decarboxylase activity and the histamine concentration in urine 
during pregnancy and in the developing brain. Because of the above 
difficulties, the assay was abandoned. 
Paper chromatography. 
After evaporating the chloroform extract from the histamine 
assay to dryness, it was taken up in 100-200 il ethanol. 10 - 
20 jil aliquots were spotted on to Whatinan No. 1 chromatography paper, 
dried and equilibrated with the solvent system in a closed tank for 
thirty minutes. The sample was then cliroinatographed for 15 - 18 hours 
at room temperature. The paper was afterwards removed from the tank 
and dried in a fume cupboard with a hair drier. It was cut into one 
cm strips, which were put into glass scintill ation vials. One ml 
ethanol and 10 ml toluene scintillant containing PPO o)% and POPOP 
ooi% were added and the samples counted in a Packard Scintillation 
Counter. The solvent system used was ethyl acetate / butanol / glacial 
acetic acid / water (1:1:1:1). Ristidine, honioserine, methionine, 
SAM, histamine and methylhistamine were all identified by spraying 
the dry paper with 0'1% Ninhydrin in n-butanol (saturated with water). 
Tliiomethyladenosine was identified by eluting 1 cm strips of the 
chromatographic paper into three ml distilled water and reading the 
absorbance at 260 rim. The Rf values of standards and unknowns run 
in this system are shown in Table 2:2. 
Determination of nucleic acids. 
Ribonucleic acid (RN) was determined by the orcinol reaction 
and checked by measuring the ultraviolet absorbance in perchloric 
acid extracts. The orcinol reaction (Ceriotti, 1 955) was carried out 
by diluting the sample with 0°36N-perchloric acid to a volume of 3 ml 
and adding 3 ml freshly made reagent (orcinol 0o2 g + 10 nil CuCl2 
0.0014 M in conc. HC1). The mixture was vortexed and put in a constant 
so 
volume boiling water bath for 40 minutes then returned to ice. 
The green colour was concentrated by adding 3 ml isoamyl alcohol 
and the tubes were vortexed. They were then centrifuged in an 
MSE bench centrifuge (speed 6) for five minutes. An aliquot of 
the upper organic phase was removed and its absorbance read at 
675 iiM in a Beckman DB spectrophotometer. A standard curve was 
constructed using yeast RNk (Sigma) which gave a linear relation-
ship in the range 5 - 60 jig/mi. The RNA estimations were checked 
by measuring the ultraviolet absorbance of perchlorate extracts. 
Samples or standards were made up in 0'36N-perchloric acid and the 
absorbance at 260 nN and 232 nN was read. The reading at 232 nN 
was used to correct for small amounts of hydrolysed protein present 
in samples, as suggested by Fleck and Begg (1965). The RNA concen-
tration was calculated from the formula:- 
C RNA 
a A260 - b A232  
- where a and b are constants, A260 is the absorbance at 260 riM and 
A232 the absorbance at 232 riM. The constants were estimated from:- 
a 	 and b= r1-r2 P 	 r1 P -r 2 
1 
- where r1 and r2 are the specific extinction coefficients of RN!1 
at 260 riM and 232 riM respectively. The values for r and r using 
yeast RNA were found to be 200°7 (E 26o  and 60•7 (E 232 	
P1 and 
P2 are the specific extinction coefficients of the acid-soluble 
polypeptide contaminants at 260 nN and 232 riM. The ratios P1/P2 were 
estimated by measuring the absorbance of acid-insoluble proteins 
(dissolved in 0"3N-KOR) remaining at the end of the acid hydrolysis 
step, rather than the absorbance of acid-soluble polypeptides contamin-
ating the RNA fraction. The ratio A260/A232 was therefore used to 
estimate P1 /P2 and its reciprocal to estimate P2/F1. RNA concentrat-
ions were determined by this method in brain samples at the 6, 15 
and 24 day stages and gave comparable results to those obtained with 
the orcinol reaction. 
Deoxyribonucleic acid (DNA) was determined by the diphenylamine 
reaction using the method of Richards (1974). This has been reported 
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to have advantages over the methods of Burton (1 956) or Giles 
and Myers (1965) in the increased stability of the reagent,. 
increased sensitivity, lowered reagent blanks and shorter 
overall procedure. A 1 nil aliquot of the perchioric acid extract 
("DNA fraction") was added to 2 ml Diphenylamine Reagent (diphen-
ylainine 1.5%,  paraldehyde 0.01% in glacial acetic acid). The 
colour was allowed to develop at room temperature for eighteen 
hours and read at 600 nM on a Beckman DB spectrophotometer. Stock 
solutions containing 100 ig/ml calf thymus DNA (Sigma) were hydrol-
ysed by heating at 70 C for 20 minutes in 1N-perchloric acid and 
stored at L°C. A standard curve was run with each set of samples 
in the range 10 - 100 jig/ml. 
Determination of cholesterol. 
Cholesterol was determined by the method of Zak (1957) based 
on the Lieberniann-Burchard reaction. Lipid fractions stored at 
-20°C were evaporated to dryness over a water bath at 400C in a 
rotary evaporator and then dissolved in 5 ml glacial acetic acid. 
Two ml of the colour reagent (FeCl.36H20 1.1 g in 1 litre glacial 
acetic acid) was added to 2 ml sample in glacial acetic acid and 
vortexed. After standing at room temperature for 15 minutes, 2q67 nil 
concentrated sulphuric acid was added and the tube vortexed. After 
30 minutes at room temperature the absorbance at 560 n14 was read on 
a Beckman DB spectrophotometer. A standard curve was run with each 
batch of samples, using concentrations of authentic cholesterol 
(Sigma) in the range 0"01 - 0.125 mg/nil which gave an approximately 
linear relationship. A stock solution containing 1 mg/nil cholesterol 
in glacial acetic acid was stored at room temperature. The method 
is not completely specific for cholesterol since it also measures 
the cholesterol precursor desmosterol, and cholesterol esters, which 
are, however, only present in small amounts relative to cholesterol 
in the developing brain (Davison, 1968, 1970). 
Determination of protein. 
Protein was determined by the method of Lowry et al. (1 951). 
The sample was made up to a suitable concentration with water or 
buffer and to a final volume of 0°4 ml. Two ml of solution "C" 
[50 nil of solution "A" containing 20 g anhydrous sodium carbonate, 
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g sodium hydroxide and 0°2 g hydrated sodium potassium tartrate 
in a 1 litre volume, plus 1 ml of solution 1Btt containing 2°5 g 
hydrated copper sulphate in a 05 litre volumeJ was added to the 
sample and vortexed. This was allowed to stand for 20 minutes at 
room temperature. Then 02 ml of the Folin-Ciocalteau Reagent 
(freshly diluted 1:1 with water) was added and vortexed immediately. 
After 30 minutes at room temperature, the absorbance at 750 nM was 
read on a Beckman DB spectrophotometer. Standard curves were prepared 
from dilutions (10-1400 jig/ml) of a stock dilution of bovine serum 
albumen (Sigma) containing 014 mg/mi. The stock solution was stored 
in aliquots at -20 
0C. Standard arid blanks containing buffer or 
distilled water were run with each batch of samples. 
Determination of water content. 
Brain samples were removed from the liquid nitrogen store and 
allowed to warm to room temperature in a dessicator. Samples were 
then put on to squares of aluminium foil of known weight and weighed. 
They were then dried to constant weight in a 60°c oven. 
Desalting. 
Liver supernatant was put into Visking dialysis tubing and 
dialysed overnight at 140c against sodium phosphate buffer 001 M 
pH 7.14 containing dithiothreitol 1 mM. The wild-type enzyme lost 
30 - 140% of its activity and the mutant enzyme 80 - 90% of its 
previous activity following dialysis. Since commercially obtained 
dialysis tubing may be contaminated with proteases and suiphydryl 
compounds, the mutant histidase activity was compared before and 
after dialysis in tubing previously boiled for 15 minutes in distilled 
water compared with dialysis in imboiled tubing. This experiment 
showed a complete loss of activity in the unboiled tubing and 50% 
loss of activity after dialysis in boiled tubing. The loss of activity 
was not reversible by preincubation with 2 mN glutathione. Substitution 
of Tris for phosphate buffer in the dialysis medium was also without 
effect. Desalting in this way was effective in that the pre-dialysis 
his/his liver extract had a histidine concentration of 19°1 jimol/g wet 
weight while the post-dialysis extract contained no detectable histidine. 
However, the marked loss of mutant histidase activity led to the 
development of an alternative method. 
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Desalting by gel filtration was then tried, since this procedure 
is rapid and suitable for unstable proteins. Sephadex G_25 granules 
(coarse, 100 - 300 mesh) were swollen and applied to a Pharinacia 
column sized 1 -6 x 28 cm. This was then equilibrated with Tris HC1 
0o 05 M pH 9 buffer. A sample of crude liver extract in a volume less 
than 20% of the bed volume was applied to the column in a cold room 
and eluted at a flow rate of 0°4 ml/min. Thirty diop fractions were 
collected in a Gilson fraction collecter and the reddish coloured 
fractions were pooled and concentrated through a Column KLuate 
Concentrator (CEC-1, Aniicon). With this technique, the histidine 
concentration of his/his liver extracts was again reduced to below 
the limit of detection but without significant loss of activity. 
(xvi) &izyine purification procedures. 
Imidazole-N--methyltransferase (INMT). This enzyme was partially 
purified for the radioenzymatic assay of histamine by the method of 
Brown et al. (1959) modified by Snyder (1971). Six adult male guinea 
pigs were killed by carbon dioxide inhalation and decapitation. The 
brains were rapidly removed and pooled on ice before being weighed. 
All procedures were carried out at 40C. The brains were homogenised 
in ten volumes of ice-cold sucrose 025M in a blender, then with 5 up-
and-down strokes of a glass-Teflon homogeniser (speed 10). The pooled 
homogenate was centrifuged at 78,000 g in a refrigerated MSE Highspeed 
50 centrifuge (angle rotor) for 30 minutes. To 180 ml of the clear 
supernatant, 50 g ammonium sulphate (grade I, Sigma) was added with 
stirring (45% saturation). The solution was stirred for 15 minutes 
on ice and left to stand for 60 minutes. It was then centrifuged 
at 101000 g for 20 minutes. The supernatant was removed and 33 g 
ammonium sulphate was added (70% saturation). This was stirred for 
15 minutes and left to stand for 60 minutes on ice before centrifuging 
at 10,000 g for 20 minutes. The supernatant was decanted and the 
precipitate dissolved in 25 ml sodium phosphate buffer 0°01M pH 7.4 
This was dialysed overnight at 40C in Visking Dialysis tubing (size 
18-32, boiled for 15 minutes previously) against two litres of sodium 
phosphate buffer 0°001M pH 7°4. The final extract was stored in 200 il 
aliquots at -50°C. 
Mouse liver histidase. The reported methods for purifying 
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mammalian histidase (Mehier and Tabor, 1953;  Kato et al., 1955; 
Cornell and Villie, 1968; Okamura et al., 19714; Lamnartiniere and 
Feigelson, 1975;  Brand and Harper, 1975, 1976) are unsuitable for 
purifying the mutant enzyme, which is likely to differ from the 
wild-type in its stability and chromatographic properties. Most 
procedures use a heat step and ammonium sulphate fractionation in 
the early stages, both of which are likely to result in a marked 
loss of activity, without achieving more than a three or four fold 
purification. Since overnight storage of the mutant enzyme at 140C 
also results in loss of activity, it was felt that a short non-
denaturing technique was required. 
The first attempt to solve this problem was to use gel filtration, 
since this offered a relatively rapid means of achieving a limited 
purification, under conditions in which the enzyme should be stable. 
Sephadex G-150 (140-120 i diameter, Pharmacia) is suitable for fraction-
ating proteins in the range 5,000 - 1400,000 daltons (cf. histidase 
molecular weight ca. 200,000 daltons). A Pharmacia column sized 
2°7 x 146 cm was packed with swollen Sephadex G-150 gel particles and 
equilibrated with Tris HC1 0002M pH 7-4/NaCl 01N/dithiothreitol 0.3 
mN/MgC12 1mM, in a cold room. A 5 nil sample of crude liver supernatant 
(2 of the bed volume) was applied to the column and eluted with 
buffer at 016 ml/min using a peristaltic pump. The column eluate 
was run through a Uviscan recorder which measured the absorbance of 
the eluate at 2514 nM. The eluate then passed through a Column Eluate 
Concentrator (CEC-1, Amicon) set at a concentration ratio of 14:1. One 
ml fractions were collected in a Gilson fraction collector. Fractions 
were then assayed for histidase activity. Histidase activity from 
±1-i- extracts was found to elute near the front of the protein peaks 
(Figure. 2:2). The five fractions containing most activity were found 
to be the first five turbid fractions, which were combined and assayed 
for histidase and protein content (Warburg-Christian method) in 
comparison with a sample taken prior to gel filtration. The purification 
achieved with this method is shown below:- 
i4. I' if O 42 *at 1.4 IIJ 30 Ii 34 
Fraction number 
FIG. 2:2 Gel filtration of +/+ liver extract on Sephadex G-150.  Histidase activity (change in A277 per minute) X- - -X. 
Protein concentration (A25 ) 	. The sample was eluted and collected as described in the text. 
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Specific activity 
+/+ liver extract - - (nmol./min./mg. protein) Total Units 
Before gel filtration 3°22 500.7 
After 	gel filtration 12°12 1426.5 
This achieved a four-fold purification with 85% recovery in ±/±_ extracts. 
The same procedure was repeated with the mutant enzyme. A similar 
elution profile on the tJviscan was obtained. Since the his/his enzyme 
was expected to chromatograph in the same way as +/+ extracts on 
Sephadex (since it depends largely on molecular size), the first five 
or six fractions containing visible turbidity were pooled, as with 
the ±/± enzyme. The combined fractions were then assayed for histidase 
and protein as before, together with a sample taken before gel filtrat-
ion. The results are shown below:- 




Before gel filtration 0052 6.8 
After 	gel filtration 0 151 3.5 
This represents a three-fold purification with 51% recovery. It also 
showed that at least half the mutant histidase chromatographed on 
Sephadex G-150 in the same region as wild-type histidase. 
An alternative method of partial purification was suggested by 
a communication from W.C. Hanford and S.M. Arfin, who had purified 
mouse liver histidase 500-fold (later published in Hanford and krfin, 
1977). The procedure started with a protamine sulphate precipitation, 
which gave a twenty-fold purification and 90 - 100% yield, in a single 
step. The method was used with some minor modifications which are 
described below. 
Female mice were killed by stunning and cervical dislocation. The 
liver was rapidly removed and put on to aluminium foil on ice. After 
weighing, 3 x w/v Tris HC1 005M pH 7°14 /MgCl2lmN/ sucrose 025M was 
added and the samples homogenised with five strokes of a glass-Teflon 
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homogeniser. The homogenate was then centrifuged at 100,0009 
for 30 minutes in an MSE Highspeed SO centrifuge at )4°C. The 
clear supernatant (SN) was removed and the volume measured and 
assayed. One fifteenth volume of 2% protamine sulphate (Sigma, 
grade II, freshly prepared in distilled water, unneutralised) was 
added drop by drop to the stirred supernatant, in an ice bath. The 
sample was then centrifuged at 25,000g for 20 minutes at 40C. This 
supernatant (SN-1) was found to contain little active enzyme and so 
was discarded in subsequent experiments. The pellet was extracted 
first with one sixth the original extract volume of Pipes 50 inJi 
PH 7°2/MgCl21mN/NaC1 40 inN. The extract was then centrifuged at 
25,000g for 20 minutes at 40C.  The supernatant (SN-2) was removed 
and kept on ice. The pellet was then extracted with one tenth the 
original extract volume of Pipes 100mM pH 7°2/NgC12151M/NaCl 200 mM. 
The extract was centrifuged at 25,000g for 20 minutes at 14°C and 
the supernatant (SN-3) removed. Aliquots of each fraction were 
assayed for histidase activity and protein. The results obtained 
with +/+ liver extract are shown below:- 
liver extract 




100,000 g SN 3729 33 12306 
SN-1 - - - 
SN-2 109 3.7 40-4 
SN-3 136 149.3 669°9 
The ±/+ histidase activity was found predominantly in the SN-3 fraction, 
extracted from the protamine sulphate precipitate at high ionic strength, 
giving an approximately fifteen-fold purification and 514% yield. It 
was not clear why the yield was lower than that of Hanford and Arfin 
(1977). 
The same procedure was applied to 	liver extracts. The 








100,000 g SN 6316 0.06 3709 
SN-i 5800 0.01 58 
SN-2 235 2•2 51.7 
SN-3 37.5 1•9 71 0 3 
Mutant histidase activity is found almost equally in SN-2 and SN-3 
fractions in this experiment. Unmasking of mutant activity occurs 
since the total units increase by a factor of three after protamine 
sulphate precipitation. This could be the result of the removal of 
urocanase activity, although this was not verified. In general, the 
effect of urocanic acid removal by another enzyme will be greater with 
low histidase activity than with high activity. In the wild-type, 
recoverable enzyme activity did not increase on purification. The 
specific activity of mutant histidase increased thirtyfold with this 
procedure. In SN-3 extracts, the specific activity was variable, 
ranging from 0 to 46 nmol/min./mg. protein in four experiments. 
This variation may have been due to differences in the duration of 
exposure to the high ionic strength extraction buffer. 
Since the protamine sulphate method achieved a better increase 
in histidase specific activity it was used in preference to the gel 
filtration method to contrast the mutant and wild-type enzymes. 
(xvii) Disc Electrophoresis. 
Analytical polyacrylamide gel electrophoresis was carried out 
by the procedure of Davis (1964). The electrophoresis reservoirs, 
gel tubes and electrodes were made by Shandon Southern. The gals 
were prepared from the Davis stock solutions "A" to !?F!I • A 7% small-
pore gel was prepared by mixing 2 ml solution "A" with 4 ml solution "C" 
and 2 ml distilled water. The solution was mixed and degassed under 
vacuum. 1-3 ml of this solution was rapidly pipetted into a series of 
6 rim (i.d.) x 65 mm plastic gel tubes, sealed at the lower end with 
Parafilm. The gels were then carefully overlayed with distilled 
water (or Tris HCl 038M pH 89 if prepared the night before) 
using a 1 ml syringe (23G needle). 	The tubes were placed vertically 
in the reservoir grommets and allowed to polymerise for 30 - 60 
minutes at room temperature. The 3% large-pore gel was prepared 
by mixing 005 ml solution IIBII, 1 ml solution "D", 0.5 ml solution 
11E't and 2 ml solution "F". The solution was degassed as before. 
The gel tubes were given a preliminary rinse with a small volume 
of this solution, which was then discarded and 0.15 nil was pipetted 
into each tube and carefully layered with water. The gel tubes were 
positioned vertically in the reservoir grommets and allowed to poly-
merise under an ultraviolet light for about 60 minutes. The Parafilni 
was removed and the gel tubes and reservoirs placed in a cold room 
at b°c. The reservoirs were partially filled with two litres of ice-
cold Tris glycine pH 83 reservoir buffer (diluted 1:10 prior to use). 
After cooling the gels for one hour the samples were applied to each 
gel. Samples were prepared in two volumes of Lo% sucrose containing 
5 il of 0o05% bromophenol blue marker dye (0.1% in initial experiments) 
and applied to the gels using a plastic-tipped Gilson pipette. The 
samples were carefully overlayed with Tris glycine buffer and the 
upper reservoir filled with the remaining buffer. Bubbles of air 
were removed from the bottom of the gels with a syringe. The electrodes 
were placed into the reservoir and connected to a Vokam stabilised 
DC power pack (Shandon Southern) set to deliver a constant current 
of 1-5 - 2.0 mA per tube. The current was switched off when the 
bromophenol blue marker was close to the bottom of the gel tube 
0 - L hours). The gels were rimmed with a blunt needle and propelled 
out of each tube with an air-filled syringe. The position of the 
bromophenol blue tracking dye was marked by cutting the gel with a 
scalpel. The gels were kept on ice until assayed for histidase activity. 
In a preliminary experiment the gels were removed and frozen on dry 
ice. The frozen gels were then cut into 1 miii slices with an automatic 
gel slicer. Gel slices were then immersed overnight in ice-cold buffer 
and crushed to elute the enzyme, which was later assayed for histidase 
activity. 
The position of the histidase band was routinely detected by a 
method based on that of Hassall et al. (1970). These workers detected 
59 
histidase on polyacrylaimide gels by photographing the gel in a 
medium containing histidine with transmitted ultraviolet (UV) 
light. The position of histidase is indicated by the appearance 
of a 1111.-absorbing band because of the high extinction of urocanate 
at 277 nm. In these experiments, the gel was placed in a quartz 
cuvette and overlayed with 7 ml Tris HC1 0°02M pH 9 (diethanolamine 
buffer was used initially) containing 10% sucrose. The gel was 
equilibrated with this mixture for five minutes before addition 
of 1o5 ml histidine HCl 018M pH 9, which was mixed with the buffer 
using a pipette. A clock was started on addition of histidine and 
the cuvette containing the gel was then scanned with a Joyce-Loebl 
chromoscan containing a liv light source and 24 nm filter. The gel 
was scanned at regular, timed intervals. Each scan was recorded on 
a chart recorder. The position of the histidase band became apparent 
within a few minutes in gels containing ±/+ extract by a sharp increase 
in the UV absorbance. After about fifteen minutes, the band broad- 
ened markedly, due to diffusion, which decreased resolution. Gels 
were stained for protein by immersion in 1% naphthalene black (BDH) 
in 7% acetic acid for 30 - 60 minutes and destained in 7% acetic 
acid. Stained gels were scanned on a Kipp and Zonen (KS3 damLscan) 
microdensitometer. 
CHAPTER 3 
DEVELOPMENT OF THE HISTIDINAEMIC MOUSE I ENZYME AND METABOLITE PROFILES 
The status of the histidine catabolic enzymes and their major 
products have been well characterised in the adult his/his mouse 
(Kacser et al., 1 973; Bulfield and Kacser, 1974, 1 975). The aim of 
this part of the work is to extend that characterisation to the 
developing his/his mouse in parallel with a study of brain growth 
and differentiation (Chapter )1). Any disorder of brain growth in 
his/his mice can therefore be compared directly with concurrent 
metabolic differences between i-/-'- and his/his mice. His/his offspring 
of his/his x his/his crosses have been examined throughout these 
experiments, since the combination of maternal histidinaemia and 
histidase deficiency could be expected to have a more drastic effect 
on brain development than histidase deficiency alone. 
The activity of the various enzymes utilizing histidine are 
likely to develop at different rates; substrate and cofactor concen-
trations may also change as development proceeds, so that the relative 
fluxes through these pathways may differ markedly from those in the 
adult. Other factors can accentuate these differences, including 
changes in the compartmentation of enzymes or metabolites and develop-
mental changes in isozyme pattern. The activity of skin and liver 
histidase and histidine aminotransferase have been investigated during 
postnatal development. Experiments investigating the development of 
histidine decarboxylase were abandoned because of the histamine 
assay difficulties discussed in Chapter 2. Amino and imidazole acid 
concentrations have also been estimated in foetal and maternal samples 
and in blood and brain during postnatal development. 
(i) The development of liver histidase activity. 
Liver histidase activity was examined in +/+ and his/his mice 
during the first five weeks after birth. Males and females were 
examined separately after the first two weeks because of the reported 
sex difference in liver histidase activity. The results are shown in 
Table 3:1 and Figure 3:1. On the day after birth, +/+ mice have 1-2% 
of the five week activity, which then increases steadily during the 
third and fourth weeks. The sex difference starts to emerge in the 
TABLE 3:1 
The development of liver histidase activity in i-/i- and his/his mice. 
Genotype Age (postnatal days) 
Sex Specific Activity + S.E.M. 
(Fol./min./g. wet weight) 
No. 
1 pooled 00052 8 
2 pooled 0.0087 
3 pooled 0-0181 3 
5 pooled o•o258 
8 pooled 0.0645 2 
11 pooled 0.0581  2 
15 female 0.105 + 0.025 3 
15 male 0.118 	-f- 0.063 3 
24 female 0.347 + 0.027 
24 male 0•308 ± 0.010 
35 female 0439 -I- 0•024 
35 male 0•284 + 0.059 2 
us/his 0 (birth) pooled 0.0067 + 0.0018 8 
1 pooled 0•0041 	+ 0.0007 8 
3 pooled 0•0012 ± 0.0008 
5 pooled 0•0046 ± 0.0011 3 
7 pooled 0•0071 	+ 0.0015 
10 pooled 0.0094 + 0•0013 8 
15 pooled 0•0176 + 00020 
24 female 0.0056 + 0.0011 3 
24 male 00045 1  0.0014 3 
35 female 0•00)4)4 + 0.0005 
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FIG. 3:1 Liver histidase activity in +/-'- (i 	) and his/his (.- -.) mice during postnatal development. 
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the fourth week and by five weeks the fiiale has about 50% higher 
specific activity than the male. 
In his/his mice, the activity at birth and day 1 is about the 
same as in the +/+ genotype, showing that the genetic difference at 
the his locus only becomes manifest in the liver after birth. In 
contrast to the +1+ enzyme, mutant histidase then declines briefly 
before rising to a maximum at 15 days after birth. At this stage, 
the specific activity is about 15% of the wild-type. Mutant histidase 
activity then declines steadily to reach one-quarter of the 15-day 
activity by five weeks. The mutant histidase at five weeks has only 
1-2% of wild-type activity. No sex difference is present in the 
mutant. 
There are differences in the pattern of liver histidase develop-
ment between the two genotypes. Firstly, the mutant reaches a peak 
at two weeks after birth compared with at least five weeks in the 
wild-type. Secondly, after reaching a peak, mutant histidase declines 
by a factor of four over the next 3 weeks. Thirdly, there is loss of 
the sex difference in histidase activity in his/his mice which suggests 
that the mutation also causes a loss of responsiveness to pubertal 
oestrogen (Feigelson, 1973b). This cannot wholly explain the genetic 
difference in histidase activity since the loss of mutant activity is 
apparent before the sex difference is manifest. These differences in 
the development of histidase activity in -1-/-1- and his/his mice could 
also be explained if the residual activity in the mutant is due to 
a separate enzyme. This will be examined further in Chapter 5. 
(ii) The development of skin histidase activity. 
Skin histidase activity was assayed during the first two weeks 
after birth in -i-/-i- and his/his mice. Although the development of skin 
histidase has not been reported in the mouse, the most striking activity 
changes in the rat occur during the first two weeks after birth 
(Lamartiniere and Feigelson, 1976a). Confining the study to the first 
two weeks also avoids the difficulty of extracting the enzyme from 
older animals in which the skin is tougher and the hair denser. 
The results are shown in Table 3:2 and Figure 3:2. Atbirth, 
±/-'- histidase activity is already about 60% of its maximum while 
mutant activity is undetectable. Both genotypes then rise to a maximum 
TABLE 3:2 
The development of skin histidase activity in ±/+ and his/his mice. 
Genotype Age (postnatal days) 
Specific activity + S.E.N. - (junol./min./g. wet weight) % maximum activity No. 
0 (birth) 0.0757 ± 0.0035 59 14 
1 0.1290±0.0118 100 14 
3 0.0953 ± 0•00037 74 14 
5 0.1040 	-'- 0•02)43 81 2 
7 0.0775 + 0.0041 60 14 
10 0.0151 	+ 0•0016 12 14 
15 0.0034 + 0•0012 3 14 
his/his 0 (birth) zero 0 14 
1 0.0005 ± 0.0005 5 3 
3 0.0053 + 0.0016 58 14 
5 0.0091 	± 0.0025 100 14 
7 0.0053 + 0.0005 58 7 
10 0•0038 + 0.0005 142 14 
15 0.0038 + 0.0004 142 14 
0-14 
FIG. 3:2 The postnatal development of skin 
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within the first week, and fall off sharply in the second. By 
fifteen days, the activity in +/+ extracts has fallen to only 2-3% 
of its activity during the first five days after birth, reaching a 
specific activity almost identical to the mutant. 
There is more similarity between the development of histidase 
activity in +/-'- and his/his skin than in the corresponding liver 
extracts. Both reach a maximum within the first week and decline 
in the second. However their activities at birth are very different 
and at fifteen days, his/his skin activity is 42% of five day activity 
compared with 3% in +1 skin. Two further points are of interest. 
First, the genetic difference at the his locus would seem to be manifest 
before birth in the skin, unlike the liver. Second, there is no 
difference in skin histidase activity between -'-1+ and his/his mice 
at fifteen days. If this were simply a consequence of incomplete 
extraction of histidase activity in the maturing skin, the genetic 
difference should still remain, unless activity was undetectable 
in both genotypes. In fact, a low but measurable activity was 
discerned in each extract. 
The relative activities of skin and liver histidase during the 
first two weeks after birth are shown in Figure 3:3. In the wild-
type, during the first week the liver histidase specific activity is 
considerably lower than in skin, but as the skin activity declines 
during the second week, liver activity increases sharply, so that by 
fifteen days it already has some 30 times higher specific activity. 
In the mutant, the skin activity is also higher than the liver for 
part of the first week, then it declines as the liver increases. By 
fifteen days, the liver specific activity is 4-5 times higher than 
skin. Since the total wet weight of skin in the mouse is considerably 
greater than that of liver during the first ten days, the skin would 
appear to be the more important site of histidine degradation at this 
stage. However the blood supply to the liver and its relationship to 
the gut may provide a richer supply of substrate. 
(iii) The development of liver histidine aiitLnotransferase activity. 
The development of liver histidine-pyruvate arninotransferase 
(combined ndtochondrial and cytosolic) activity was investigated in 
+1± and his/his mice during postnatal development. The results are 
TABLE 3:3 
The development of liver histidase aminotransferase 





(pinol./min./g. wet weight) 
No. 
1 0•720 8 
3 2.190 3 
14 1.580 2 
5 1.530 14 
8 3°070 2 
11 30040 2 
15 3o490 + 0283 6 
24 1.53)4+0.111 8 
35 1•427 	+ 0.1714 11 
>50 1.383 ± 0.135 6 
his/his 1 0.1430 7 
3 1 .750 14 
6 2•)450 6 
9 1.685 6 
15 3.167 + 0.193 10 
24 2.311 	± 0•199 5 
35 1.617 + 0•172 6 
Litter segregating for 
±/hjs and 20 3•355 + 0•298 6 
'Livers were pooled up to the 15 day stage. Sexes were analysed separately 
from the 15 day stage but since no sex difference in activity was found, 
the results from males and females are combined in this table. Means ± SEM  
are given from the 15 day stage onwards. 
LIVER HISTIDINTRANSAMINASE ACTIVITY 	(1lmoI./mun./g. wet weight) 







FIG. 3:4 The development of histidine aminotransferase activity in ±/± 
(A), his/his (•) and segregating +/his and his/his (U ) 
litters during postnatal development. 
TABLE 3:tj 
The effect of histidine concentration on histidine aminotransferase 
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FIG. 3:5 A. The effect of histidine concentration on histidine amino-
transferase activity in mouse liver extracts. 
B. Lineweaver-Burke plot of histidine aminotransferase activity. 
S = histidine concentration, mM. 
V = reaction rate, piiiol min- 1 g 1 . 
Data from Table 3:4 
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shown in Table 3:3 and Figure 3:4. The activity rises steeply 
after birth to reach a specific activity 2-25 times that of the 
adult by about ten days. It then plateaus for a further ten days 
before falling sharply to reach adult activity levels by four to 
five weeks. No consistent difference between the +/+ and his/his 
arninotransferase activities is present, despite the marked difference 
in flux through this pathway caused by the high mutant histidine 
concentration (see (iv)J. 
The effect of histidine concentration on histidine amino-
transferase activity was determined in adult wild-type liver extracts 
dialysed overnight against 0002M Tris HC1 pH 74 at 40G. The results 
are shown in Table 3d and the Lineweaver-Burke plot in Figure 3:5. 
The apparent Km for histidine is 147 mM which is in the same region 
as the mutant 15-day liver histidine concentration (8°8 pnol/g). The 
Vmax is 180 pnol/min/g liver. Since the enzyme does not appear to 
be saturated,/difference in histidine concentration between wild-
type and mutant could result in a corresponding difference in flux, 
provided the enzyme is not compartmented separately from the substrate 
or limited by pyruvate (see (vi)J. 
(iv) Blood amino acid concentrations. 
The concentrations of histidine, alanine, phenylalanine, lysine 
and glutainic acid were determined in whole blood during postnatal 
development. A.lariine and glutamate were examined since there are 
reports of a raised plasma alanine and a lowered glutamate concentration 
in human histidinaemia (Ghadimi, 1974). Alanine is one of the products 
of histidine transamination with pyruvate, while glutamate is one of 
the major products of histidine catabolism via urocanic acid. The 
concentrations of phenylalanine and lysine were determined since the 
former is thought to share a transport system for neutral amino acids 
with histidine, while the latter uses a separate system for dibasic 
amino acids (Neame, 1968). A raised histidine concentration would 
therefore be more likely to influence the transport of phenylalanine 
than of lysine. 
The results are shown in Table 3:5. Marked increases in blood 
histidine concentration are apparent in his/his mice from 	day 1 
onwards (Figure 3:6) and by five weeks there is a 16-fold difference 
between the two genotypes. In contrast, there are no statistically 
TABLE 3:5 
Whole blood amino acid concentrations during postnatal development in -'-/+ and his/his mice. 
Values are means + standard errors in pmol g 1. 
Genotype Age  Histidine Alanine Phenylalanine Lysine Glutainic acid No. 
1 0092 ± 0'007 0298 + 0028 0o061 + 0.005 0346 + 0028 0°110 + 0008 3 
6 0.161 	± 0°019 0-4)43 + 00029 0o077 + 0.008 0.625 ± 0.039 0149 + 0.010 6 
15 0c123 + 0.016 0.428 + 0.085 0.102 + 0.014 0•607 ± 0.036 0.118 ± 0008 4 
24 0065 ± 0.008 0483 + oo61 0.055 + 0.006 0•423 ± 0.037 0.180 	+ 00)4)4 4 
35 0.090 	-- 0016 0.396 + C°069 0°091 	± 0.017 0°)4)42 	± 0.038 0°211 	+ 0°035 L 
his/his1 1 0.548 +0•05i'  0.307 ±0027 0.057  +0006  0389  +0.0)41 0o089+0o008 3 
6 0e71 3 + 0°0' 0°)46)4 + 0059 0076 + 0.009 0.566 + 0.038 0.166 + 0.006 8 
15 1o243 + 0•073 0°294 + 0.041 0062 + 0•00 0600 ± 0049 0.111 	+ 0.014 4 
24 1Q019  + 0Q0 0696 + 0.112 0.059 + 0007 0.358  + 0.011 0.152 + 0°024 4 
35 1°439 + 0.108  0.530 + 0e116 0057 + 0°011 0.486 ± 0.028 0163 + 0°010 4 
Offspring of his/his x his/his crosses. 
	 *p<Q,Q5 : 
'8* P<0-01  




FIG. 3:6 Blood histidine concentration in ±/+ (A -A) and his/his 
(.- -.) mice during postnatal development. 
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significant differences in the blood alanine, lysine or glutamate 
concentrations at any stage. The blood phenylalanine concentration 
is significantly reduced (P< 0.05) in the mutant at the 15-day stage 
only, perhaps suggesting competition for amino acid entry in the 
gastro-intestinal tract. The concentration of histidine in gastro-
intestinal fluid was not determined, but may be raised in the mutant 
sufficient to inhibit entry of amino acids using a common carrier. 
However the blood concentration is the net result of uptake, removal 
by the tissues and excretion, any or all of which could be altered 
by raised histidine concentrations. 
The increase in blood histidine concentration in histidinaemic 
mice is apparent as early as day 1, presumably because of the transfer 
a 
of/raised maternal histidine concentrations via the milk. A prenatal 
skin histidase deficit may also contribute (see above). As the 
histidase defect becomes increasingly manifest after weaning (21 days), 
the histidine concentration difference increases further. 
(v) Amino acid concentrations in foetal and maternal samples. 
The concentrations of histidine, lysine, alanine and glutamic 
acid were determined in foetal and maternal blood or amniotic fluid 
samples on the 16th, 17th and 18th days of gestation. It has been 
reported that in man (Butterfield and O'Brien, 1963), rat (Boggs and 
Waisman, 1 96L), monkey (Kerr and Waisman, 1966) and the mouse (Lajtha 
and Toth, 1973), foetal amino acid concentrations are higher than 
maternal ones. An active transport system is therefore presumably 
present in the placenta, but the significance of the higher foetal 
concentrations is not known. The foetal/maternal ratio of amino acid 
concentrations is reported to be between 1 and 3 for most amino acids. 
It has also been shown that this ratio is maintained even in the presence 
of elevated amino acid concentrations, achieved by dietary loading in 
rats (Kerr and Waisman, 1966), or in human PKU (Thomas et al., 1971 ). 
These findings suggest that in histidinaemia, the offspring of his/his 
mothers could be exposed in utero to even higher histidine concentrations 
than the mother. 
The results are shown in Table 3:6. At the 16th gestational day 
(G) stage, the histidine concentration in the blood of his/his embryos 
Cross Sample Genotype Age Histidine Lysine Alanine Glutami..c acid No. 
Maternal blood +/± Adult 0.071 o8124 0601 0°157 1 
Foetal blood +/his 16G 0•136+0°006 1°2433+0.122 0.971+0069 0°717 ± 0.080 24 
Amniotic fluid +/his 16G 0158+0•022 0907+0•102 0.579+0.062 00203 + 0.033 24 
Maternal blood his/his Adult 1.338 0.871 0•992 00389 1 
Foetal blood his/his 16G 2°568+0•03 1•095+0•02" 1-361+0-051"  0.973 + 00111 6 
Amniotic fluid his/his 16G 1.357+09524 0.535+0.379 0.683+0.2471 0•5224 + 0389 2 
II Maternal blood +/+ Adult 0°102 0980 1026 0.505 1 
Foetal blood -t-/± 17G 0138 2.219 1.077 0.596 1 
Amniotic fluid +/+ 17G 0430 2818 1.824 0.7824 1 
Maternal blood his/his Adult 0•829+0122 0.5242+0.021 0821+0037 0.256 + 0.085 2 
Foetal blood his/his 17G 2.687+0.0249  1.3924-1-0.066 1200+02246 02421 	+ 00243 8 
Amniotic fluid his/his 17G 3729+0•2924 1.337+0.026 1.565+0.1 29 0283 ± 0.060 6 
III Maternal blood his/his Adult 0°930 0.506 052424 0288 1 
Foetal blood his/his 18G 2•2479+0°306  1.700±0o191 1.066+0.085 0.7247 	+ 0°0249 3 
Amniotic fluid his/his 18G 58724 2.571 29240 0.655 1 
*P005 *P<Q0o11HK7 P0°001 
TABLE 3:6 Amino acid concentrations in blood and amniotic fluid of foetal samples at 16, 17 and 18 days of gestation. 
I Maternal and foetal concentrations from a cross of +/+ female x his/his male, in comparison with his/his 
xhis/his (16 dagestation). 
II Maternal and foetal concentrations from a cross of -'-/+ x .1/.j, in comparison with his/his x his/his 
(17 days gestation). 
III Maternal and foetal concentrations from a cross of his/his x his/his (18 days gestation). Values 
are means + S.E.M. in piol/ml. 
TABLE 3:7 
Foetal/Maternal ratios of amino acid concentrations 
in whole blood in +/+ and his/his mice. 
Genotype Age 
Foetal/Maternal ratios1 
Histidine 	Lysine 	Alanine 	Glutamic acid 
+1+ and ±/his 16G2  1°9 18 1.6 o6 
his/his 16G 1.9 1.3 iL 25 
17G 2•3 1.05 1•2 
his/his 17G 3°2 26 1.5 16 
his/his 18G 27 3•4 20 
1 Ariino acid concentration in foetal blood/amino acid concentration 
in maternal blood, in pmol ml- 1. 
2 The suffix G refers to gestational days. 
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is 19-fold higher than in +/his embryos, which is about the same as 
the genotypic difference in maternal bloods. The molar histidine 
concentration in his/his foetal blood is almost double that in his/ 
his adults however. Despite the 19-fold difference in maternal 
histidine concentrations, the foetal/maternal ratio (F/N ratio) of 
histidine concentrations is 19 in both genotypes. The F/N ratios 
for all the amino acids measured are shown in Table 3:7. Each amino 
acid has a F/N ratio greater than 1 at all stages, regardless of the 
maternal concentration. At the 17G stage, foetal blood histidine is 
again 19-fold higher in his/his than +1+ embryos and the F/N ratio is 
even higher at 32 compared with 1-4 in -'-/+ animals. 
At the 16G stage, foetal blood lysine and alanine concentrations 
also appear to be different in his/his and +/his embryos (Table 3:6). 
The lysine concentration is 24% lower in his/his embryos while the 
maternal blood lysine concentrations are about the same. At the 17G 
stage, the lysine concentration is again reduced in mutant embryos but 
this may only reflect a lower maternal concentration in the mutant. 
The blood alanine concentration in 16G his/his embryos is higher than 
in +/his embryos although this may again reflect a higher maternal 
concentration, since there is nTo marked difference at the 17 day stage. 
Amniotic fluid histidine concentrations are also higher (by a 
factor of 9) in his/his compared with ±/+ embryos at the 16G and 17G 
stages. The lysine concentration is lower in his/his samples at both 
the 16G and 17G stages, as found in foetal blood. 
(vi) Imidazole acid concentrations. 
The concentrations of iniidazolepyruvic acid (IPA), imidazolelactic 
acid (ILk), imidazoleacetic acid (IAA) and N-acetyl histidine were 
determined in foetal and maternal samples on the 17th day of gestation 
in +/± x ±/-'- and his/his x his/his crosses (Table 3:8). These compounds 
were undetectable in amniotic fluid, foetal and maternal blood samples 
in the wild-type. In the mutant, the largest chromatographic peak was 
IPA combined with N-acetyl histidine (not separable chromatographically 
at this stage), which had a concentration of 0•024 p101/mi in maternal 
blood and 0096 piol/mi in amniotic fluid. ILk and IAA were undetect-
able in his/his maternal blood and present at concentrations of 0.057 
pilol/mi and 0°017 pnol/ml in pooled his/his amniotic fluid samples. 
TABLE 3:8 
Imidazole acid concentrations (A) in foetal blood and amniotic fluid, in comparison with maternal 
blood ()imoi ml): 	(B) in the brain (cerebrum) of mice from his/his x his/his crosses during 
postnatal development (paiioi g). 
Cross Tissue Age  mi lactate 1111 acetate Im pyruvate + Ac histidine1 No. 
his/his x his/his Foetal 
17G <0°009 (0.008 0025 6 Blood 
Pnniotic 17G 0057 0.017 0•096 3 Fluid 
Maternal AcLit  (0.007 <0•006 0•024 1 Blood 
x -'-/+ Foetal 17G <0009 (0.008 <0025 1 Blood 
Amniotic 17G < 0o003 (0.002 0004 1 Fluid 
Maternal 
~dult (0.007 (0.006 0.01 1 Blood 
his/his x his/his Cerebrum 6P (0.018 (0.015 <0.025 5 
15P (0.018 co.oi5 0o14I 1 
24P O.018 K0o015 (0025 1 
35P <0.018 0.015 (0025 1 
These compounds were not resolved chromatographically. Values represent the sun of both peaks. 
2The suffix G refers to gestational days and P to postnatal days. 
lxii, imidazole 	Ac, N-acetyl 
None of these imidazoles were detectable in foetal his/his blood 
samples. As in adult mice, the imidazole acids are barely detectable 
in tissue or body fluids other than urine. In amniotic fluid. 
concentrations are considerably higher which supports the suggestion 
that this fluid serves as an excretory reservoir for the embryo. 
These same imidazole compounds were then measured in his/his 
brain (cerebrum) during postnatal development (Table 3:8). The 
combined IPA/N-acetyl histidine peak was then the only measurable 
peak, and this only on the 15th day after birth, when a concentration 
of 0•14 pnol/g was found. The higher brain concentration at the 
15 day stage is paralleled by higher imidazole acid concentrations 
in the urine at 10 - 20 days (see below). 
Urinary histidine, IPA, ILA, IAA, and N-acetyl histidine 
concentrations were determined in +/+ and his/his mice during post-
natal development. The results are shown in Table 3:9 and Figures 
3:7 - 3:11. Changes in urinary histidine are shown in Figure 3:7. 
On day 1, the ±/+ urinary histidine concentration is thirty times 
that on day 30, despite the similarity in blood histidine concen-
trations at these stages (Figure 3:6). The renal reabsorption 
capacity for amino acids may be poorly developed at this stage, 
contributing to the almost four-fold drop in +/+ urinary histidine 
concentration in the first five days after birth as transport systems 
mature. While the wild-type histidine concentration falls steadily 
through postnatal development, in the mutant it maintains a high 
concentration. The highest absolute concentration is found at ten 
days, but owing to the decline of wild-type levels, the ratio of 
mutant/wild-type increases as development proceeds. 
The concentration of IPA in urine is about the same in the two 
genotypes on day 1, then increases in the mutant to plateau between 
10 and 21 days before falling slightly at 30 days (Figure 3:8]3). 
Wild-type IPA concentrations gradually fall throughout development so 
that the ratio of- mutant/wild-type increases between birth and 30 days, 
when it reaches 19. ILA concentrations show a similar trend (Figure 
3:8A). IAA concentrations in urine (Figure 3:9) are highest in both 
genotypes on day 1, falling off by a factor of 2 - 25 within the first 
five days. Between 3 and 30 days, IAA maintains a high concentration 
TABLE 3:9 
Urinary iimidazole concentrations in -'-/+ and his/his mice during postnatal development. 
Values are means + standard errors inwuol mg 1 creatinine. 
Genotype Age  Histidine 1111 pyruvate 1111 lactate Im acetate Ac histidine No. 
1 1193 + 2o42 2.80 + 044 0.57  + 0.08 2.85 ± 012 0.51+  0014 2 
5 3.10 ± 0.39 226 + 0•62 036 + 0.10 062 + 008 O23± 0° 03 7 
10 234 -- 0°46 1 56 + 062 073 ± 0.11 0.60 + o.oL 0°41  +0.03 6 
21 0.82 	+ 013 1-78 	+ iLi 0°12 	+ 002 055 	+ 0•16 0.37 +Q13 3 
30 0.37 + 0.05 0•37 + 0.13 0o04 ± 00001 013 + 0.02 0.19 +002 3 
1 20°21 + 592 348 + 1.31 0056 + 0°14 2.62 + 063 080+0.16 5 
5 
* .* 
23°03 + 3'12 6°15 + 3.16 o64 + 017 1.35 + 0°25 
-3H 
1q20 +0.15 24 
10 
** 
3643 + 989 
** 
8.77 	+ 1q87 
** 
2005 + 0.241  189 + 0.19 
iW 
2q76 +0.70 5 
21 2694 + 8o46 9°27 ±382 1.74 + 0•30 2°27 + 0•34 269 +05i 24 




3°21 	+0.60 3 
p<0o01 : 
1 offspring of his/his x his/his crosses. 
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FIG. 3:7 Changes in urinary histidine concentration during 
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FIG. 3:9 Changes in urinary imidazole acetate concentration during postnatal development in 
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FIG. 3:10 Changes in urinary acetyl histidine concentration during postnatal development 
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FIG. 3:11 Total urinary imidazole acid (IPA + ILA. + IAA) concentrations 
(A..) in comparison with urinary histidine concentrations 
(, 0) during postnatal development, in -'-/± ( A , 	and 
his/his (.,o) mice. 
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in the mutant while steadily falling in wild-type. A comparison 
of total urinary imidazole acids (IPA + ILA + IAA) with histidine 
concentrations during development (Figure 3:11 ) shows that in both 
genotypes, the two run parallel. The blood histidine concentration 
(Figure 3:6) shows a similar trend. Comparison of the histidine 
aminotransferase activity (Figure 3:4) with the urinary histidine 
and imidazole acid concentrations (Figure 3:6) shows that the high 
imidazole acid excretion between 10 and 20 days is probably not a 
consequence of the high liver aminotransferase activity at this time. 
It is explicable in terms of changes in the histidine concentration. 
Urinary N-acetyl histidine concentrations (Figure 3:10) rise 
sharply in the mutant during the first ten days after birth, then 
level out. In +1+ animals, N-acetyl histidine concentrations show 
only a slight decline during the same period. By 30 days the 
concentration in his/his urine is 17-fold higher than in +/± urine. 
One other unidentified Pauly-positive chromatographic peak was 
found to be increased in the mutant compared with wild-type urine. It 
chrornatographed close to, but distinct from, IAA. It could be methyl-
imidazoleacetic acid but this was not verified. 
(vii) Discussion. 
Changes in the histidine catabolic enzymes have been examined 
during the first five weeks after birth. Wild-type skin histidase 
activity is high at birth and remains so for the first five days, then 
declines sharply to about 2-3% of the peak activity (Figure 3:2). 
Wild-type hepatic histidase activity is low at birth, increases steadily 
during the first and third weeks in both sexes, then rises some 50% 
higher in females than males during the fourth and fifth weeks (Figure 
3:1). These findings are very similar to those obtained in the liver 
(Auerbach and Waisman, 1959; Feigelson, 1968; Makoff and Baidridge, 
1969) and skin (Bhargava and Feigelson, 1976a) of the developing rat. 
Mutant histidase activity shows a rather different development. In 
the liver, activity increases steadily during the first 2 weeks after 
birth, then declines slowly to about a quarter of the peak activity 
(Figure 3:1). No sex difference is present. it is therefore unlikely 
that the mutant and wild-type enzymes differ onlSr in catalytic efficiency 
(turnover number). If this was the case, their developmental courses 
WO 
should run parallel. The fact that they do not suggests (1) 
different rates of enzyme synthesis, perhaps due to differing 
responses to hormonal induction; (2) different rates of enzyme 
degradation; (3) different susceptibility to activators or 
inhibitors; (IT) methodological difficulties with the histidase 
assay due to interference from the developing urocanase activity; 
(if) that the residual histidase activity is due to a distinct 
enzyme with a low activity that is normally masked by the more active 
enzyme species. This last possibility is also suggested by the 
development of skin histidase activity in the two genotypes. Wild-
type activity is considerably higher than the mutant during the 
first week, but then declines sharply to the same level as the mutant 
(Figure 3:2). This could be explained by the occurrence of two skin 
isozymes of histidase with high and low activities. The former is 
present in ±1+ skin before birth and during the first week of life 
then disappears. The low activity isozyme is present in both geno-
types but is masked by the high activity enzyme until this disappears 
in the second week. The mutant may either have a variant form of the 
high activity enzyme with greatly reduced activity accounting for the 
slight developmental rise or a complete absence of this enzyme. Against 
this interpretation is the fact that the enzyme in adult rat skin is 
reported to be identical to the major liver enzyme by three criteria 
(immunological properties, Km for histidine, isoelectric point) which 
suggests that there is only a single histidase species in the rat 
(Thargava and Feigelson,  1976a). However these studies were carried 
out on purified enzyme and the purification procedure could have led 
to loss of a minor histidase species, especially if it is less stable. 
Another explanation for the identical skin histidase activity iia the 
two genotypes at 15 days, is that the his locus mutation does not 
alter the catalytic efficiency of the enzyme, only its responsiveness 
to hormonal induction. This is also compatible with the identical, low 
levels of liver activity in -i-/+ and his/his mice on the day after birth, 
after which only the wild-type shows the expected increase. However 
the rise in histidase activity after birth can be attributed to a 
number of distinct processes (Feigelson, 1968; 1973a, b). The neo-
natal rise has been attributed to the effects of glucagon and gluco- 
corticoids. The adolescent increase in the male may also be due 
to glucocorticoid action and the pubertal rise in females to oestrogen. 
It would therefore be necessary to invoke a loss of responsiveness to 
two or three distinct hormonal influences to explain the findings. The 
neonatal increase in mutant activity is greatly reduced and the adoles-
cent and pubertal increases absent. Mutation at a regulatory locus 
controlling the induction of histidase by several hormones is however 
a possibility. An alteration in the rate of histidase synthesis 
could also arise from mutation at the histidase structural locus 
(see Chapter 5). 
An increased rate of histidase degradation could account for 
the observed differences in histidase development. This could arise 
either from a structural locus mutation leading to altered stability 
(often coupled with impaired catalytic function) or from mutation at 
another, processing locus which specifically increases the rate of 
histidase degradation (see Recigl and Heston, 1 967). 
An alteration in the response of mutant histidase to activating 
or inhibiting influences could lead to the different developmental 
courses observed. A structural locus mutation could for example lead 
to increased inhibition either by substrate or product. Reduced 
activation or increased inhibition by one or more effector molecules 
could arise from the same cause or from mutation at another locus. 
Finally, the differing profiles of histidase development in the 
liver in the two genotypes might be due t in part at least, to inter-
ference with the histidase assay by the next enzyme in the pathway, 
urocanase. This is suggested by the progressive decrease in mutant 
histidase activity from 15 days onwards, which could be related to 
a developmental increase in urocanase activity, and by the unmasking 
of mutant activity alter protamine sulphate precipitation (see Chapter 
2). Urocanase activity is greatly reduced,but not eliniinatedby the 
high pH of the histidase assay, but any interference is expected to be 
greater with a low activity than a high activity histidase. 
One of the main alternative pathways through which the rising 
liver histidine concentration can be catabolized is by transainination 
with pyruvic acid, by means of histidine aminotransferase. The combined 
initochondrial and cytosolic activity increases from a low level at 
birth to reach a high activity during the second and third weeks. It 
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then declines sharply to 140 - 50% of the peak activity (Figure 3:14). 
This finding has not been reported previously but is similar to the 
high neonatal phenylalanine-pyruvate aminotrarisferase activity in the 
rat liver, which then falls to a lower level (Auerbach and Waisniari, 
1959). There is no consistent difference in liver histidine amino-
transferase activity between +1+ and his/his fnice. The high in vitro 
activity found early in development, could lead to a corresponding 
increase in flux in both genotypes. Unless the enzyme is already 
saturated with histidine or limited by pyruvate, the tenfold higher 
blood histidine concentration in the 15 day old mutant will also 
increase this flux. In the adult mutant, an increased concentration 
of urinary IPA is a cardinal feature showing that neither of these 
limitations apply. The apparent Km of the adult liver enzyme for 
histidine was determined and found to be 114°7mM, so that the liver 
histidine concentration (20"9 )inol/g wet weight or roughly 20 mM) would 
not be expected to saturate the adult enzyme. However, regardless of 
substrate concentrations, the high neonatal amninotransferase activity 
should lead to a corresponding increase in the flux to IPA, compared 
with older animals, unless it is compartmented such that the increased 
activity occurs in a quantitatively minor histidine (or pyruvate) pool, 
so contributing little to the overall flux. The urinary concentrations 
of IPA in the wild-type are not in fact higher in the second and third 
weeks after birth than in older animals (Figure 3:8B). In the mutant, 
IPA is higher at this stage but so is the concentration of histidine, 
which is therefore a sufficient explanation. In wild-type urine, IPA 
is higher on days 1 and 5 than on day 10 despite a considerably lower 
aniinotransferase activity. It therefore seems unlikely that the high 
neonatal aninotransferase activity is reflected in a corresponding 
increase in flux to IPA or its derivatives (see Figures 3:8-9). Since 
only the imitochondrial isozyme of histidine amninotransferase is 
inducible by glucagon in the rat (Morris et al., 1973; Nogachi et al,, 
1976a), the high total activity observed between 10 and 20 days may be 
dito an increase in the activity of tlüs component only. This would 
suggest that the mitochondrial isozyne contributes little to the over-
all flux to IPA. 
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The concentration of histidine in the blood of histidinaemic 
mice varies considerably during development. In 16-18 day old embryos 
the concentration is 25-27 p.mol/ml compared with 1.0-15 jimol/inl 
in the adult. Although most amino acid concentrations are higher in 
foetal than maternal blood, the results confirm that histidine is 
transported into the foetus against a concentration gradient, even 
when the maternal concentration is raised almost 20-fold (Table 3:7). 
The blood histidine concentration of his/his embryos is 19 to 20-fold 
higher than in +/+ or +/his embryos. After birth, the enzyme defect 
is not immediately apparent in his/his mice, so that the neonatal 
increase in blood histidine concentration (Figure 3:6) may be due to 
the transfer of a raised histidine concentration via the his/his 
mother's milk. This is supported by the fact that after weaning at 
21 days, the blood histidine falls by almost 20% before rising again 
at five weeks, by which time the enzyme defect is almost fully 
developed (Figure 3:6). 
The effect of a raised histidine concentration on other amino 
acids was investigated during embryonic and postnatal development 
(Tables 3:5-6). Alanine, which is one of the products of histidine 
transamination, is increased by 20 - 30% in the blood of his/his 
mice at some stages before and after birth, but this did not reach 
statistical significance. The concentration of lysine in foetal blood 
and amniotic fluid samples from his/his mice is lower than from ±/± 
mice, although the reason for this is obscure. 
In some azninoacidopathies, the metabolites may be more toxic than 
the affected amino acid itself (e.g. branched chain ketoaciduria). 
The concentrations of the histidine metabolites IPA, ILA, IAA and N-
acetyl histidine were therefore measured in the brain and body fluids 
during development (Tables 3:8-9), In  ±1+ mice, none of these metabol-
ites are detectable in 17-day foetal blood or amniotic fluid or in 
maternal blood. Bulfield and Kacser (1974) were also unable to measure 
these compounds in the plasma or brain of +/+ adult mice. In the 
developing his tidinaeinic brain, the only measurable chromatographic 
peak was a combined IPA and N-acetyl histidine peak, found only at 
15 days of age at a concentration of 0141. pinol/g wet weight. The 
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ratio of these two compounds can be estimated from their relative 
urinary concentrations at the same stage of development (when they 
were separable chromatographically). This gives a ratio of approx-
imately 2"5:1  for IPA to N-acetyl histidine, so that the peak brain 
concentration of IPA would be in the region of 0°1 pnol/g (roughly 
0.1mM). The concentrations of ILA and IAA in the developing brain 
are less than 0•018 irnol/g and 0.015 piol/g respectively. These 
concentrations are too low to act as inhibitors of any enzymatic 
reactions known to be influenced by these compounds. Small et al., 
(1 970)  have reported that IPA and IAA can inhibit rat brain glutamate 
decarboxylase in vitro by about 10 - 30%, but the concentrations 
required (705 InN) are two orders of magnitude higher than those found 
here. However the leucine metabolite, o&-ketoisocaproic acid, has 
been reported to inhibit rat brain pyruvate dehydrogenase with a Ki 
as low as 0'1inN (Bowden et al., 1970), so that IPA cannot be ruled 
out as a metabolic inhibitor. 
These same histidine metabolites were measured in the his/his 
embryos from histidinaemic mothers (Table 3:8). Although undetectable 
in foetal blood, amniotic fluid samples showed the concentrations of 
IPA/N-acetyl histidine, hA and IAA to be 0•096, 0.057 and 0017 piol/ 
ml respectively. In the mouse the amniotic fluid composition is largely 
foetal rather than maternal in origin (Renfree and McLaren 1974; Renfree 
et al., 1975).  These compounds would therefore appear to be readily 
excreted by the .foetal kidney so that blood and tissue concentrations 
are kept low. IPA is unlikely to be formed to any extent by trans-
amination of histidine in the foetal liver, since the aminotransf erase 
activity is very low until after birth (Figure 3:)4). It would seem 
therefore that these metabolites of histidine are passively transported 
into the foetus via the placenta and rapidly cleared into the amniotic 
fluid. It was not possible to determine foetal:rnaternal concentration 
ratios. 
The urinary concentrations of histidine and its metabolites are 
measurable in both wild-type and histidinaeimic mice:  so that the two 
genotypes can be compared directly (Table 3:9). In +/± urine, the 
histidine concentration falls by a factor of 30 between day 1 and 
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day 30 (Figure 3:7). This may be due to the increasing reabsorption 
capacity of the renal tubular transport system. In the mutant, 
urinary histidine concentrations rise from about twice the wild-type 
level on day 1 to a peak at 10 days which is sixteenfold higher than 
the wild-type then fall to about Lo% of this value at 30 days, 
although the mutant/wild-type ratio increases to almost 40. The 
changes in urinary histidine concentration in the mutant parallel 
those in the blood (Figures 3:6-7). 
The concentrations of IPA, ILA and IAA in his/his urine tend 
to change in parallel (Figures 3:8-9). Also the combined IPA, ILA 
and IAA concentrations show a close relationship to changes in the 
urinary histidine concentration (Figure 3:11). This suggests that 
the availability of histidine is the major determinant of the 
trans aminat ion flux. 
One unexpected finding is the high urinary IAA concentrations 
found on day 1 in both genotypes (Figure 3:9). In the wild-type, 
this falls to about 20% of this level over the next four days and 
in the mutant to about half. One possible reason for this finding 
is the high histamine formation during the pre- and perinatal 
periods (Rosengren, 1963), which can be metabolized in the mouse 
to IAA (Schayer, 1959; Kapeller-Adler, 1970). It is also possible 
that the IAA chromatographic peak is a composite of IAA and methyl-
imidazoleacaetic acid, the latter (or its riboside) being the major 
end-product of histamine metabolism. It was not possible to verify 
this, since the compound is not available commercially. 
Urinary N-acetyl histidine shows a slightly different develop-
mental course from the other histidine metabolites (Figure 3:10). 
It increases sharply in the mutant during the 10 days after birth, 
plateaus then increases further at 30 days. In +/+ urine, its 
concentration remains fairly constant although there is a slight 
decline at 30 days. 
The relative molar concentrations of the various urinary 
metabolites of histidine show relatively little change during develop-
merit. The major histidine metabolite at all stages is IPA, comprising 
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about 30% of the total urinary imidazoles. The IAA concentration 
is about one-quarter of this and ILA about one-tenth. The relatively 
high IAA concentration on day 1 is one exception. Another is the 
four to five-fold increase in the proportion of the total imidazoles 
found in N-acetyl histidine between days 1 and 30. The relative 
concentrations of these urinary histidine metabolites is different 
from those in human histidinaemia, where ILA is the major urinary 
metabolite (Wadman et al., 1971, 1 973). 
These results show that in the his/his offspring of his/his 
mice, the histidine concentration is raised about twenty-fold towards 
the end of gestation and an average ten-fold during the first five 
weeks after birth. The enzyme defect in the liver does not appear 
till the first week after birth although in the skin it is probably 
present before birth. Whether the latter gives rise to a difference 
in histidine concentration before birth could be answered by examining 
the his/his offspring of heterozygous mothers. This last cross might 
also help to distinguish between the relative contributions of maternal 
histidinaemia and histidase deficiency in producing a raised neonatal 
histidine concentration. However, since it would be difficult to 
distinguish young his/+ from his/his offspring in the segregating litter, 
a reciprocal cross of +/+ x his/his mice would be a better way of 
examining the maternal effect per se. Differences in the transport 
or metabolism of histidine in foetal and postnatal mice are shown up 
by the considerably higher molar histidine concentration in the former. 
A previously unreported increase in liver histidine aminotran.sferase 
activity has been found, although this is not accompanied by a 
corresponding increase in urinary transamination products. Finally, 
an examination of -1-/+ and his/his skin histidase activity during 
development shows that, while the activities are widely different 
during the first week, they gradually converge until they are identical 
by 15 days after birth. The implications of this finding on the nature 
of the his mutation will be discussed further in Chapter 5. 
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CHAPTER ) 
DEVELOPMENT OF THE H1LSTIDINAEMIC MOUSE II BIOCHEMICAL INDICES OF 
BRAIN DEVELOPMENT 
A dramatic series of morphological and biochemical changes 
occur in the developing brain about the time of birth (Davison and 
Thbbing, 1968). These changes coincide with the maximal increase 
in brain wet weight and have come to be known as the brain "growth 
spurt". In the mouse, this occurs during the first three weeks after 
birth (Uzman and Rumley, 1958; Hiinwich, 1962; Kobayashi, 1 963; 
Agrawal et al., 1968). In man, the growth spurt starts about six 
months before birth, reaches a peak at birth, and extends for about 
eighteen months after it (Dobbing, 1970).  Multiplication of neuro-
blasts to form the adult number of neurons has largely occurred 
before this stage, although some short-axoned interneurons (micro-
neurons) develop later (Davison and Do1ing, 1968). The growth spurt 
is thought to be due primarily to (1) neuronal expansion, in which 
axonal and dend.ritic terminals grow out and establish their synaptic 
connections, (2) the multiplication of glial cells and (3) the 
deposition of myelin sheaths around the neuronal axons. These events 
occur approximately in the above sequence, although at different 
times in different parts of the brain. Major biochemical changes 
occur during this period leading to the achievement of adult patterns 
of metabolic and electrical activity (Davison and Ibbbing, 1968; 
Berl, 1973). Further growth is restricted to lengthening of axons 
and keeping pace with the increasing body size. 
In the mouse, the morphological and biochemical changes associated 
with the growth spurt occur particularly during the second and third 
weeks after birth. The ground substance (meshwork of nerve connections) 
of mouse brain appears on days 5 - 6 (Hess, 1955). Electrical activity 
changes rapidly from the patterns of the immature brain to those of 
the adult between the 6th - 9th days and 16th - 17th days (Kobayashi, 
1963). Dendritic growth is evident by day 8 and markedly increased 
or completed by day 15 (Stefanowska, 1898; Raman y Cajal,1960). The 
cortex reaches its full thickness around the 1Th day after birth (Sugita, 
1918). The packing density of neurones decreases rapidly between the 
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3rd and 7th days and does not change after the 17th day (Haddara, 
1956). By the 15th - 17th days after birth, the neurohistological 
development of cerebral cortex is indistinguishable from the adult 
and the growth rate has subsided dramatically (Kobayashi, 1963). 
Fox (1965) divided the behavioural and neurological development of 
the mouse into five characteristic periods. The third period, between 
the 9th and 15th  days after birth, is associated with a rapid transition 
to the adult pattern of behavioural and neurological responses. Fox 
regarded this as a "critical period" of behavioural and neurological 
ontogeny. Other workers have considered the brain growth spurt as a 
whole to be a "critical" or "vulnerable" period of development 
(Flexner, 1955; Dobbing, 1968, 1974; Agrawal and Davison, 1973). 
Although the concept has been criticised (Bobbing, 1968) there is 
no doubt that a wide range of nutritional, netabolic and hormonal 
factors acting on the brain at this time can permanently affect 
its structure or function. In man, the extended period of myelination 
is particularly susceptible to interference, although it is perhaps 
the formation of synaptic connections and proliferation of glial 
cells that are most crucial to laying the foundations of intelligence 
(Davison, 1977). 
Biochemical measures of mouse brain maturation also change most 
dramatically during the three weeks after birth. There is a loss of 
water and increases in total protein, lipid and nucleic acid. Changes 
in DNA content reflect changes in cell number (Handel and Bieth, 1 952; 
Gayet and Bcnichxi,1961; Hurthani Jacobson, 1971 ; Dickerson and Bobbing, 
1967; Howard, 1968; Altman, 1969), since the great majority of cells 
in the brain are diploid (Swift, 1950;  Heller and Elliot, 1954; Lapham, 
196.8) and the amount of DMA per diploid cell is constant (Boivin 
et al., 1948; Vendrely and Vendrely, 1949; Mirsky and His, 1951). The 
water content of the brain probably falls as a result of the accumul-
ation of solid matter (Davis and Himwich, 1973). Because of these 
changes in the solid constituents of the developing brain, it is use-
ful to express the concentrations of chemical constituents in terms 
of the DNA content. The concentrations of RNA and protein per unit 
of DNA give some indication of changes in cell size or cytoplasmic/ 
nuclear ratio (Hess and Thalheimer, 1965;  Balazs et al., 1968; Davison 
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and Dobbing, 1968; Winick and Rosso, 1973; Yates et al., 197)4). 
Such parallels between structural and biochemical entities should be 
drawn with caution however, especially in a heterogeneous tissue such 
as the brain. Brain cholesterol has been suggested as a useful 
"marker" for the deposition of myelin lipids (Davison and DDbbing, 
1968). The major myelin lipids are cholesterol, phospholipids and 
galactolipids (cerebrosides and suiphatides), which are present 
in approximate molar ratios of 4:3:2 (Autilio et al., 196)4). 
Cholesterol estimations in the developing brain have been found to 
give much the same information as more complex lipid analyses (Davison 
and Thbbing, 1968). 
Changes in constituents such as DNA, RNA, protein and cholesterol 
provide a relatively crude insight into brain differentiation compared 
with the dramatic functional changes occurring for example in amino 
acid compartmentation (Berl, 1973) or energy metabolism (Gaitonde 
and Richter, 1966). However these static measures of brain maturation 
and growth have shown up important pathological changes in conditions 
such as thyroid deficiency (Balazs et al., 1968), undernutrition 
(Winick and Rosso, 1973), X-irradation (Patel and Balazs, 1975), and 
experimental amino acid imbalance (Chase and O'Brien, 1970). 
Brain development has been investigated in +/+ and his/his mice 
using the biochemical indices of growth discussed above. His/his 
mice were obtained from his/his x his/his crosses, so combining the 
effects of maternal histidinaeimia and histidase deficiency. His/his 
offspring of heterozygous (his/±) mothers would only be exposed to 
increased histidine concentrations during the latter part of the brain 
growth spurt. Intrauterine exposure to high histidine concentrations 
might be expected to interfere predominantly with morphogenesis and 
neuronal multiplication. Postnatal exposure to high histidine concen-
trations, particularly during the "critical period" of brain growth, 
might be expected to impair neuronal expansion, glial multiplication 
and myelination. 
Brains were therefore removed from mice on 1, 6, 15, 24 and 35 
days after birth. To allow for variation in the extraction and assay 
procedures between experiments, equal numbers of same-aged animals from 
both genotypes (+/+ and his/his) were examined in each experiment. 
The brain had previously been split into forebrain (cerebrum) and 
cerebellum, while the remainder of the brain stem was discared. 
The cerebrum was of particular interest because of the reported 
effects on higher mental function in human aininoacidopathies. The 
cerebellum was investigated separately, since with the exception of 
a small number of macroneurons which are laid down before birth, its 
niorphogenesis and maturation are essentially postnatal phenomena 
(Altman, 1969). The cerebellum is ther&ore a relatively discreet 
brain region, easily isolated from other parts of the brain, whose 
development can be examined almost in toto after birth. 
(i) Brain and body weight. 
Body weight was measured in +/± and his/his mice from birth to 
35 days. The results are shown in Table 4:1 and Figure 4:1. At birth, 
+/+ mice are slightly (7%) heavier than his/his mice (P< 0-05). There 
is no significant difference in litter size. In +/+ mice, the mean 
(+ S.E.N.) litter size is 768 + 0.53 (n = 25) compared with 7.00 + 
0•53 (n = 29) for his/his mice (P> 0.1). On the 3rd and 6th day after 
birth, his/his body weights are again lower by some 9 - 1 2%. This 
reached statistical significance on the 6th day (P< 0-01). Thereafter 
the two genotypes converge and grow at the same rate, with the exception 
of animals at the 18 day stage. Here the his/his mice are lighter than 
their +/+ counterparts (P< 0.001). There are two possible reasons for 
this difference. Firstly the numbers of his/his mice at this stage are 
much lower than for -f-/+ and all come from a single litter, which may 
have been neglected or ill-nourished by the mother. Secondly, it was 
noticed that the mother often stops feeding the litter before weaning 
and that some balance defective offspring have more difficulty in 
getting food from the cages at this stage than behaviourally normal or 
older mice. This could lead to a temporary reduction in growth in 
his/his litters, but the fact that the body weights are again identical 
in the two genotypes at 21 days and subsequently makes this unlikely. 
These results show that there is a small reduction in the weights of 
his/his compared with -'-/+ mice at birth and during the first week but 
thereafter the genetic difference at the his locus does not affect 
overall growth. 
Brain weight was examined in +/+ and his/his mice between birth 
and 35 days. The results are shown in Table 1:2 and Fgure 4:2. On 
TABLE )4:1 
Body weight in +/+ and his/his mice during postnatal development. 
2 Age 
his/his1 
Weight, g + S.E. No. Weight, g + S.E. No. 
0 (birth) 1297 + 0.031 45 1'211 + 0.025* 42 
3 2•34 + 0o07 21 2•13 + 0.10 26 
6 3.49 + 0.10 49 3•08 + o-or )4)4 
9 ).1.)40 + 0°24 14 4o07 + 0020 13 
12 6•0i + 0°23 40 5o93 + 039 29 
15 7.83 + 0°24 28 7°51 ± 0o19 55 
18 8.53 + 021 34 7.07 + 0°1' 9 
21 10096 + 109 4 1088 + 0.47 13 
24 11.90 + 0•32 31 1180 + 0.34 25 
27 1296 + 067 10 14.11 ± 0•39 16 
30 13.85 ± 1.08 6 - 0 
35 17.43 + 0.)41 18 15.98 + 0•72 25 
p<0.05 : 4 'pK001 :'"p<0001 
Offspring of his/his x his/his crosses. 
2Age is given in days after birth. 
birth 	 6 	 ic 	 24 	 35' days 
AGE 





Brain weight in -4-/+ and his/his mice during postnatal development. 
Cerebrum 
2  Age __________________ 
h/h1 is 
Weight, g. + S.E. No. Weight, g. + S.E. No. 
1 0.068 + 0.005 14 0071 	± 0•002 14 
6 0.1147 	+ 0•007 9 0.169 	- 0-005* 17 
15 0282 + 0007 7 0•256 ± 0.o10 6 
214 0316 ± 0006 14 0•281 	+ O•OO" 14 
35 0•298 + 0.005 14 0.293 + 0.0114 14 
Cerebellum 
Age 2 
Weight 	in 	g. No. Weight 	in 	g. No. 
6 00214 + 0°002 6 0•023 + 0•002 13 
15 0.051 	± 0•000 7 0.053 + 0002 6 
214 0060 + 0•002 14 0•062 + 0•002 14  
35 0•068 + 0•002 14 0.065 ± 0.001 14 
* <005 : "p<O•Ol :"p<O•OOl 
10ffspring of his/his x his/his crosses. 
2 
Age in days after birth. 
Dirth 	 6 	 15 	
AGE 	









FIG. 4:2 Cerebral ( A • ) and cerebellar ( t, a ) wet weight in ±/+ ( A, A solid lines) and 
his/his (a. broken lines) mice during postnatal development. 
TABT1 
Ratios of brain/body weight in -'-/+ and his/his 
mice during postnatal development. 
Values are means + S.E.M. 
Genotype AgJ Brain/Body weight ratio No. 
6 0•0143 ± 0°001 8 
15 0o041 	+ 0°002 6 
24 0•027 + 0.001 
35 0017 + 0o0003 
his/his 2 6 0•046 + 0•002 9 
15 0039 + 0•004 6 
24 0.026 + 0002 
35 0°020 + 0001" 
'P< 0.01 	
1
Age in days after birth 








birth 	 6 	 15 	 24 	 35clays 
AGE 
FIG. 4:3 Brain/body weight ratios in ±/± (*---A) and his/his (- -) mice during 
postnatal development. 
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day 1 there is no difference in cerebral weight between the two 
genotypes. Between the 6th and 24th days, the pattern of cerebral 
growth appears slightly different in his/his mice. At six days, 
cerebral weight is 13% lower in +/+ mice (pc 005) but by the 15 and 
24 day stages, cerebral weight is about 10% lower in his/his mice. 
By five weeks, cerebral weight is again the same in both genotypes. 
In the wild-type there is a 6% fall in weight between 24 and 35 days, 
as observed by others (Uzman and Rarriley, 1958), but this is not seen 
in his/his brains. 
In contrast to the pattern of cerebral growth, there is no 
difference in the cerebellar weights of +1+ and his/his mice at any 
stage. It was not possible to dissect out the small cerebellar 
primordium on the first day after birth. 
Brain weight is very closely related to body weight during the 
development of all species examined and the ratio of brain weight / 
body weight is high in early life and falls as the animal matures 
(Bobbing, 1968). An analysis of brain weight / body weight ratios 
during postnatal development in several species shows an abrupt 
change in this ratio coinciding with the period of brain maturation 
(Kobayashi, 1 963). In the mouse this was found to occur around the 
1 5th day. This ratio has been plotted in -'-/-'- and his/his mice between 
6 and 35 days after birth (Figure 4:3 and Table )4:3). The timing of 
the fall in the ratio almost coincides in the two genotypes, although 
the ratio is slightly higher in his/his mice at 35 days (P< 0.01) 
because of the lower body weights of his/his mice used for analysis 
(Table )4:12). 
(ii) Amino acids. 
The concentrations of cerebral histidine. alanine, phenylalanine, 
lysine, glutainic acid and GABA were determined in +/+ and his/his mice 
during postnatal development. The concentrations of histidine, glutamate 
and GABA were also examined in a small number of cerebellar samples for 
comparison. The results are shown in Tables )4:)4, 4:5 and Figures )4:)4, 
4:5. 
The cerebral histidine concentration is significantly raised in 
the mutant at all stages of development (Figure )4:4). Unlike the non- 
essential amino acids, the net entry of histidine from blood into the 
TABLE 14:14 
Cerebral amino acid concentrations during postnatal development in +/+ and his/his mice. Values are 
means + standard errors of 14-8 samples, in unol g 1. 
Genotype Age Histidine Alanine Phenylalanine Lysine Glutainic acid GABA 
1 0°087 + 0012 0•620 -I-  0•1214 0106 + 0°0014 0265 -i- 0.018 14.575 + 0 1 80 1.013 + 0030 
6 0°302 + 0020 1.3148 ± 0163 0.137 + 0°0114 0•1427 ± 0•033 8.14514 + 1.057 2509 ± 0.218 
15 0.2145 ± 0025 1738 + 0•227 0120 ± 0°010 0638 ± 0.052 12.692 ± 044.145 33614  + 0262 
224 0182 + 0°0240 0906 + 0108 0°1124 ± 0•020 0918 + 0•2242 15.662 + 0.1624 24717 + 0°519 
35 01240 ± 0°020 1o092 + 0°099 01242 + 0°028 0.510 + 0.0614 18.3714 + 2309 24.24240 + 02496 
his/his 1 06224 + 0•052 0862 + 0.1248 0.090 + 0o008 0381 + 0.0241  24293 ± 0.5149 1308 + 0.189 
* 
6 1°290 ± 0°072 1.2452 + 0.095 0o119 -'- 0.015 0.571  + 0.0240 8663 ± 0.675 2.242424 + 0.151 
15 3°501 + 0°2485 1 2248 + 0°207 0.139 + 0021 0°878 + 
.3 	. 
0.03412.137 + 1.998 32430 + 0.533 
224 2.831 + 0•272 1 °271  + 0.023 0.120 + 0.013 0.2486 + 0066 16.269 + 0.2438 24°706 ± 0527 
35 3•230 + 0'21 0.997 ± 0110 0.1147 ± 0•028 0'2455 + 0.058 17.953 + 1.1469 14.165 + 0°31 2 
** 
pO°Ol : 	pO°OOl 
TABLE h :5 
Cerebellar amino acid concentrations in +/+ and his/his mice during 
postnatal development. Values (means + standard errors in 6 and 15 
day samples) are given in jun01 g. 
Genotype Age  Histidine Glutamic acid GABA No. 
6 0206 + 0•039 0997 + 0078 3378 + 0.455 4 
15 o188 + 00043 2•579 + 0•309 11947 ± 1.257 4 
24 0234 3•634 14153 1 
35 0.150 3°020 15.349 1 
his/his 1 6 1•422 + 0.509 1.165 + 0.382 3.407 + 0.589 4 
15 2•619 + 0263 1.989 + 0285 9•592 -F 0.818 4 
24 3088 4o958 20•600 1 
35 2.598 2•422 11.845 1 
1 Offspring of his/his x his/his crosses. 
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FIG. L:L Brain histidine concentrations in -i-/-i- (cerebrum A, cerebellum E, 
solid lines) and his/his (cerebrum., cerebellum o, broken lines) 
mice during postnatal development. 
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FIG. 4:5 Cerebral glutamic acid (A• ) and y- auinobutyric acid ( 	o ) 
concentrations in ±/± (A, L solid lines) and his/his (,o broken 
lines) mice during postnatal development. 
brain is relatively unrestricted (Table 411). The largest concent- 
ration difference between the genotypes is found at five weeks when 
the histidine concentration is increased twentythree-fold (Table )4:11). 
In the cerebellum, similar increases are found in the mutant (Figure 
4:)4). The histidine concentration in his/his brain is therefore in 
the region 1 - 3 pmol/g (about 1 - 3mM) during the brain "growth spurt" 
compared with 0.1 - 03 1imol/9 in the wild-type, roughtly a ten-fold 
difference. 
There is no significant difference between the cerebral concent- 
rations of alanine or phenylalanine in ±/+ and his/his mice (Table Lj:L). 
Any effect of a raised histidine condentration on the net uptake of 
these amino acids with overlapping transport specificity (Neame, 1968), 
is not enough to affect the total pool size. A more subtle effect on 
quantitatively minor pools cannot be excluded. A tracer experiment 
would be necessary to examine this possibility. 
The cerebral concentration of lysine is significantly increased 
in his/his mice on the 1st, 6th and 15th days after birth (Table 4:)4. 
Since there is no evidence that lysine and histidine are transported 
into the brain by a common carrier, this effect may result from an 
alteration in the metabolism of lysine, induced by the histidine ab- 
normality. A generalised alteration in protein metabolism would 
presumably be reflected in the pools of other amino acids, such as 
phenylalanine, which remain the same. The explanation for this 
interaction is obscure. 
There are large changes in the concentration of the putative 
neurotransmitter amino acids glutamate and GABA during the period 
of rapid brain growth in all species examined (Davis and Himwich, 
1973). A delay or alteration in their rates of accumulation would 
imply abnormal development. However, there are no significant differences 
between ±/+ and his/his mice in the concentrations of glutamate or 
GABA at any stage of development, either in cerebrum or cerebellum 
(Tables L:Lt, 4:5 and Figure 4:5). The concentrations of glutamate 
and GABA both increase about four-fold between 1 and 35 days. 
(iii) Water content. 
The water content of +/+ and his/his mouse cerebrum was determined 
during postnatal development. The results are shown in Table 1:6 and 
TABLE ).:6 
Water content of cerebrum in +7+ and his/his 
mice during postnatal development. 
Genotype Age  Water Content 
% 	Wet Weight 
No. 
1 92•23 + 0•62 4 
6 85•08 + 0.34 4 
15 82•32 + 0•26 4 
24 79.01 	+ 0.46 2 
35 7752 	0•66 3 
his/his 1 9026 + 0•21 3 
6 85.20 + 0•46 5 
15 82-41 	± 0•52 3 
24 80.55 + 0.59 3 
35 78.06 + 0.40 4 
*P <0.05 
1 Age in days after birth. 
2offspring of his/his x his/his crosses. 
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FIG. 4;6 Water content of cerebrum from +/+ (A 	A) and his/his (.- -.) 
mice during postnatal development. 
Figure 4:6. The water content of the cerebrum falls sharply during 
the first week, then more gradually until five weeks. On day 1, 
water represents 90 - 92% of the total wet weight, falling to 77 - 
78% at five weeks. This change coincides with an increase in the 
solid constituents of brain and shrinkage of the extracellular 
spaces. Comparison of the two genotypes shows that on the first day 
after birth, the water content of ±1+ cerebrum is slightly (2%) 
higher than that of his/his cerebrum (P< 0°05). This difference 
does not persist at later stages of development. 
Cholesterol. 
The cholesterol content of ±/+ and his/his cerebrum was determined 
during postnatal development. The results are shown in Table 14:7 and 
Figures 14:7 and 14:8. There is a four to five-fold increase in the 
cerebral cholesterol content between the 1st and 35th days after birth 
(Figure 14:7). The increase is most marked in the second and third 
weeks during which time myelin is actively being laid down in nerve 
tracts. At 6 days, the cholesterol content of his/his cerebrum is 
19% higher than that of +/+ cerebrum (Pc 001). In contrast, at 
later stages of development the cholesterol content of his/his cerebrum 
falls below that of the wild-type, although these differences are not 
statistically significant. While there are no differences in the 
cholesterol concentration (mg cholesterol/g wet weight) of +/± and 
his/his cerebrum at any stage, when expressed in terms of DNA content, 
there is a small (12% : P< 005) increase in the mutant at 6 days only 
(Figure 14:7). The cholesterol content per cell is therefore slightly 
higher in the mutant at the 6 day stage of development but the differ-
ence disappears subsequently. 
Nucleic Acids. 
The total DNA content of cerebrum and cerebellum was determined 
in -f-/± and his/his mice during postnatal development. The results are 
shown in Table 14:8 and Figures 14:9-10. The total DNA content of mouse 
cerebrum doubles between the 1st and 214th days after birth (Figure 14:9). 
By 35 days, it has fallen some 2 - 6% suggesting that cell degeneration 
has occurred. The latter finding has been rt 	by other workers 
(Uzman and Runley, 1958; Howard, 1968). The DNA content of mouse 
cerebellum increases six to eight-fold between the 6th and 35th days, 
TABLE )4:7 
Choltrol content of cerebrum in ±/± and his/his mice during postnatal development. 
Genotype 
1 
Age Total cho1eol mg 
Cholesterol Wet weight 1  
mg g 
Cholerol 
mg No.  
6 0-998 + 0•038 6.319 + 0-109 3.815 + 0115 6 
15 3.120 + 0-276 10995 + 0.619 7.637 ± 0.389 L. 
24 606 ± 0160 14587 ± 0.260 11e754 + 0432 
35 5-000 + 0427 16.583 	+ 1-178 13°421 	+ 0-856 3 
his/his 2 6 1.188 + 049  6.215 + 0.153 4-276 + 0.11L 6 
15 2.561 	+ 0.275 9-786 + 1-359 7471 	+ 0-000 3 
24 4•020 ± 0.295 14288 + 0808 10897 + o841 Lj. 
35 4.669 + 0.153 16006 ± 0356 12895 ± 0125 
* 	** 
p<0• 05 : pKOO1  
1 Age in days after birth 
2offspring of his/his x his/his crosses. 
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FIG. 4:7 Cholesterol content of cerebrum in +/-'- (A 	A) and his/his  
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FIG. 14:8 Cholesterol/DNA ratios in cerebrum of 1+ (A 	A) and his/his  
mice during postnatal development. 
showing that almost 90% of its cells are formed postnatally 
(Figure 4:9). The increase is most marked during the second 
week. There are no significant differences in the DNA conrent 
of cerebrum or cerebellum between +/+ and his/his mice. The 
total number of brain cells is therefore not altered by pre- and 
postnatal exposure to a raised histidine concentration. Since 
there is an estimated 5 x 10 12g DNA per somatic cell in the mouse 
(Howard, 1965), the five-week old mouse cerebrum contains approximately 
75 million cells. The cerebellum has a similar number of cells at 
this stage. 
The DNA concentration (DNA/wet weight) of mouse cerebrum falls 
sharply between days 1 and 6, then more gradually during the next 
three or four weeks (Figure 4:10). This is in keeping with neuro-
histological studies showing that the packing density of neurons is 
high in early cortical development then falls as neuronal processes 
expand during maturation (Eayrs and Goodhead, 1959). There are no 
significant differences in cerebral DNA/wet weight between the geno-
types at any stage of development. In the cerebellum, the DNA/wet 
weight rises between 6 and 16 days after birth as cell proliferation 
proceeds, then falls, as in the cerebrum (Table 1:8). Again there 
are no differences between the two genotypes at any stage. 
The RNA content of cerebrum (Table 4:9, Figure )4:11) increases 
five to six-fold during the first two weeks after birth, then slowly 
declines by about 10% over the next three weeks. Similar, but less 
marked changes in cerebellar RNA content occur during this period. 
RNA/wet weight increases during the first 1 - 2 weeks in cerebrum and 
cerebellum then declines slowly. No genotypic differences either in 
total RNA or RNA/wet weight are found at any stage of development. The 
raio of RNA/DNA (Figure 4:12) in cerebrum increases dramatically between 
the 1st and 6th days then remains at about the same level. At the 6 
day stage, the ratio is 14% higher in his/his cerebrum (P< 0°05), but 
the difference disappears at later stages. In the cerebellum, RNA./DNA 
falls between 6 and 15 days, then remains relatively constant. The 
observation that RNA/DNA does not increase between 6 and 15 days in the 
cerebrum at a time when neuronal processes are expanding enormously, 
suggests that this ratio cannot be used simply as an index of cyto- 
TABLE )4:8 
DNA content of cerebrum and cerebellum in +1+ 




Age Total 	DNA 
DNA Wet weght 1 
rig g 
No. 
1 179.5 + 1 0•3 2655 + 0o079 
6 223°5 + 18•0 1.593 ± 0.058  10 
15 3496 	-I- 10.0 1.295 + 0•012 
24 392•5 + 1105 1.2)4)4 + 0•029 
3.5 3696 + 	5•8 1 .243 + 0.017 
his/his 
2 1 211.4 + 12•8 2•993 ± 0.130 
6 242°9 + 1 5.8 1.466 + 0'023 11 
15 331.2 + 186 1•260 + 0•022 3 
24 369•4 + 	85 1•318 + 0•033 




Age Total DNA DNA Wet weight -1 mgg 
No. 
6 )47.)4 	+ 11o0 3•070 + 0.601 6 
15 2883 + 140 5.597 + 0266 
24 335.0 + 25•3 5.590 ± 0259 
35 361•7 	1- 3.0 5•455 + 0.110 3 
his/his 6 55•2 + 13°4 3•117 + 0•676 9 
15 2799 + 	5.3 5•552 	-4- 0.173 
24 350.3 + 19.3 5.685 + 0.158 
35 3)42')4 	+ 12.6 5.320 + 0.091 3 
1Age in days after birth. Values are means ± standard errors. 
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FIG. 4:9 DNA content of cerebrum ( A,• ) and cerebellum (, a) in ±/-'-
(A, á solid lines) and his/his (s , o broken lines) mice 
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FIG. 4:10 DNA concentration (mg per g wet weight) of cerebrum in -i-/+ (*. 	A) and 
his/his (.— —.) mice during postnatal development. 
TABLE )4:9 
RNA content of cerebrum and cerebellum in +/+ and 





Total 	RNA RNA Wet weight -1 
mg 9-1  
RNA DNA-1  
Fg 	-i 
No. 
1 220•8 + 15-5 3-253 + 0.030 1-228 + 0-026 4 
6 6879 + 57.1 4°699 + 0257 3°109 + 0-139 10 
15 1307-8  + 280-0 4.810 + 0-821 2-755 + 0-202 6 
24 1231.1 	+ 95-8 3.900 + 0-293 3-143 -F 0-262 4 
35 1233-2 + 	75-8 14.140 	-'- 0-208 30339 ± 0.217 14 
his/his 1 259-8 + 	20-6 3-672 + 0-221 1-225 -F 0-032 14 
6 867-6 + 	691 50130 + 0•112 3-549 + o-1 05 11 
15 1367-6 -F 3243 5.374 + 1-232 2.732 + 0-252 5 
24 1165-5 	-'- 111-3 14-172 	- 0.1448 3.145 + 0-261 14 
35 1106-7 + 	7205 1 	3.854 + 0-166 3.117 	+ 0-161 3 





Total 	RNA RNA Wet weight-1  




6 64.5 + 	10-5 3823 ± 0-784 1.650 + 0.319 6 
15 238-8 + 	141-0 14.691 	± 0-814 0.651 	+ 0.119 6 
24 22709 + 	27-3 3•800 ± 0-386 0.691 	+ 0.095 14 
35 233•6 	-4- 14-0 3.522 + 0.031 0-646 + 0.014 3 
his/his 2 6 73.0 + 	14-3 14.099 + 0-873 1.612 + 0220 9 
15 255-2 + 	53.0 14.747 + 0-907 0.719 	- 0-218 6 
24 23904 -f 	17.5 3-905 + 0-313 0-689 ± 0-063 14 
35 237-3 + 	16.8 3-657 + 0•204 0-694 + 0-042 14 
1 Age in days after birth. Values are means ± standard errors. 
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FIG. 411 Ri'Th. content of cerebrum (A,.) and cerebellum (, o) in -'-/+ 
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FIG. 4:12 RNA/DNA ratios of cerebrum (As) and cerebellum (,o)  in +/+ 
(A?  E solid lines) and his/his (so broken lines) mice during 
postnatal development. 
TAPT 1.ir 
Protein content of cerebrum and cerebellum in +/+ 
and 	/his mice during postnatal development. 
T erhriim 
Genotype Age1  Total protein 
mg 
Protein Wet weight 1  
mg g 1  
Protein DNA 1  
jig 
No. 
+1+ 1 2•782 + 0•204 40•98 + 0.77 15.148 + 0.57 ) 
6 8.581 	+ 0°619 6042 + 175 38.80 + 0•98 10 
15 24-998  + 0-816 92-69 + 3.18 71-56 ± 2-08 14 
24 35.1495 + 1.908 112.52 + 5-86 90-27 + 2-55 11 
35 34-575 + 0-645 116-25 + 1.26 93.56 + 1-24 14 
his/his 1 3•380 ± 0-271 )4780 + 3-04 15.93 + 0.141 14 
6 10-647 + 0•66 62.82 + 1-36 144.18 	+ 1. 11 
15 21970 + 1.717 83.51 	+ 14.14 66.19 ± 2-12 3 
214 34-025 + 0.625 107-148 + 6•69 92•14 + 0-97 14 
35 3)4-3)43 	+ 1.910 117.34 +2•25 94.58 + 1.54 14 
TT cr&l1iim 





ig jig- I 
No. 
6 0-692 + 0°214 34-56 + 8.99 9.36 + 2•33 3 
15 14.161 	+ 0.117 80.57 + 2-73 13.94 + 0•39 3 
24 5.893 + 0-1413 98.30 + 2-92 17-68 + 0.82 14 
35 6.540 + 0.181 96•20 + 1.73 17-81 	± 0•73 14 
his/his 2 6 0- 694 ± 0•111 36-147 + 3.14 9-92 + 2-23 14 
15 14-378 + 0.140 86•72 + 2-26 15.65 + 0.50 14 
24 6-320 + 0•336 102-80 + 14.54 18.11 	+ 0.85 14 
35 6.1406 + 0.175 99.03 + 3.18 18.34 + 0.86 14 
Age in days after birth. Values are means + standard errors. 
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FIG. 4:13 Protein content of cerebrum ( A.) and cerebellum (,o ) in +/+ 
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FIG. 4:14 Protein/DNA ratios in cerebrum (A,.) and cerebellum (,o ) in 
+/-1- (A,E solid lines) and his/his (so broken lines) mice 
during postnatal development. 
plasmic nuclear ratio. No difference in cerebellar RNA content, 
concentration or RNA/DNA ratio is present at any stage. 
Protein. 
The protein content of mouse cerebrum increases ten to twelve-
fold between the 1st and 24th days, then remains constant (Table 4:10, 
Figure )4:13). Comparison of the two genotypes shows that at 6 days, 
his/his mice have a 224% higher (P< 0.05)  protein content than ±1± 
mice. When expressed as the protein/DNA ratio, this genotypic 
difference remains (Pc 0001) (Figure 4:14).  The amount of protein 
per cell is therefore higher in the mutant cerebrum at an early 
stage of development but the difference disappears subsequently. 
The protein concentration (mg/g wet weight) of cerebrum increases 
steadily during the first three weeks after birth in both genotypes 
and thailevels off. 
In the cerebellum the total protein increases about nine-fold 
between 6 and 24 days, then levels off. In contrast to the cerebrum, 
there is no difference between the genotypes at any stage. Similarly 
the protein/DNA and, protein/wet weight in cerebellum are identical in 
both genotypes throughout development. 
Discussion. 
The biochemical changes accompanying maturation have been well 
documented in the mouse brain (Roberts et al., 1951;  Folch-Pi,  1955; 
Albrecht, 1956;  Uzman and Rumley, 1958; Himwich, 1962; Agrawal et al., 
1968; Howard, 1968; Lehrer et al., 1970; Van den Berg, 1970; Lajtha 
and Toth, 1973).  The concentration of most amino acids decreases 
during postnatal development while those of glutamic acid, glutamine, 
GABA and aspaxtLc acid increase (Agrawal et al., 1968). The water 
content declines as total solids, proteins, myelin, proteolipid protein, 
lipids, cholesterol and phosphatides accumulate (Foich-Pi, 1955). 
During the third week, the fresh weight of brain actually decreases, 
because although solids are still accumulating, as seen by the continuing 
increase in dry weight, this cannot compensate for the rapid loss of 
water (Uzman and Ruinley, 1958)0 Total brain lipids increase steadily 
during the first 18 days after birth, then more gradually into adult-
hood (Uzman and Rumley, 1958). Myelination occurs first in the mouse 
brain at about ten days after birth and the last areas to begin myelin- 
21 
ation do so between 15 and 21 days (Folch-Pi, 1955;  Uzman and Ruinley, 
1958; Jacobson, 1970). Coinciding with this, the maximum rate of 
cholesterol deposition in the rat and mouse brain occurs between ten 
and 20 days after birth, although deposition continues into adulthood 
(Davison, 1970). In the rat, the highest rates of cholesterol 
synthesis and deposition coincide with maximum myelination as judged 
by histocheniical means. The total DNA content of mouse brain increases 
two-fold between 1 and 114 days after birth (Uzman and Ruznley, 1958), 
while in the cerebellum it increases by580% (Howard, 1968). In the 
cerebellum virtually all the neurons and glial cells are formed after 
birth (Altman, 1969). In cerebrum, Uzman and Rumnley (1958) found a 
drop in the DNA content during the third week suggesting that cell 
degeneration occurs. This will contribute to the full in brain weight 
noted at this stage (Uzman and Rumnley, 1 958; Howard, 1968). Degener-
ation of glial cells has been directly observed in the brain of young 
adult mice, which may account for the DNA loss (Smart and Leblarid, 
1961). The concentration of DNA (ig/g wet weight) in mouse brain 
decreases by 37% from birth to adulthood, reflecting the relative 
increase in other constituents and changes in cell packing density. 
The RNA content of mouse brain rises progressively until three weeks 
then falls by about 10% (Uzman and Ruimiley, 1958). 
The results of this study confirm many of these biochemical changes 
previously reported in the developing mouse brain. The pattern of 
brain growth, with a slowing and then slight decline after the third 
week (Figure 14:2) contrasts with the continuing high rate of body 
growth (Figure 14:1). Changes in the amino acid concentrations of the 
cerebrum (Figures 14:14-5) show some differences from whole brain 
(Agrawal et al., 1968; Lajtha and Toth, 1973), but the dramatic in-
creases in glutamnic acid and GABA during development are confirmed. 
The maximum rates of decline in water content and increases in cholest-
erol, protein and nucleic acid content show differences in timing which 
reflect the sequence of morphological changes. Rate curves of the 
changes in cerebral wet weight, DNA, cholesterol and water content are 
shown in Figure 14:15. This shows that the peak rate of cellular 
multiplication (change in DNA content) immediately precedes the period 











FIG. 4:1 5 Rate curves of the increases in wet weight  
DNA (a 	a) and cholesterol (A----A) content, and 
decrease in water content (. •) in the developing 
mouse cerebrum. Changes are shown as a percentage 
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guinea pig and pig brains (Davison and Dobbing, 1968). While cell 
proliferation has fallen to a low level by the end of the third week, 
cholesterol deposition is continuing at an appreciable rate even 
at the end of the fifth week, reflecting the continued niye lination 
of nerve tracts. It is not clear to what extent this postnatal phase 
of cell proliferation is due to the formation of microneurons as well 
as glial cells. The latter are almost wholly formed after birth in 
the cerebrum, while inicroneurons are only known to be formed post-
natally in the cerebellum, h.ippocampus and olfactory bulb (Altman, 
1969). Probably the majority of cells formed during this period are 
glial, especially the myelin-forming oligodendrocytes (Smart, 1961; 
Davison and Dobbing, 1968; Altman, 1969). This is consistent with 
the observed sequence of cell formation preceding myelination. In 
contrast to the cerebrum, where the DNA content on the day after 
birth is 149% of the five week value, cerebellar DNA is only 13% of 
the five week value by 6 days after birth. More than 90% of cere-
bellar cells are therefore formed postnatally, compared with about 
half the cerebral cells. 
The cerebral "growth spurt" can be seen in Figure 4:15 to reach 
its peak at 8 - 10 days. The peak rate of water loss occurs before 
all these events. It falls off almost exponentially during the first 
week, perhaps indicating the end of the prenatal wave of cell (neuron) 
formation. Dendritic outgrowth is reported by histologists to be at 
its highest between 8 and 15 days (Stefanowska, 1898; Ramon y Cajal, 
1960), This coincides with the broad peak rate of protein deposition 
between 9 and 17 days (data not shown). 
What effect does a raised histidine concentration have on these 
indices of growth and differentiation? The developing cerebellum is 
exposed to seven to seventeen-fold increases in histidine concentration 
throughout its development and yet there is no measurable effect on any 
of the indices measured. The cerebrum is also exposed to increases in 
histidine concentration ranging from four to twentythree-fold (averaging 
about ten-fold) during the five weeks after bQi 	r?1c?cntrast to the 
cerebellum, some biochemical differences between -'-/+ and his/his 
cerebrum do emerge. Before considering these further, a number of 
difficulties inherent in a study of this nature should be discussed. 
TABLE t:11 
Increases in the histidine concentration of blood and brain 







1P 6.0 7•2 - 
6P 6.9 
15P 101 14.3 13•9 
24P 15'7 13°2 
35P 16o 23•1 17°3 
The suffix P refers to postnatal days 
M. 
The biggest problem in studies of brain development is the 
wide variation in maturity among animals of the same chronological 
age (Himwich, 1962; Davison and Dobbing, 1968). Variation in rates 
of development among animals of the same age has been attributed to 
nutritional and genetic factors. Only the former are likely to be 
important in this study since, apart from the his locus difference, 
the mice are on the same relatively inbred genetic background. One 
factor known to affect the rate of brain development, probably via a 
nutritional mechanism, is litter size (Davison and Thbbing, 1968). 
In rats, a large litter size (with roughly 10 - 18 young) appears 
to have much the same effect on brain development as undernourishment 
during the suckling period (Winick and Rosso, 1973). Chase et al. 
(1969) compared the effects of large (16) and small (Lb) litter size 
on brain development in rats. In the large litter group, cerebral 
and especially cerebellar weights were reduced, which was mainly 
attributed to a reduction in cell size (protein/DNA ratio) in the 
cerebrum and to a reduction in cell size and number (DNA content) 
in the cerebellum. Undernourishment at a time when cell proliferation 
is high (especially before birth) leads to a permanent deficit in 
cell numbers and overall weight: undernourishment at a time when 
cells are mainly growing or myelinating (especially the post-weaning 
period) leads to a reversible reduction in indices of cell size or 
myelination (protein/DNA or cholesterol/DNA) (Altman et al., 1970; 
Winick and Rosso, 1973). Amino acid imbalance appears to give rise 
to similar deficits (Chase and O'Brien, 1970) so that the tinting of 
the developmental disturbance may be more important than its nature. 
When a large number of litters (n=54) from -'-/+ aid his/his nice 
were examined, there was no significant difference in litter size 
between the genotypes. Because smaller numbers of animals were used 
for the biochemical analyses, sampling error could have resulted in 
a difference in the size of the litters used leading to a spurious 
biochemical difference. Similarly, although no difference in body 
growth rate was found between ±/+ and his/his mice apart from a small 
difference during the first week (Figure 4:1), sampling error could 
have led to the analysis of animals from litters receiving inadequate 
nutrition, leading to a reduced rate of body and brain growth. Table 
11:12 provides data on the litters from which the mice used for 
biochemical analyses were drawn. The most marked difference is 
in the -'-/+ litter size at 6 days which is almost double that of 
the his/his mice. However the mean litter weights at this stage 
are almost identical in the two genotypes. The most marked 
differences in body weight are for the animals used for analysis 
at the 211 day (111% higher in -4-/+) and 35 day (10% higher in /•) 
stages. 
The method used to determine the age of animals is another 
factor to be considered. Because of the rapidity of changes in 
the developing brain, even a few hours difference in conceptual 
age can lead to a significant difference in maturity (Himwich, 
1962). The mice in these experiments were aged by determining 
the time of birth. Differences of up to 12 hours are inevitable 
since the cages were only checked twice daily. Small differences 
in maturity may become particularly important around the time of 
birth where slight physiological differences can be exaggerated by 
the trauma of birth. Changes found only around the time of birth 
should therefore be viewed cautiously, since they may be temporary 
fluctuations. Finally, the rapid changes occurring in the composition 
of the developing mouse brain make it essential both to express each 
result in terms of different constituents (e.g. absolute amount, per 
fresh weight, per weight of DNA) and to compare simultaneous changes 
in several different constituents. 
The only genotypic difference found at day 1 is a 2% higher 
water content in -1-,1-i- cerebrum (P< 0.05) (Figure 11:6). A difference 
of this magnitude at a stage so soon after birth is probably of 
little real significance, especially when followed by an essentially 
identical rate of water loss in the two genotypes at later stages. 
This conclusion is reinforced by the fact that the one day old samples 
came from single litters, whose weights were not recorded and which 
might therefore have been at slightly different stages of maturity. 
The rate of water loss is also at its highest at this stage of 
development (Figure 11:15), which will tend to accentuate small 
differences in maturity. 
TABLE )4:12 
Details of the mice used for biochemical analyses; 
number of litters from which animals were drawn, 
mean litter size and weights, body weights 
of animals used for analysis. 

















1+ 1 8.0 1 - - 8 
6 9o5 4 3049 3.57 14 
15 47 3 647 7°05 10 
24 6o 2 1215 126O 6 
35 5.0 2 17°56 17.65 7 
his/his 1 7.0 1 - - 7 
6 48 4 3055 3.61 16 
15 7•0 3 6•51 6•68 9 
24 6•0 3 11°25 1089 7 
35 90 1 16•29 15.93 8 
1Age is given in days after birth 
There are a number of differences between +/+ and his/his 
cerebra at the 6 day stage. Cerebral weight is 13% lower (P< 0-05); 
total cholesterol is 16% lower (P< 0-01) and cholesterol/DNA 11% 
lower (P<0.05); total RNA is 21% lower (F> 0.05< 001) and PLNA/NDA 
12% lower (P<0.05); total protein is 19% lower (P< 0-05) and protein/ 
DNA. 12% lower (P <0-01) in -f-/+  mice. Since the total DNA content is 
not significantly different in the two genotypes, cell growth or 
differentiation rather than cell numbers is relatively retarded in 
the +/± cerebrum. There is no difference in water content however at 
this stage. Although body growth is slightly depressed in his/his 
mice at this stage (P<0.01: Table 14:1), there is no difference in 
the mean body weights of the animals used for analysis (or their 
littermates) (Table 14:12). However, as mentioned above, the mean 
size of the litters from which the +/-i- mice were drawn was 905 
(weighted mean 9°3), compared with 4°8 (weighted mean 6°7) for the 
his/his mice (Table 14:12). This could therefore result in nutritional 
differences which would be reflected in the biochemical parameters. 
Against the idea of a nutritional cause for the 6 day differences is 
the absence of similar changes in the cerebellum. Another possible 
interpretation is that differences in maturity of this magnitude 
could arise from the method used to age the mice, allowing differences 
of up to 12 hours in the timing of birth. These differences would be 
more prominent at stages soon after birth as discussed above. 
A third explanation for the 6 day differences would be that an 
increased concentration of a neuroactive metabolite of histidine, such 
as histamine (Schwartz, 1 977) or iinidazole acetic acid (Phillis et al., 
1968; Tunnicliff et al., 1972) temporarily enhances the rate of cerebral 
development. This possibility,hough intriguing, would be more 
plausible if similar biochemical changes were present at earlier or 
later stages of development. This is not the case, since no other 
significant differences emerge other than small (9- 11%) reductions in 
his/his cerebral weight at 15 and 214 days. This last finding is partly 
explained by reductions in cholesterol (13 - 18%) and protein (14 - 12%) 
content, which do not reach statistical significance. 
What effect does a raised blood and brain histidine concentration 
have on other amino acids in the brain? The concentrations of the 
neutral amino acids, phenylalanine and alanine, were the same in 
mutant and wild-type, so that any inhibitory effect of histidine 
on the blood-brain transport of these compounds is not revealed by 
analysis of the total amino acid pools. It may be that histidine 
is transported into the brain by a histidine-specific as well as 
a shared carrier mechanism (Sabater et al.., 1976), so that it is a 
less effective inhibitor of uptake than amino acids only using 
shared systems. The cerebral concentration of lysine is increased 
in his/his mice during the first two or three weeks after birth 
(Table L:Li), although this amino acid is not krio.m to utilize a 
transport system common to histidine. The reason for this change 
is obscure. The large increases in the glutainic acid and GABA pools 
that have been reported by others in the developing mouse brain 
(Agrawal et al., 1968) have been confirmed (Figure )4:5) although no 
difference between ±1+ and his/his mice was found. 
In summary, the postnatal growth of the brain has been examined 
in +/+ and his/his mice. Although small differences in the cerebral 
fresh weights were found during the third and fourth weeks after 
birth, these were not accompanied by significant differences in water, 
cholesterol, nucleic acid or protein content. The only biochemical 
difference of note was found on the sixth day after birth, when the 
cerebral cholesterol/DNA; RNA/DNA and protein/DNA ratios were all 
higher in his/his mice, in the absence of a change in DNA content. 
These differences disappear at later stages of development and 
might be due to (1) the 6 day old +/+ mice being reared in larger, 
nutritionally deficient litters, (2) small differences in chronological 
age, or (3) a short-lived stimulatory effect of a neuroactive histidine 
derivative on brain development. There was no change in the cerebral 
concentrations of alan±iae, phenylalaiaine, GABA or glutaznic acid in 
histidinaemic mice, although an unexplained increase in the lysine 
pool was observed. There were no differences in cerebellar growth 
or biochemical parameters at any stage of development. Despite an 
approximately ten-fold increase in brain histidine concentration after 
birth and similar or greater increases before birth, there is no clear 
evidence of impaired brain development in histidinaemic mice. 
CHAPTER 5 
CHARACTERIZATION OF LIVER HISTIDASE IN MURINE HISTIDINAEMIA 
(i) Biochemical genetic aspects of histidase deficiency. 
It is only in comparatively recent times that the first genetically 
determined differences in enzyme phenotype were demonstrated (Figge 
and Strong, 1941; Khanolkar and Chitre, 1942; Sawin and Glick, 19)13). 
Despite the rapidity of subsequent progress in understanding the 
genetic regulation of enzymes in micro-organisms much less is known 
of this in higher organisms. As increasing numbers of genetically 
determined enzyme differences were found in mammals, regulatory 
analogies drawn from microbial systems were at first too readily 
applied (Howell, 1970). It has also become amply clear that the 
distinction between a "regulatory" mutation, in which the protein 
is present and correctly coded but not fully expressed, and a 
"structural" mutation where the protein is absent or coded incorrectly, 
is not easy to make (Paigen, 1 971). Interpretation is further 
complicated by the existence of mutations outside the enzyme structural 
locus concerned with the post-translational "processing"of enzymes 
into their final form. So far, relatively few mutations have 
satisfied the criteria for a regulatory mutation in higher organisms. 
If most enzyme deficiencies turn out to be structural locus mutations, 
there are few that fail to highlight some novel aspect of enzyme 
structure or function. The first reason for studying the biochemical 
genetics of a histidase deficiency is therefore to characterise the 
mutant enzyme in terms indicating either a structural, processing 
or regulatory locus mutation. 
As increasing numbers of kinetic and physical studies are carried 
out on enzyme variants, the importance of genetic heterogeneity in 
human metabolic illness has become apparent (Childs and DerKaloustiari, 
1968). This implies that treatment will have to be tailored in many 
cases to the specific protein variant rather than to the metabolic or 
clinical expression. Already treatment aimed at increasing the activity 
of the defective enzyme has led to some surprising successes. For 
example, there are some fourteen vitamin-responsive inborn errors of 
metabolism (Scriver, 1973; Brock, 1978). These conditions may show 
altered coenzyme binding, reduced stability or defective coenzyme 
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synthesis. The administration of large doses of a vitamin such as 
pyridoxine in many cases increases enzyme activity sufficiently to 
restore function. Often only a small (about three-fold) increase 
in activity is necessary (Mudd et al., 1970). This situation also 
applies to mouse histidinaexnia, where the relationship between histidine 
concentration and enzyme activity shows that a three or four-fold 
increase in histidase activity from around 5% could restore the 
histidine concentration to normal (Kacser et al., 1973) The 
increasing use of cell culture in mammalian genetics will undoubtedly 
facilitate the search for activating, stabilising or other therapeutic 
measures that increase defective enzyme function. A second reason 
for studying the biochemical genetics of histidase deficiency is 
therefore to explore enzyme properties. such as stability, substrate 
or cofactor requirements, which could indicate an appropriate method 
of treatment. 
(ii) Criteria for identifying a mutation at the structural locus of an 
enzyme. 
In order to show that a mutation has occurred in the structural 
gene coding for an enzyme, a change in some property that depends on 
the amino acid sequence of the enzyme must be demonstrated (Paigen, 
1971 ). These "structural" properties include kinetic constants, 
stability to physical denaturation, electrophoretic mobility, immuno-
logical specificity and of course direct sequence determination. 
Fortunately enzyme deficiencies in higher organisms are rarely complete: 
between 0°1 and 20% of the normal activity often remains (Kirkman, 
1972). The residual activity can then be examined for evidence of a 
structural change. If a difference emerges between the mutant and 
normal enzyme, this usually implies either a mutation at the structural 
locus for the enzyme or that the residual activity belongs to some 
other enzyme. It is not unknown for two enzymes to catalyse the same 
reaction, one of which only contributes a small proportion of the 
total activity (Ohno et al., 1966; Srivastava and Beutler, 1969). If 
the major enzyme activity is lost or diminished through mutation, the 
residual activity would be largely due to the minor enzyme, (Kirkman, 
1972). Guinea pig strains have been described with high and low 
activity in the hydroxylation of cortisol by the liver (Burstein et al., 
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1 967). The high activity strain turned out to have two 
enzymatic components, one with a high Vmax and high Kin, 
the other with a low Vmax and 30 times lower Km. Only the 
second component was present in the low activity strain. 
If the residual activity is not due to another enzyme, does 
a change in the structural properties of the enzyme necessarily 
imply a mutation at the structural locus? In most instances, this 
is the case, but the occurrence of multiple forms of some enzymes 
showing similar substrate specificity (isozymes) complicates the 
issue. For example, electrophoresis of the enzyme nucleoside 
phosphorylase in the red cells of a patient with an unknown haemolytic 
disease might show an abnormal pattern with a predominance of slower 
moving isozymes compared with a normal individual (Edwards et al., 
1 971). In this case, the difference can be simply accounted for by 
the presence of more young and immature cells in haemolytic blood, 
together with a tendency of this enzyme to undergo secondary 
structural modifications in aging red cells. Other possible causes 
of altered "structural" properties in an enzyme, which may not be 
due to structural locus mutation include: (i) aggregation or poly-
merization of the enzyme (Smithies and Connell, 1959; Klee, 1 970): 
(2) stable changes in the tertiary or quaternary structure, induced 
for example by varying concentrations of substrate, cofactor or other 
effector molecule (Blume et al., 1971; Smith et al., 1971;  Fisher 
and Harris 1971a, b; Padua et al., 1978): (3) deamidation of amino 
acids such as asparagine or glutainine in the enzyme molecule which 
can alter the electrophoretic mobility (Funakoshi and Deutsch., 1969; 
Midelfort and Mehler, 1972; Karn et al., 1 973): (1) artefactual 
changes arising from extraction, purification or analytical procedures 
(Hopkinson and Harris, 1969;  Hopkinson,  1970; Fisher and Harris, 1972): 
(5) mixed disulphide formation with glutathione (Muller, 1961): (6) 
acetylation, methylation, phosphorylation, adenylation or conjugation 
with carbohydrate moieties (Krebs et al., 1958; Schroeder et al., 1962; 
Shapiro et al., 1967; Shapiro and Stadtrnan 1967; Robinson and Stirling, 
1968): (7) Schiff's base formation with the N-terminal amino group 
(Holmquist and Schroeder, 1966): (8) polypeptide cleavagerproteolytic 
enzym (Marti et al., 1967; Rubenstein and Steiner, 1970): (9) 
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sulphydryl oxidation (Klee, 1970). Undoubtedly many other causes 
exist. It is therefore less surprising that an enzyme known to be 
coded by the same structural gene is found to differ in urea sensitivity, 
depending on the source of extraction (Schwartz, 1964; Endo and Schwartz, 
1966) or to differ in electrophoretic mobility, depending on the sub-
cellular localisation (Gan chow, 1971). Many of these modifying factors 
are themselves under separate genetic control. An enzyme defect in-
herited as a single factor, and associated with a non-artefactual 
change in some "structural" property of the enzyme is therefore quite 
possibly due to a mutation at another enzyme "processing" locus, 
secondarily and stably affecting the enzyme conformation or covalent 
structure. Post-translational processing of an enzyme into its final 
functional form is probably a common feature in higher organisms. This 
may involve conjugation or some other form of chemical modification, 
but can also involve incorporation of the enzyme into a particular 
subcellular organelle. Paigen et al. (1975) suggested the term 
"processing" mutant to describe mutations concerned with this aspect 
of metabolic regulation. Processing mutants have been particularly 
well characterised in lysosomal enzymes such as -glucuronidase (Eg 
and bg loci), acid phosphatase (Api locus) andd-mannosidase (Map-1 2  
Map-2) (Paigen et al., 1975; Lalley and Shows, 1977; Dizik and Elliott, 
1978). Another consequence of post-translational processing is that 
a structural mutation can lead to loss of the recognition features in 
the molecule necessary for such processing. It may be difficult to 
distinguish between a structural mutation and a processing mutation 
affecting the same enzyme. Loss of a conjugant group or a change in 
subceflular location would indicate a processing mutant. Both types 
of mutation can stably affect the three-dimensional structure of the 
enzyme and hence change its heat stability, kinetic or electrophoretic 
properties. It may be necessary to sequence the enzyme for a definitive 
answer although genetic criteria usually provide a simpler, means of 
distinction (see below). 
The relative efficacy of properties such as the heat stability 
or electrophoretic mobility as indicators of a change in amino acid 
sequence has been discussed by Paigen (1971 ). In general, a heat 
O. 
ability change is likely to occur after ami ,,no acid substitution at 
one-half to three-quarters of all sites (Langridge, 188 Lehmann and 
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Carrell., 1969). About one-third of all amino acid substitutions 
resulting from a single base change will change the net charge and 
hence electrophoretic mobility of a protein (Sick et al., 1 967; 
Lehmann and Carrell, 1969). Where mutant enzymes are pre-selected 
by a change in kinetics, these proportions may be considerably higher. 
While some change in the velocity constant (Vmax) usually follows a 
structural locus mutation, only about 5% have an altered affinity for 
substrate (1(m) (Langridge, 1968b). Imniünological methods of disting--
uishing protein variants are relatively inefficient (Reichlin, 1972, 
1975). linniunoprecipitation or complement fixation techniques are 
only sensitive to variation at about 3% of the amino acid sites in 
haemoglobin. A point mutation is therefore unlikely to lead to a 
loss of antigenicity, but it may reduce it (Brock, 1978). One 
consequence of this is that such methods are correspondingly efficient 
means of comparing the amounts of normal and mutant enzyme. 
Estimating the amount of immunologically cross-reacting material 
(CRM) is often an important part of a biochemical genetic analysis. 
While a reduction in CRI'I is an essential feature of a regulatory 
mutation, it is also a common finding in structural mutations. In 
the latter, this may be due to altered antigenicity, reduced stability 
or reduced de novo synthesis. What proportion of mutations affecting 
enzyme function are CRI{-positive? Many mutations are likely to lead 
to a polypeptide that cannot fold into the normal tertiary or quarter-
nary structure, in which case QRN is unlikely to be present. Enzymes 
that are denatured or dissociated into subunits react poorly with 
antisera (Gelehrter et al., 1 970; Celada and Strom, 1972). A reduction 
in enzyme stability is another property commonly resulting in loss of 
GRN. Boyer et al., (1973) compared the reported incidence of CRN-
positive and CRM-negative mutations in inborn errors of metabolism. 
They collected data from 260 kindreds in 214 distinct genetic conditions 
and found a ratio of CRM-positive:CRM-negative of about 3:2. This 
provides only a rough measure. CBI4-negative mutations may only 
reflect limitations in the immunological techniques, so that the 
ratio is probably too low (Brock, 1978). Enzyme instability is 
certainly a frequent consequence of structural mutation. It is 
reported to be a major problem in about 20% of 123 haemoglobin 
variants associated with amino acid substitution 
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(Stamatoyannopoulos, 1972) The unstable haemoglobin variants 
mainly involve substitution of polar for non-polar amino acids 
in the hydrophobic interior of the molecule, which distorts the 
three-dimensional structure (Perutz and Lehmann, 1968). About 
one-third of all known glucose-6-phosphate dehydrogenase (G6PD) 
variants have reduced stability to physical denaturation (Beutler, 
1972), in some of which the reduced activity is wholly attributable 
to in viva denaturation rather than altered catalytic function 
(Piomelli et al., 1968). Finally, reduced synthesis of a structural 
variant is not uncommon, although the mechanism is unclear. Virtually 
all known amino acid substitutions in haemoglobin show a reduced rate 
of synthesis: on the other hand G6PD structural variants are mostly 
synthesized at the normal rate (Sutton and Wagner, 1975). 
Investigation of an enzyme variant may reach the stage of 
showing that (1) there is no evidence of a change in the primary 
structure of the enzyme and (2) there is a change in the amount of 
identifiable enzyme protein (CRN). This suggests the possibility of 
a regulatory mutation. It is then necessary to show that the putative 
regulatory mutation maps separately from the structural gene. Paigen 
(1971 ) stated the criteria for identifying a regulatory gene mutation 
as follows:- (1) the mutation must alter the rate of enzyme synthesis 
or breakdown, not merely the measurable level of activity: 
(2) the mutation must be at a genetic locus separate 
from the structural gene for the enzyme. 
Paigen later classified enzyme degradation mutants among the group of 
processing rather than regulatory mutants, the distinction being made 
on whether the mutation affects the enzyme before or after its messenger 
RNA. is translated (Paigen et al., 1 975). 
The term regulatory mutation should be used cautiously in mammals 
because of its prokaryotic associations. In bacterial operons, regulatory 
genes include promoter, operator and repressor sequences (Jacob and 
No-nod, 1961). The cis-active genes (operator and promoter) imply an 
involvement with the binding of RNA polymerase or initiation of trans-
cription, while trans-active genes (activator or repressor) appear to 
control protein synthesis via a diffusible product which is generally 
a protein. In enkaryotes there are a few examples of cis-active genes 
which map separately from the structural locus (Swank et al., 
1973; Chovnick et al., 1976) but most regulatory genes are of the 
trans-active type. Here the prokaryotic concept of regulatory 
gene may be too restrictive since it is often unnecessary to 
distinguish between a gene coding for a protein that controls gene 
expression at the level of the genome (transcription) rather than 
at some other level prior to translation of the messenger RNA. A 
loss of cytoplasmic testosterone receptors with consequent loss of 
the hormonal induction of mouse p-glucuronidase in the Tfm mutant 
could legitimately be regarded as a regulatory mutant, although it 
is probably also the structural gene for the receptor (Bardin et al., 
1973; Lyon et al., 1975; Shire, 1976). Apparent regulatory mutations 
sometimes turn out to result from deletion of a structural gene when 
these exist in multiple copies which may be closely linked, (e.g. 
o-thalaemia; see White, 1978). The problems of genetically dist-
inguishing between closely linked loci in higher organisms are often 
insurmountable so that resort to nucleic acid hybridisation may be 
necessary. 
The importance of genetic criteria in identifying regulatory 
mutations was mentioned above. The regulatory locus must be separate 
from the structural locus. The few regulatory mutations known in 
higher organisms are all very closely linked to the structural genes, 
so that it is difficult to show their physical separation (Paigen et 
al., 1975). The above criterion implies that there is a clearly 
defined structural locus variant available for mapping the putative 
regulatory mutant. This is often not the case. Napping of a process-
ing mutant will also show it to be at a separate site from the structural 
locus. In general, these mutants have not been found to be closely 
linked to their structural genes (Paigen et al., 1975). 
A cross between the structural and putative regulatory or process- 
ing mutant homozygotes will show whether they are functional allelic, 
which can be another useful genetic criterion. This is only informative 
in the case of recessive mutants, where the heterozygote will be mutant 
if there is allelism. Rarely, allelic mutants affecting a multiiueric 
enzyme show complementation and restoration of activity in the hetero- 
zygote. 
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Another criterion for distinguishing a mutation at the structural 
locus of an enzyme from a mutation at another locus is that of co-
dominance (Paigen, 1971). Most inborn errors of metabolism show 
recessive inheritance at the clinical or metabolic level and co-
dominance at the enzyme level. Heterozygotes therefore express 
both mutant and normal alleles and show an intermediate level of 
enzyme activity. Failure to find codominant expression of enzyme 
activity is strong evidence against there being a mutation at the 
structural locus, although there are rare exceptions (Morrow et al., 
1949, 1950). A processing gene may or may not show codominant 
expression. While a trans-active regulatory gene is likely to 
show complete dominance, a cis-active gene will also be codominant. 
The codominance criterion is therefore most useful when it is absent 
in the heterozygote. 
These considerations show that the distinction between structural 
processing and regulatory locus mutations cannot be made easily. The 
problems are even greater where the residual mutant activity is as 
low as it is in the his/his mutant. Kinetic and physical parameters 
can be compared between two enzyme forms provided good measurements 
are possible in both. In the present case, the mutant activity is 
near the limit of the assay method, so that comparisons using crude 
extract are subject to some reservations. The work with partially 
purified extracts largely overcomes this problem, since the specific 
activity is substantially higher. The instability of the residual 
(SN-2 extract) activity remains a problem, so that purification and 
analyses always have to be carried out on the same day, otherwise 
significant loss of activity occurs. 
Previous studies of liver histidase in wild-type and histidinaemic 
mice (Kacser et al., 1973; Bulfield and Kacser, 1974) have shown that 
histidinaemia is associated with a defective liver histidase (0.00 - 
0.05 pmol/min/g liver) with less than 5% of the activity found in wild-
type. Heterozygotes show activity that is intermediate between that of 
the mutant and the wild-type. Recessive inheritance at the metabolic 
level is therefore associated with codominance at the enzyme level. 
Since the available evidence from studies of bacterial and mammalian 
systems suggests that histidase is a multimeric protein made up of 
identical subunits (Chapter 1 (iv)J, it is likely that there is only 
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one structural locus. If there is more than one copy of this 
gene then homozygous mutants should retain relatively high 
residual activity, which is not the case. The activity of the 
next enzyme in the pathway, urocanase, has been shown to be un-
changed in histidinaemic mice (Kacser et al., 1973) and there is 
nothing in the metabolic profile to suggest a block at a more 
distal point in the pathway. The only other tissue expressing 
histidase activity is the skin, which is again found to have 
reduced activity in young mice (Chapter 3; Bulfield and Kacser, 
19Th). 
The purpose of the experiments described below was firstly 
to contrast some of the physical or structural properties of liver 
histidase in mutant and wild-type mice. A difference in one of 
these properties would support the hypothesis that the his locus 
is the structural locus for histidase. A failure to find such a 
difference might suggest the presence of a regulatory gene distinct 
from the structural locus, or alternatively a gene affecting only 
the measured activity of the enzyme. Secondly, by investigating 
the properties of the mutant enzyme, it might be possible to devise 
a therapeutic approach to increase the residual activity sufficient 
to reverse the metabolic error. 
(iii) Tests for the presence of dissociable activators or inhibitors. 
Dialysis. Mutant livers were extracted by homogenisation 
in Tris/sucrose medium and the 60,000g supernatant dialysed overnight 
as described in Chapter 2 (xv). An aliquot of undialysed supernatant 
was retained for histidase assay in comparison with the dialysed 
sample. The pre-dialysis activity is 0°11 pinol/rnin/g liver compared 
with 0°005 piaol/rnin/g liver after dialysis. Dialysis therefore 
results in an approximately 50% loss of histidase activity, rather 
than the increase in activity that would be expected in the presence 
of a dissociable inhibitor of histidase activity. This loss of 
activity, which does not occur in wild-type extracts, is the first 
evidence of a difference in stability between mutant and wild-type 
histidase. 
Gel filtration. Mutant liver extracts (60,000g supernatants) 
were desalted by gel filtration on Sephadex G-25 as described in 
Chapter 2(xv). The total histidase activity prior to gel filtration 
is 0.032 units  compared with 0026 units after gel filtration. The 
total activity recovered after desalting by this method is therefore 
about 80% of the initial activity. This again shows that there is 
no enhancement of mutant histidase activity following removal of 
dissociable small molecules. 
(c) Mixing experiments. Wild-type and mutant liver extracts 
(60,000g supernatants) were assayed for histidase activity, either 
alone or in combination with each other. The combined extracts were mixed 
briefly in a test tube before starting the reaction with histidase/ 
buffer pre-warmed to 30°C. This provides a further test for the 
presence of dissociable inhibitors or activators of histidase activity. 
The results are shown in Table :1. It can be seen that when extracts 
from -'-/+ and his/his mice are mixed, the combined activities are ess- 
enally additive. There is no enhancement of mutant activity or 
inhibition of wild-type activity. This rules out the possibility 
that wild-type extracts contain a dissociable activator (e.g. a divalent 
metal) which is lacking in the mutant or that mutant extracts contain 
a dissociable inhibitor which is absent in the wild-type. 
(iv) Inhibition by nitromethane. 
Nitromethane has been reported to inactivate bacterial and 
mammalian histidase irreversibly in vitro and in vivo, probably by 
reacting with a dehydroalanine residue at the active site (Givot et 
al., 1969; Wickner, 1969; Givot and Abeles, 1970; Okainura et al., 
1974; Hanford and Arfin, 1977).  It is a relatively specific in- 
hibitor of histidase. The aim of these experiments was therefore to 
compare the inhibition of mutant and wild-type histidase by nitro- 
methane. If it proved possible to inactivate mutant and wild-type 
histidase in vivo, measuring their rates of recovery would provide 
an estimate of their relative rates of in vivo synthesis and degradation 
(Rechcigl and Heston, 1 967). 
Mouse liver histidase activity is reported to be more than 90% 
inactivated in vivo within 3 - 5 hours of a single intraperitoneal 
injection of 05 ml of 0°5 M nitromethane (Hanford and Arfin, 1977). 
1 Change in absorbance at 277 nm per minute. 
TABLE S:1 
Tests for the presence of inhibitors or activators 
of liver histidase activity by mixing extracts from 
+/+ and his/his mice. Each value is the mean of 
triplicate determinations. Histidase units are the 
change in absorbance at 277 nm per minute. 
Liver supernatants (genotype) Ristidase activity 
50 	(./.t) 0-0410 
50 	(:/i:.) 00006 
50 	50 (2!/2!..) 0-0403 
100 	(.t/) 0°0792 
100 	(fl!./.!.) 000011 
100 (+/+) 100 (his/his) 00781 
100 
Four +1-I- and four his/his five-week old mice were injected intra-
peritoneally with 0°5 ml of 05M nitromethane in 0°9% saline and 
killed after 12 hours. The livers were removed and extracted for 
histidase assay. The results are shown in Table 5:2A. Wild-type 
histidase activity is reduced to 7% of control values (P< 0.001), 
while mutant histidase is not significantly different from controls. 
In a further experiment, four his/his males were injected as before 
with 005 ml 05M nitromethane and killed three hours later. Liver 
histidase activity is again found to be the same as controls. 
However, since nitromethane is thought to bind to the active site, 
the twenty-fold higher liver histidine concentration in the mutant 
could be competing with nitromethane at this site and so preventing 
it from inhibiting the enzyme. Three male his/his mice were there-
fore injected intraperitoneally with 0°5 ml of 08M nitromethane, 
1-OM nitromethane and 0.9% saline respectively. They were killed 
five hours later and the livers assayed for histidase activity. The 
results are shown below:- 
Treatment Ristidase Activity 
0.9% saline 0•012 pmol/min/g liver 
08M nitromethane 0.016 piiol/min/g liver 
1-OM nitromethane 0•010 piiol/min/g liver 
Mutant histidase is again not inactivated by nitromethane even at 
double the concentration required in the wild-type. A single his/his 
mouse was injected intraperitoneally with 1-0 ml of 1-OM nitromethane 
and liver histidase assayed after five hours, but no significant change 
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in activityfound. In vitro experiments were then carried out to 
determine the effect of nitromethane on mutant histidase. His/his 
liver extracts were pre-incubated for 30 minutes at 300C with or without 
14mM or 20in14 nitromethane (made up in Tris buffer, pH 9°0) and assayed 
for histidase activity. The results are shown in Table 5:2B. In this 
case exposure to nitromethane reduces the activity to 10% of the 
control (which was not pre-incubated for 30 minutes at 30°C). In 
order to ensure that the loss of activity is due to specific inhibition 
TABLE :2 
Liver histidase activity 12 hours after intraperitoneal 
injection with 0-5 ml of 0M nitromethane in 0.9% saline, 
in comparison with roninjected controls. 
Liver histidase activity in his/his extracts following 
pre-incubation for 30 minutes at 30°C with and without 
nitromethane or nitromethane plus histidine. 
Genotype 
I-iistidase activity, uinol/min./g. liver 
Nitromethane injected Control 
+1+ 0°019 + 0°003 0282 	+ 0°0" 
0009 + 0•003 0o005 + OoOOl 
Preincubation Histidase activity 
p.mol/min./g. liver 
None 0010 
L mM nitromethane 0001 
mM nitromethane + 
30 inN histidine 0.001 
20 inN nitromethane 0.001 
20 mM nitromethane + 




by nitromethane rather than a non-specific mechanism such as enzyme 
denaturation, samples were pre-incubated with nitromethane in the 
presence of 30 inN histidine, which should compete with the nitro-
methane and reduce or abolish any specific inhibition. Histidase 
activity under these conditions is still reduced to about 10% of 
control values (Table 5:2B) suggesting a non-specific mechanism 
for the loss of activity. 
The above evidence suggests that while the wild-type histidase 
is inactivated in vivo by nitromethane injection, this does not occur 
in the mutant. Mutant histidase may be protected as a result of the 
considerably higher endogenous histidine concentration, although higher 
concentrations of nitromethane still failed to inactivate the enzyme. 
Pre-incubation of mutant liver extracts with nitromethane in vitro, 
where the histidine concentration is very low (circa 0•4 mm) compared 
with the nitromethane concentration ()4 inN or 20 inN), results in a 
significant loss of activity. This inactivation still occurs in the 
presence of a seventyfive-fold higher histidine concentration, suggest-
ing that the mechanism of inactivation is non-specific. 
( V  ) Divalent metals. 
A divalent metal ion requirement has been reported for bacterial 
and mammalian histidase (Klee, 1972; Okanura et al., 197)4). The effect 
of a divalent metal on wild-type and mutant histidase was therefore 
examined in crude liver extracts (601000g supernatants). Extracts 
were assayed in the presence and absence of manganous chloride at a 
concentration of 10 3M. The results are shown in Table 5:3. Addition 
of Mn
+2  did not result in a significant change in histidase activity 
in either genotype. 
(vi) Suiphydryl reagents. 
The effect of sulphydryl reagents on histidase activity was 
examined in crude liver extracts (60,000g supernatant) in ±/+ and his/ 
his mice. The liver of a single +/+ or his/his mouse was extracted 
in Tris/sucrose medium in the presence and absence of dithiothreitol 
10 3M. Histidase activity was then determined as before. The results 
are shown in Table 5:4. The histidase activity in both genotypes is 
unaffected by the presence of thiol reagent. The effect of thiol 
reagents on partially purified histidase was not determined. 
TRT.1 
Effect of a divalent metal on liver histidase 
activity in crude +7+ and his/his liver extracts. 
Values are the means of duplicate determinations, 




-NnCl2  10-3M 	+MnC12  10-3M 
+7-'- 0110 0°102 
OOO7 OOO9 
TABLE 5:L 
The effect of dithiothreitol (DTT) in the extraction 
medium at 10 3N on crude liver histidase activity (jmmoi/ 







(vi Heat stabilit 
A change in the heat stability of an enzyme variant provides 
evidence for a mutation at the structural locus. Dr G. Bulfield 
carried out a preliminary examination of the relative heat stabil-
ities of mutant and wild-type histidase activities between 35°C and 
82°C. This showed that the mutant loses about 50% of its activity 
in 30 minutes in the region ho - 42 0  C compared with 70 - 72 0C in 
wild-type. Four +/+ and seven his/his mice were therefore killed and 
the livers extracted and dialysed overnight in the presence of 10 5M 
glutathione, as described in Chapter 2 (xv). An aliquot of -'-1+ 
enzyme extract was then incubated in pH 92 phosphate buffer at 70°C 
for varying periods of time, then returned to ice before assay for 
histidase activity. His/his extracts were extracted and dialysed in 
the same way, but pre-incubated for varying periods of time at 40 o 
before assay. The assays were carried out in quadruplicate, using 
a discontinuous assay method with a 15 minute incubation at 30°C. 
The results are shown in Figure 5:1 and Table 5:5. In +1+ extracts, 
half of the initial activity is lost (t1) after 16 minutes at 70 0C 
2 
compared with the his/his enzyme which has a t1 of 195 minutes at 
40 
0C. When log histidase activity is plotted against pre-incubation 
time, the +/+ enzyme appears to show a biphasic decay, with a more 
rapid component initially, followed by a slower, linear decay. This 
might suggest the presence of more than one enzyme species or altern-
atively interference by urocanase. On the other hand, the mutant 
enzyme shows a linear decay (Figure 5:1) which makes the latter 
explanation unlikely. 
The heat stability of partially purified liver histidase was 
examined. The low ionic strength extract (SN-2) following protamine 
sulphate precipitation was compared in ±/-f- and his/his mice. Aliquots 
of SN-2 enzyme were incubated in pH 7°2 Pipes buffer for 2 - 30 minutes 
i 	
0n a ho C waterbath, then returned to ice before assay. The results 
are shown in Table 5:6 and Figure 5:2A. The first experiment was 
carried out on his/his extracts only and shows a markedly heat labile 
SN-2 activity with a t1  of 9 minutes at bO°C. The second experiment 
examined the heat inactivation of SN-2 extracts from +/+ mice and 
shows an almost identical inactivation curve (Figure 5:2A). When the 
TABLE 5:5 
Heat inactivation of liver histidase at 
700C and bO°C in crude +/+ and his/his extracts. 
Genotype Fraction Temp. Time 
mins. 
Residual histidase activity 
pinol/min./g. liver 	% maximum 
60,000g 70 0 0262 	 100°0 
supernatant 15 0-133 	 5o8 
30 0°054 32°1 
60 0036 	 13•7 
his/his 60,000g 40 0 0°0076 	 100.0 
supernatant 15 0•0043 	 56°6 
30 00026 34•2 
64 o°oo 	 0•0 
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	Heat inactivation of his/his liver histidase in crude extracts 
at 40 0C. The log plots of histidase residual activity (V) 
against preincubation time are shown above, in each case. 
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TABLE 5:6 
Heat inactivation of partially purified liver 
histidase at 140°c, in +/+ and his/his extracts. 
Pre- Residual histidase activity 
Genotype Fraction incubation nmol/uñrVing. protein 	% maximum 
tine, mins. 
±/+ SN-2 0 50014 914 
2 5o323 100 
5 3•726 70 
10 1.1411 27 
15 0°772 15 
20 1.384 26 
30 1o224 23 
his/his SN-2 0 1.51 6 100 
2 1•087 72 
3075 1.172 77 
505 0.850 56 
7•5 0•719 47 
11 0.595 39 
15 0.566 37 
18.5 0°)40)4 27 
22.5 0•336 22 
30 025)4 17 
SN-3 0 51 -38 84 
2 148.13 79 
5 59.8)4 98 
10 60o49 99 
15 55.93 91 







10 	 20 	 30 
time at 40 °C (mini.) 
FIG. 5:2 Heat inactivation of partially purified liver liistidase at LO°c. 
The low ionic strength extract activity (SN-2) is shown for +1+ 
(A 	A) and his/his (s- ---S) mice. The high ionic strength 
activity (SN-3) is shown for the +/± (. 	.) genotype. 
A 	The % residual activity is plotted againt incubation time at )40°C. 
B Log residual activity against preincubation time. The lines were 
fitted by eye. 
B 
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log residual activity was plotted against pre-incubation time, 
an identical linear relationship is obtained with the SN-2 enzyme 
from +/+ and his/his livers (Figure :2B). In -4-/+ samples, most 
of the histidase activity is recovered in the high ionic strength 
extract (SN-3) following protamine sulphate precipitation. The 
heat inactivation of SN-3 extracts from +1+ mice was then examined. 
This activity is found to be heat stable at LjO°C (Figure :2A and B). 
The heat stability of SN-3 extracts from his/his mice was not tested. 
Although the +1+ SN-3 enzyme is in a higher ionic strength medium 
than the SN-2 enzyme, this difference is eliminated in the assay 
mixture so that two clearly distinguishable enzyme species with 
histidase activity appear to be present in the wild-type. The heat 
labile component is also found in SN-2 extracts from his/his livers. 
The heat stable component in +/+ samples can beidentified with the 
major histidase species, which is known to be stable at this temp-
erature [see Chapter 1 (iv) and crude extract results above]. In 
crude his/his extracts, histidase is heat labile with a t1 of 19•5 
2 
minutes at 40 
o  C compared with the heat labile component in SN-2 
fractions with a t1 of 7 minutes at )40°C. This relatively small 
difference could result from the removal of adsorbed material on 
purification or from the fact that crude extracts were incubated at 
pH 9°2 compared with pH 72. Although the heat stability of SN-3 
extracts from his/his mice has yet to be determined, the above results 
suggest that the residual mutant activity could be due to a distinct 
histidase isozyme unaffected by mutation at the his locus and capable 
of deaminating histidine to urocanic acid at a low rate in both geno-
types. 
(vii) Kinetic constants. 
The effect of substrate concentration on histidase activity has 
been investigated in crude and partially purified liver preparations. 
Because of the twenty to twentyfive-fold difference in liver histidine 
concentration between +/± and his/his mice (Bulfield and Kacser, 197)4), 
it was necessary to desalt the samples by dialysis or gel filtration 
beforehand. Livers from wild-type females were extracted to obtain a 
60,000g supernatant. This was dialysed overnight to remove endogenous 
histidine as described in Chapter 2 (xv). Dialysed samples were then 
TABLE 	:7 
Comparison of apparent Michaelis constants (Kin) 
for histidine and velocity constants (Vinax) in 
crude liver extracts from 3 strains of mice. 
The constants were determined from double reciprocal plots. 
Inbred strain Km for histidine Molar 
Vinax 
mol/min./g. liver 
PERU 068 x 0•341 
C57BL/6J 06 	x 0358 
DBA/2J 0o5 x 10 0372 
TART. 	R 
The effect of histidine concentration on liver 
histidase activity in crude (60,000g supernatant) 
extract from +/-i-  mice. 










FIG. 5:3 A The effect of histidine concentration (s) on histidase 
activity (V) of dialysed liver extracts from +/± mice. 
B Double reciprocal plot of histidine concentration against 
histidase activity. 







9 — liver 
0- 
0• 
002 	 0-04 	 006 	 0-08 









u-Us 	0-Ub 	007 	008 
HISTIDINE concentration, M 
FIG. 5:4 The effect of histidine concentration on histidase activity in three 
inbred strains of mouse; Peru (.), C57BL/6J ( A ) and DBA/2J (.). 
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assayed in the presence of varying concentrations of histidine. 
The result of one experiment is shown in Table 5:8 and Figure 5:3. 
A double reciprocal plot of histidine concentration against histidase 
activity was used to estimate the Km for histidine and velocity 
constant (Vmax). The Km for histidine was 0o81 x 10 3M and Vmax was 
0-51 2 inol/Inin/g liver. The experiment was repeated using +/+ males 
from three different strains of mice to examine, the possibility of 
kinetic variation between strains. Samples were not dialysed in this 
experiment. The strains examined were Peru (genetic background of 
the his mutant), C57BL/6J and DBA/2J. The kinetic difference in 
histidase activity between inbred strains reported by Hanford and 
Arfin (1977) was not known at this time. All three strains have 
closely similar kinetic constants, as estimated from double reciprocal 
plots. (Table 5:7 and Figure 5:)1). These data provide no evidence 
for heterogeneity between these strains of mice and show that the 
Peru strain is in the Tthight! histidase activity group reported by 
Hanford and krfin (1977), since C57BL/6J and DBA/2J are both found 
in this group [see Chapter 1 (v)J. 
The substrate affinity of +/+ and his/his histidase was compared. 
Livers from +/+ and his/his female mice were extracted and dialysed 
overnight. Dialysed samples were then assayed in the presence of 
varying concentrations of histidine. Assays were carried out using 
both the discontinuous method modified from Kacser et al., (1973) with 
a ten minute incubation time and the continuous method used routinely. 
The results are shown in Table 5:9 and Figure 5:5. The two assay 
methods give closely similar results. -t-/-t- histidase shows a very 
different kinetic response to changes in histidine concentration 
compared with the his/his enzyme. The his/his enzyme does not show 
typical Michaelis-Menten kinetics, since the activity falls off 
sharply at higher histidine concentrations. The Km for histidine 
appears to be higher in the his/his enzyme than the +/+ enzyme, although 
it is not possible to measure it accurately in the mutant since the 
activity may or may not be saturating in the region 20 - 30 niN, above 
which the activity falls off. The decrease in activity with increasing 
histidine concentration suggests that substrate inhibition is occurring. 
There is no evidence of this with the -'-/+ enzyme. 
TABLE 5:9 
The effect of substrate concentration on histidase activity 
in crude liver extracts from +/+ and his/his mice. 
Assay method Genotype 
Ristidine Histidase activity 
inN maximum 
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FIG. 5:5 The effect of histidine concentration on histidase activity in dialysed 
liver extracts from +/+ (A, continuous assay; e,, discontinuous assay) 
and his/his (s, continuous assay; o, discontinuous assay) mice. 
TABLE 5:10 
The effect of histidine concentration on his/his liver histidase 
(1) after desalting by fel filtration on Sephadex G25, 
(2) after partial purification by protamine 







 his/his 60,000g 3 7305 
supernatant, 6 93o0 
desalted 	on 18 100•0 
Sephadex G25 30 61.3 
60 523 
 his/his SN-2 0°02 260 
9.02 9509 





10 	 20 	 30 	 40 	 50 	 60 
HISTIDINE concentration mM 
FIG. :6 The effect of histidine concentration on his/his liver liistidase 
after desalting by gel filtration on Sephadex G-25 (0), 
partially purified by protarnine sulphate precipitation 
(SN-2 fraction) (•). 
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The kinetics of the histidase response to changes in 
substrate concentration were examined further in crude his/his 
extracts desalted by gel filtration on Sephadex G-.25. This method 
allowed the enzyme to be assayed on the day of extraction, so 
reducing the likelihood of changes in the enzyme due to ageing. 
The results are shown in Table 5:10(1) and Figure 5:6A. The affinity 
for histidine appears to be higher than observed in dialysed extracts 
and saturation starts to occur in the region 10 - 20 mM histidine. 
The Kin for histidine therefore appears to be in the region of 2 mM. 
Again the activity falls off at histidine concentrations above 20 mM 
in a manner suggesting substrate inhibition. 
The effect of substrate concentration on mutant histidase activity 
was then determined after partial purification by protamine sulphate 
precipitation. The initial experiment was carried out on SN-2 extracts 
from his/his livers. The endogenous histidine concentration of SN-2 
extracts was found by amino acid analysis to be relatively low at 
029 p11101/nil (cf. 60,000g supernatant from ±/± mice with a histidine 
concentration of 0°22 pmol/ml). The effect of histidine concentration 
on activity was therefore examined directly in SN-2 extracts without 
further desalting. The results are shown in Table 5:10(2) and Figure 
5:6B. A similar kinetic response to that seen in crude his/his extracts 
is found. Unfortunately the lack of activity readings between 002 mM 
and 9 mM histidine make estimation of the Km unreliable. The fall in 
activity with increasing histidine concentration occurs rather later 
(> 30 inN) than seen in the gel filtration experiments. 
The activity of SN-2 histidase in the absence of added histidine 
was found to be measurable (about 20% of maximum) presumably as a 
result of the endogenous histidine concentration of SN-2 extracts 
(ca. 002 mM in the final reaction mixture). In an attempt to reduce 
the endogenous histidine altogether, the SN-2 extract was dialysed 
overnight against Tris 002M pH 74/sucrose 025M. The activity on 
the following morning was reduced to 18% of the pre-dialysis level. 
There was insufficient activity to repeat the Km experiment. It was 
not possible to examine the effect of substrate concentration on 
histidase activity in SN-3 extracts from his/his mice, SN-2 or SN-3 
extracts from +/+ mice in the time available. 
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(ix ) Ionic strength. 
The effect of ionic strength on histidase activity was examined 
in an attempt to characterise the residual histidase activity further 
in his/his mice. This experiment was suggested by the observation 
that mutant SN-2 histidase activity decreases markedly at high sub-
strate concentrations (see above). It is possible that the activity 
decreases not because of substrate inhibition but because of an 
accompanying change in the ionic strength of the assay med:iuin. This 
was tested by adding increasing amounts of 2M NaCl to the standard 
assay mixture. keeping everything else constant. The results are shown 
in Table 5:11 and Figure 5:7. SN-2 histidase activity decreases by 
a factor of 10 as the salt concentration is increased from 0•01M to 
0-1 N in both ±/+ and his/his extracts. This again suggests that 
the residual histidase activity in the mutant is not a product of 
the major histidase structural locus. Histidase activity with an 
almost identical sensitivity both to thermal denaturation and to 
ionic strength is present in mutant and wild-type extracts, suggesting 
that "unmasking" of a quantitatively minor histidase activity has 
occurred following loss or reduction of the major activity component 
by mutation. It was not possible to examine the sensitivity of SN-3 
extracts to ionic strength in the time available. 
( x ) pH optimum. 
The pH optimum of liver histidase was determined in crude extracts 
from +/+ and his/his mice. In the first experiment, the histidine 
solution was made up in 0°1N sodium phosphate buffer and adjusted to 
pH?s between 7•5 and 1005.  Although sodium phosphate (pKa 72) is 
only an effective buffer in the region of 6.2 - 82, histidine itself 
is an effective buffer at the higher pH's used (pica3 9.2). The 
results are shown in Table 5:12 and Figure 5:8A. Histidase activity 
in both genotypes shows a broad pH optimum lying between 8.5 and 9.0. 
Mutant histidase activity falls off more sharply on the alkaline side 
and less sharply on the acidic side of the optimum compared with wild-
type enzyme. The experiment was later repeated using Tris HC1 buffer 
(pKa 8.1) in the pH range 7°8 - 8°9 and diethanolamine HC1 buffer (pKa 
8°9) in the pH range 903 - 10-2. With these buffers the pH optimum 
occurs at around pH 8°9 (Figure 5:8B). The activity falls off more 
TABLE 5:11 
Effect of ionic strength on partially purified 
liver histidase activity of +/+ and his/his mice. 
The assay mixture contained 100 111  SN-2 
(500-600 jig protein), 002M Tris HC1 pH 90, 


















Effect of ionic strength on SN-2 histidase activity 
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TABLE 5:12 
The effect of pH on histidase activity in crude 





phosphate/ 7•5 22•2 71.5 
histidine 80 68°9 862 
8°5 95°6 100.0 
9°0 100•0 97.6 
9•5 85.8 72°2 
100 61.8 
10o5 465 268 
Tris/ 78 87 0 
diethanol- 
83 60o9 0 amine 
85 76°1 46•9 
8°9 10000 100.0 
9.3 891 65.6 
9•7 630 37°5 
10°2 1 478 0 
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FIG. 5:8 The effect of pH on crude liver histidase activity in ±/+ (A- A) 
and his/his (- -.) mice. 
A pH-activity curve in the presence of phosphate/histidine buffer. 
B pH-activity curve in the presence of'Tris or deithanolaimine buffer. 
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steeply on either side of this pH compared with the phosphate 
buffer, particularly in his/his samples. 
There is therefore no difference in the optimum pH of -f/-F 
and his/his histidase, which lies in the region 85 - 9.0, although 
there are minor differences in the pH profiles of the two genotypes. 
(xi) Electrophoretic mobility. 
The electrophoretic mobility of crude -4-/+ and his/his liver 
histidase was examined as described in Chapter 2 (xvii). In a 
preliminary experiment, the liver from a +/± C57BL/6J mouse was 
extracted as before and 50 p.l  or 100 111  aliquots of the 60,000g 
supernatant applied to polyacrylarnide gels. These were run until 
the marker dye was close to the bottom of the tube. The position 
of the dye was marked and the gels were frozen and cut into 1 mm 
slices. Groups of three adjacent slices were each put into test 
tubes containing 03 ml Tris HC1 0025M pH 74 on ice. The gels 
0 were crushed with a glass rod and left overnight at 2 C. They were 
then assayed for histidase activity by adding a 0°2 ml aliquot to 
2°8 ml of the routine assay mixture. The assay tubes were incubated 
at 300C for one hour and the reaction stopped by adding 0°5 ml of 
ice-cold 20% trichloroacetic acid. The samples were frozen until 
the absorbance at 277 nm was read. The results are shown in Figure 
5:9. Ristidase activity is found in corresponding positions on both 
gels with a mobility of 044 relative to the bromophenol blue marker 
dye. Another +/+ C57BL/6J mouse was sacrificed and the liver ex-
tracted and subjected to electrophoresis as before. The whole gel was 
then repeatedly scanned directly with a Joyce Loebl UV Chrornoscan 
after immersion in assay medium containing histidine, buffer and 
sucrose to reduce diffraction at the gel-solution interface. A 
single, strongly UV absorbing band can be identified and increases 
linearly with time (Figures 5:10-11). The position of this band 
corresponds to that identified in the previous experiment. 
When the 60,000g supernatant from a +/-f- Peru mouse is subjected 
to polyacrylaimide gel electrophoresis and assayed for histidase activity 
with the chromoscan, a single ISV absorbing band is again found. The 
mobility relative to the bromophenol blue (BPB) marker is 0°16. Gels 
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activity 
FIG. 5:9 Histidase/eluted from polyacrylainide gel slices after 
electrophoresis of (A) 50 Fl crude liver extract and (B) 
100 )il crude liver extract from a 	mouse. The position 
of the bromophenol blue (BPB) marker dye is shown. 







FIG. :11 Gel scans of crude -'-/± liver supernatant (20 ii) run on 
a 7 poly-acrylamide gel at pH 8•9. The direction of 
mobility is anodal. (A) - (C) 1 5, 29 and 247 minutes after 






FIG. 5:12 Gel scans of crude ±/+ liver extract (20 pi)  run on a 7% 
polyacrylamide gel at pH 8.9. The direction of mobility is 
anodal. (A) Before addition of Iiistidine to the gel. 
(B) - (B) 3, 7 and 23 minutes after addition of histidine 
(2•5 volts sensitivity). The estimated size of a peak with 





ans of crude his/his liver extract (40 pi) run on a 
7% polyacrylavide gel at ph 8•9. The direction of 
I 	mobility is anodal. (A) Before addition of 
histidine to the gel. (B) - (F) 1, 11, 20, 40 and 
60 minutes after addition of histidine (25 volts 




FIG. 5:14 Gel scans of crude -i-/his liver extract (20 pi)  run on a 7% 
polyacrylamide gel at pH 8•9. The direction of mobility is 
anodal. (A) - (F) 1, L, 8, 20, 30 and 45 minutes after 
addition of histidine to the gel (25 volts sensitivity). 
+ 
I; 
a peak area after 20 - 30 minutes which is large enough for even 
3 - 5% of this activity to be distinguishable from background, 
(Figure 5:12). When 20 or LiD F1 of mutant liver supernatant is 
applied under identical conditions, there is no clear evidence of 
a histidase peak at any point in the gel (Figure 5:13). The 
identification of small 1W absorbing peaks corresponding to the 
mutant activity is complicated by the fact that increases in the 
size of all peaks occurs to a limited extent with increasing assay 
time (see Figures 5:13-14), probably due to diffusion of proteins 
within the gel. Loading larger amounts of enzyme extract leads to 
loss of resolution. Electrophoresis was carried out at 40C using 
a very low current (1 - 2 mA per tube) so that sample heating was 
minimised (Davis, 1964) but in view of the lability of his/his 
histidase some loss of activity during electrophoresis could not 
be ruled out. 
Samples containing 20 F' of liver extract from -i-/his mice were 
run under the same conditions (Figure 5:14). A single IN absorbing 
peak is found with the same mobility relative to BPB as found in 
-'-/± extracts, but no additional peaks. Since mammalian histidase is 
likely to be a tetrameric protein, the existence of a mutant structural 
gene could lead to formation of hybrid proteins in heterozygotes (Harris, 
1975). Five distinct tetrameric enzymes might therefore be expected 
in a heterozygote if the mutant and wild-type polypeptides were able 
to associate into a tetrametic structure. Some, or all, of the three 
hybrid forms could retain histidase activity and all five could be 
electrophoretically distinguishable. This possibility is ruled out 
by the above finding with +/his extract, since no additional 1W 
absorbing peaks are distinguishable. Mixing of -1-/-i- andhis/his 
extracts might give rise to hybrid enzyme formation in vitro, even 
if this does not occur in viva. 10 F1 of +/+ extract was therefore 
mixed with 10 Fl of his/his extract prior to electrophoresis and then 
run in parallel with ±/+ and his/his samples. A single histidase peak 
can be identified with identical mobility to that in -i-/+ extracts but 
no additional peaks are present. 
The problem of determining the significance of small 1W absorbing 
bands led to the attempts to purify mutant histidase. It seemed to 
be impossible to distinguish a band with low histidase activity from 
A 
+ 	- 	 4- 
D 
FIG. 5:15 Gel scans of partially purified his/his liver histidase 
(60 Fl : SN-2 fraction) run on a 7% polyacrylamide gel at 
pH 8•9. The direction of mobility is anodal. (A) - (D) 
6, 16. 30 and 52 minutes after addition of histidase to 
the gel (2 volts sensitivity). 
A 	± 
C 
FIG. 5:16 Gel scans of partially purified ±/-f- liver extract (10 il 
SN-3) rim on a 7% polyacrylaimide gel at ph 8•9. The direction 
of mobility is anodal 	( A) - (C) 1-5., 3•5 and 7•75 minutes 
after addition of histidine to the gel (2.5 volts sensitivity). 
A 
:1 
FIG. 5:17 Gel scans of partially purified +/+ liver extract (50 p.l : SN-3 
fraction) run on a 7% polyacrylanide gel at ph 8•9. The direction 
of mobility is anodal (A) - (B) 10 and 20 minutes after addition 





FIG. 5:18 Gel scans of his/his liver extract (20 Ill : SN-3 fraction) run 
on an 8% polyacrylaiiiide gel. The direction of mobility is anodal. 
(A) - (B) 2. 14, 32 and LiJ minutes after addition of liistidine 
to the gel (2.5 volts nsitivity). 
FIG. 5:19 Densitometer tracing of crude his/his liver extract (20 ul) run on a 7% polyacrylamide 
gel, fixed and stained with Arriido Black. The anodal peak is probably due to retained 
bromophenol blue marker. 
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one in which diffusion of protein was causing the peak to change. 
Partially purified histidase extracts were therefore subjected to 
polyacrylainide gel electrophoresis after protaznine sulphate pre-
cipitation. SN-2 extracts containing 120 - 360 jig protein in a 
20 - 60 p.1 volume were loaded on the gels and run as before. SN-3 
extracts containing 170 - 340 ig protein in a 10 - 20 jil volume were 
also run. When samples of the SN-2 fraction from his/his mice are 
subjected to electrophoresis and assayed by UV scanning, there is no 
clearcut histidase band that increases linearly with time, although 
three peaks running close together in an anodal position are suggest-
ive (Figure 5:15). The latter peaks could equally have been due to 
diffusion of protein as seen in Figures 5:13-14 after prolonged 
incubation.s. SN-2 extracts from +/+ mice were not examined electro-
phoreticafly because of time limitations. When SN-3 fractions from 
±/+ mice are run and the gels assayed as before, a histidase peak 
is clearly seen, with a mobility of 0024 relative to BPB (Figure 5:16). 
In one experiment, two histidase peaks can be seen with mobilities 
of 024 and 016 respectively (Figure 5:17). The slower migrating 
band probably results from aggregation of the enzyme, as observed by 
others (Okamura et al., 1974). A sample of the SN-3 fraction from 
his/his mice was also subjected to electrophoresis. The gel was 
assayed by UV-scanning and no histidase band could be detected in 
a 45 minute incubation (Figure 5:18). 
Polyacrylamide gels containing samples of crude liver extract 
were stained with Amido Black and destained as described in Chapter 2 
(xvii). A microdensitometer tracing from such a stained gel is shown 
in Figure 5:19. The gels containing partially purified histidase were 
not stained for protein. 
di) Discussion. 
The difference in liver histidase activity between wild-type and 
histidinaemic mice is not due to enzyme activation or inhibition. This 
is shown by the mixing, dialysis and gel filtration experiments. For 
example, a deficiency of metal cofactor (perhaps due to loss of the 
binding protein) could cause a histidase deficiency, but activity 
should be restored by mixing the two extracts, assuming the presence 
of free metal in the wild-type. Also, codominant expression of histidase 
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activity in the heterozygote is unlikely to occur if the his 
mutant is due to loss of an activator or formation of an inhibitor 
product. The above conclusion is supported by experiments carried 
out during the course of the thesis in collaboration with Professor 
S.M. Arfin and coworkers (unpublished). These workers had previously 
raised monospecific antibodies to 70% pure preparations of rrxnse liver 
histidase, which they used to immunoprecipitate liver histidase in 
+/+ and his/his liver extracts. The mouse livers used in these 
experiments were frozen immediately after dissection in Edinburgh 
and sent by air in dry ice to the Department of Biological Chemistry, 
California College of Medicine. Two experiments were carried out 
to determine the amount of cross-reacting material (CRM) in the two 
genotypes. 
In a constant antigen experiment, three volumes of ±/+ liver 
extract, one volume of +/+ extract plus two volumes of his/his extract, 
and one volume of +/+ extract plus two volumes of mouse kidney extract 
(i.e. a tissue lacking histidase activity) were each titrated with 
anti-histidase serum. The unprecipitated histidase activity was then 
measured using their standard assay procedure. If the his/his extract 
contained the same amount of CRM as the +1+ extract, the end point of 
the titration of one volume of ±/+ plus two volumes of his/his extract 
would be the same as that for three volumes of +/+ extract. If there 
was no CRM in his/his extracts, the end point would equal that of one 
volume +/+ extract plus two volumes of kidney extract. Any intermediate 
end point would provide an estimate of the amount of CRM present. The 
result was clear-cut, showing that there is no CRM in his/his extracts. 
In the second experiment, a constant amount of anti-histidase antibody 
was pre-incubated for 30 minutes at 37°C with his/his liver or mouse 
kidney extract, then increasing amounts of ±/+ extract were added. Any 
his/his CRM present would therefore use up antibody leading to the 
appearance of -1-/+ histidase activity at lower antigen concentrations 
than in the presence of the kidney extract. The result was that +1-i-
histidase activity appeared at the same point whether the antibody had 
been pre-incubated with his/his extract, kidney extract or nothing at 
all. Again, mutant histidase appears to be CRM-negative. 
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Arfin and coworkers concluded that if there is any CRM in 
his/his livers it must be less than 10% of that in wild-type. The 
sensitivity of the techniques could not exclude the possibility of 
5% CRM. However they were unable to detect any histidase activity 
in the frozen his/his livers received from Edinburgh so that the 
low CRM could have resulted from damage to the enzyme sustained in 
transit. It had previously been found that mutant histidase activity 
is retained (although reduced) after rapid freezing and storage in 
liquid nitrogen. Since antigenicity is thought to reside in the 
three-dimensional structure, enzymes that are denatured or dissociated 
into subunits may react poorly or not at all with antisera (Gelehrter 
et al., 1970; Celada and Strom, 1972; Brock, 1978). This possibility 
can only be excluded by the use of liver extracts taken directly from 
live his/his mice. It would also be useful to compare the amount of 
CRM in all three genotypes, 	+/his and his/his, since there is 
a report of CRM-negative homozygotes with sucrase-isomaltase deficiency, 
while heterozygotes with 50% of normal enzyme activity have virtually 
100% CRM (Gray et al., 1976). If confirmed, the finding of absent 
CRM in mutants suggests either that the enzyme is so structurally 
altered by mutation that it is no longer antigenicafly active or more 
likely (see ii, above) that there is no (or less than 10%) histidase 
present at all. The latter could result from rapid degradation due 
to molecular instability (structural variant), increased enzymic 
degradation (processing variant) or alternatively from reduced synthesis 
of normal (regulatory variant) or altered (structural variant) enzyme. 
The above results do tend to exclude the possibility of activators or 
inhibitors as causes of the difference in histidase activity. 
The difference in heat stability between crude +1+ and his/his 
histidase is evidence against a regulatory gene mutation. The +/± 
enzyme has a t1 of 16 minutes at 70°C compared with 19.5 minutes at 
400C in his/his extracts. This unambiguous difference suggests three 
possibilities; (1) mutation at the structural locus for histidase: 
(2) mutation at a histidase processing locus: (3) "unmasking" of 
activity in a distinct histidase isozyme, due to mutational loss of 
of the major enzyme species. 
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The first possibility, mutation at the histidase structural 
locus, has not been confirmed by the electrophoretic studies since 
no histidase electrophoretic band could be clearly identified either 
in crude or partially purified extracts of his/his liver. The un- 
stable mutant enzyme is presumably denatured during electrophoresis 
or during the prolonged gel assays. The sensitivity of the gel assays 
should have been sufficient to detect mutant activity in partially 
purified extracts since the specific activity in SN-2 extracts was 
1 - 2 final/mm/mg protemnmpared with about 3 nmol/rnin/mg protein 
in crude -i-/+ extracts. The latter were easily identified on gels 
using an identical assay. For example, in the gel shown in Figure 5:15, 
0°5 units of mutant SN-2 histidase (in bOB ig protein) were loaded on 
to the gel compared with 2•2 units (in 660 .ig protein) af crude +/± 
histidase, shown in Figure I:12. The mutant histidase peak in Figure 
5:15 should therefore have been the same size as that in Figure 5:12B 
by 13 minutes, while in fact there was no major peaks visible even 
after 30 minutes (Figure 5:150. These experiments again exclude the 
possibility of a reduced amount of normal enzyme as would be expected 
with a regulatory gene mutation. A regulatory mutant could however 
lead to complete loss of the major enzyme species with "unmasking" of 
a previously unrecognized form of histidase. The absence of hybrid 
enzyme bands with histidase activity in hetero zygotes or mixed ±/+ 
and his/his liver extracts can be interpreted in a number of ways. 
First, a structural locus variant could be so altered that it is 
unable to polymerise with the normal subunits. Second, the hybrid 
enzymes could be unstable under the electrophoretic or assay conditions, 
so that the activity is lost. Third, the his mutation could represent 
a null allele which produces no enzyme product, perhaps due to a deletion 
or frameshift mutation. This last possibility is supported by the 
finding that the mutant is CR11-negative. Fourth, it has not been shown 
conclusively that the native mammalian enzyme exists in multimeric 
form (see Chapter 1 (iv)J. 
A mutation at the structural locus for histidase might lead to 
a change in the response to activators, cofactors or inhibitors. However 
neither a suiphydryl reagent nor a divalent metal ion at 10 3M has 
any effect on histidase activity in crude liver extracts of either 
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genotype. Nitromethane is a relatively specific, irreversible 
inhibitor of histidase. Intraperitoneal injection of nitromethane 
reduces +/+ histidase activity to 7% of control values while having 
no effect on his/his histidase. Since the twenty-fold higher 
histidine concentration could competitively inhibit nitromethane 
inactivation in the mutant, higher concentrations of nitromethane 
were injected, still without effect. In vitro, nitromethane in-
hibits his/his liver histidase by 90% but this is unchanged by the 
presence of 30 mM histidine, which shows that inhibition is occurring 
by some means other than covalent binding to an active site residue. 
These experiments therefore do not distinguish between a structurally 
altered histidase and another enzyme with low histidase activity. A 
histidase structural variant would probably be inhibited by nitro-
methane even if with altered kinetics • An enzyme able to convert 
histidine to urocanic acid at a low rate due to cross-specificity 
is less likely to be inhibited by nitromethane. 
The kinetics of the histidase response to substrate is strikingly 
different in +/+ and his/his mice (Figures 5:5-6). The marked reduction 
in activity occurring at high substrate concentrations is only found 
in the mutant. The subsequent finding that mutant activity declines 
with increasing ionic strength could explain this result, so the 
kinetics should be re--examined under conditions of low or constant 
ionic strength. An alternative Explanation would be that substrate 
inhibition is occurring. 
The pH optimum of crude liver histidase activity has been compared 
in ±/+ and his/his mice. An identical pH optimum in the region 8.5 - 
90 is found using two buffer systems, although there are differences 
in the activity changes on either side of the optimum. (Figure 5:8). 
This finding does not help to clarify the molecular nature of the 
residual histidase activity. 
Two observations made in partially purified liver histidase 
extracts suggest that the third possibility mentioned above may be 
correct, namely that the residual mutant activity is due to ttijjijiagIHjgfl 
of another enzyme by a null allele at the major histidase locus. First, 
when the heat stability of the. low ionic strength (SN-2) extracts from 
-4-/+ and his/his mice are compared, the activity in both extracts shows 
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an identical lability to heating at 400C (t1  = 9 minutes) (Figure 
5:2). The major histidase activity of +/-4- livers is recovered in 
the high ionic strength (SN-3) extract which is heat stable at 
400C (Figure 5:2). The presence of two enzyme species with histidase 
activity in +1+ mice is supported by the heat inactivation studies 
carried out in crude liver extracts at 70°C (Figure 5:1A). A bi-
phasic rate of inactivation was found, with a faster rate during 
the first 15 minutes than between 15 and 60 minutes of pre-incubation 
at 70°C. This could be due to rapid loss of the heat labile component 
followed by a slow decay of the major species. In contrast, the 
mutant enzyme decayed in accordance with a single enzyme species 
(Figure 5:1B). 
The second observation suggesting the unmasking of a minor 
histidase species, is the effect of ionic strength on activity. 
When the activity of SN-2 extracts from +/± and his/his livers is 
compared in the presence of increasing salt concentrations, both 
sources of enzyme show the same marked loss of activity with in-
creasing salt concentration (Figure 5:7). The nature of this 
inactivation has not been investigated. It could be due to the 
effect of ionic environment on enzyme conformation leading to 
impaired catalysis, dissociation into subunits or denaturation. 
Alternatively it could be due simply to salting-out the enzyme from 
solution. 
Further support for this interpretation of the findings comes 
from the study of developmental changes in skin histidase activity 
(Chapter 3 (ii)J. Although +/± skin histidase activity is markedly 
higher than the mutant from birth to ten days, by fifteen days the 
activity is identical in the two genotypes. This would suggest 
either that the his/his enzyme is associated with a loss of inductive 
responsiveness but normal catalytic function or that only one of two 
histidase isozymes is lost in the mutant. The 15-day +/+ activity 
would, in the latter case, correspond to the minor activity component 
and show the same properties as the mutant enzyme. 
Although further confirmation is required with samples taken 
directly from intact mice. the finding of absent or less than 10% 
CRJ1 in his/his livers is also compatible with the unmasking of a 
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distinct enzyme with histidase activity. The evidence relating to 
the absent (or diminished) major histidase activity does not distinguish 
between a null allele at the histidase structural locus or at a 
regulatory locus. 
An alternative, more complex explanation for the findings 
discussed above can be made. There is good evidence from the study 
of bacterial and mammalian histidase that the enzyme can exist in 
different states of aggregation (Klee, 1970;  Okamura et al., 1974). 
While the native Pseudomonas enzyme is thought to be a tetramer made 
up of identical subunits, these tend to aggregate into polymers which 
are all enzymatically active. The relative stability of these different 
molecular forms to denaturation has not been studied, but Roth and 
Hug (1971 ) report the disappearance of a slow (polymerized) histidase 
electrophoretic band after heating the crude extract at 80°C while 
the fast (unpolymerized) band was stable to this treatment. Mutation 
at the structural locus for histidase could alter the rate at which 
the native enzyme aggregates into larger units. If the enzyme also 
becomes increasingly labile as it polymerises, the residual mutant 
activity could result from a predominance of these unstable forms 
which would also be present in the wild-type, although in a smaller 
ratio to the native form. The low ionic strength (SN-2) extract would 
contain the more polymerised forms, while the high ionic strength 
(SN-3) extract would contain predominantly native enzyme. This would 
be consistant with the reduced CHN and instability of the his/his 
enzyme. It might also explain the failure to demonstrate SN-2 histidase 
band(s) on electrophoresis. If the residual activity is split between 
three or more different polymeric forms of the enzyme, the sensitivity 
of the gel assays is probably too low to detect these components with 
confidence. The existence of such multiple forms of wild-type histidase 
is suggested by the electrophoretic demonstration of activity with 
R  values of 0)4)4 (crude extracts), 0°24 and 016 (SN-3 extracts). 
This could be confirmed by showing that these convert back to a single 
peak (Rf = 0°44), corresponding to the unpolyxnerised enzyme, on prior 
incubation with thiol reagent (see Klee, 1970;  Okamura et al., 1974; 
Bhargava and Feigelson, 1976a). It is therefore possible that mutant 
histidase is a structural locus allele which has similar catalytic 
properties to the wild-type but tends to aggregate into polymerised 
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forms more readily than the wild-type enzyme. These aggregates 
have reduced in vitro and in vivo stability, but specific activity 
similar to the native enzyme (Klee, 1970),  so that the amount of 
CRI'I is similar to the level of mutant activity. 
The hypothesis discussed above is only tentatively put forward 
since it requires careful examination of the enzyme properties in 
both genotypes in the presence and the absence of thiol reagents 
after finding the optimal concentration and incubation conditions 
for conversion of polymerised to native forms of the enzyme. Further- 
more it is difficult to explain the similar histidase activity in 
the 15-day old skin of +1± and his/his mice on this hypothesis. 
These results help to clarify the nature of the his mutation 
although they do not provide an unambiguous answer. A change only 
in the amount of measured activity due to the presence of activators 
or inhibitors is very unlikely. A processing gene mutation is also 
made improbable by the finding of an enzyme with similar properties 
to the mutant in wild-type SN-2 extracts. The results suggest three 
possibilities. Pirst, a structural locus mutation alters the ratio 
of stable to unstable forms of histidase (perhaps related to its state 
of polymerization), so that there is a predominance of the latter in 
the mutant. Second, there is a null allele at the "major" histidase 
structural locus so that no detectable CRN is present. The residual 
mutant activity is in this case due to a low activity isozynie whose 
presence is normally masked by the more active species. This would 
be coded by a distinct structural locus whose product does not 
associate into a heteropolynier with the product of the ?rnajor!  histidase 
locus. Third. there is a defective regulatory locus so that again no, 
or very little, identifiable histidase is present and the residual 
activity is explained on the same basis as above. 
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CHAPTER 6 
GENERAL DISCUSSION AND CONCLUSIONS 
More than 30 different aminoacidopathies are associated with 
mental deficiency (Woolf, 1970).  Despite this our knowledge of 
pathogenetic mechanisms is insubstantial, despite numerous theories 
and a large body of experimental work. In some arninoacidopathies, 
mental deficiency can be averted by restricting the dietary intake 
of the offending amino acid(s) during childhood. This implies that 
the developing organ is particularly susceptible to metabolic inter-
ference. The way in which amino acid excess interferes with the 
developing brain has not been established in any aminoacidopathy. 
Neuropathological findings are often misleading and only provide 
the barest indication of possible pathogenetic mechanisms (Crome and 
Stern, 1967;  Martin and Schlote, 1972a and b). These include ab-
normalities in myelination, glial cell changes and the occurrence of 
scattered, fluid filled spaces (spongy change). These are all non-
specific changes, common to numerous metabolic and other conditions. 
In PK[J, which has an obvious biochemical similarity to histidinaemia, 
myelin is often present in reduced amounts although its composition 
seems to be qualitatively normal (Gaull et al., 1975). Glial cell 
changes include both diffuse and focal areas of fibrillary gliosis - 
often a non-specific response to abnormal function or damage. Spongy 
change reflects a loss of brain substance but provides no indication 
as to the cause. There are only two reports of histidinaemic brains 
seen at autopsy (Waisman, 1967; Corner et al., 1968). Although both 
gliosis and a reduction in myelin are present, such isolated reports 
are of little value, especially since the tendency is to report only 
the more severely affected. 
A large body of experimental evidence has accumulated from the 
use of animal models on the relationship between amino acid excess 
and brain dysfunction. Many of these models have serious limitations 
(Karrer and Cahilly, 1965;  Gerritsen and Siegel, 1972; Gaull et hi., 
1975). This field has been comprehensively reviewed by Gaull et hi., 
1975 The extensive literature has tended to focus on five main ideas. 
(1) A raised concentration of one amino acid may competitively inhibit 
the transport of other amino acids into the brain or into specific 
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brain sites, as a result of a shared carrier system. For example, 
the plasma histidine concentration required to halve the influx 
of tryptophan into the rat brain in vivo is 1.0 - 1°5 mm (Daniel 
et al., 1976), which is in the same region as the plasma histidine 
concentration in histidinaemia (1 - 3 mM in the mouse; ca. 0.7 inN 
in man). The ensuing restriction of essential amino acids could 
be sufficient to interfere with the proper function or development 
of the brain. (2) Several amino acids at concentrations >, 2 mM, 
inhibit the apparent incorporation of other, radioactively-labelled 
amino acids into immature brain proteins in vivo and in vitro. If 
the de novo synthesis of proteins is inhibited, as this might suggest, 
brain development could be permanently retarded. (3) The synthesis 
of neurotransmitter substances could be reduced either by inhibition 
of precursor amino acid entry or by inhibition of transmitter-synthes- 
izing enzymes. 	t) Certain amino acids may inhibit the activity of 
enzymes concerned with energy metabolism in the immature brain, when 
their activity is already low, which would have widespread effects 
on cell division, migration and differentiation. (5) Impaired 
synthesis of myelin lipids or proteolipids, either by inhibition of 
enzymes concerned with lipid metabolism or by some of the mechanisms 
mentioned above, could lead to impaired myelination and transmission 
of nerve impulses. 
None of these hypotheses has been found adequate to explain the 
occurrence of mental deficiency in an azninoacidopathy. It is likely 
that a combination of such mechanisms, some specific to one amino acid 
or its metabolites others common to many, each acting on the developing 
brain are required to produce a lasting cognitive defect. 
Rather than investigating such pathogenetic hypotheses in murine 
histidinaemia, it was felt that the more fundamental question as to 
whether brain development or function is abnormal at all should be 
investigated. The mutant mice could not be consistently distinguished 
from controls using the rather insensitive behavioural tests available1 
In human histidinaemia, the plasma histidine concentration is about ten 
1 MacKenzie and Kacser, unpublished. 
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times normal and only 1 in 6 or 7 subjects are mentally retarded. 
Nurine histidinaemia is more akin to PKU in that the adult plasma 
histidine is about thirty times increased. In classical PKU 96 - 
98% of subjects are severely retarded (IQ< 0) (Tourian and Sidbury, 
1978). The experiments undertaken were therefore designed to provide 
a quantitative comparison of brain development in mutant and normal 
mice using indices of cell growth, cell proliferation and inyelination. 
The results of this study allow a firm conclusion. Although 
small (generally 10 - 15%) differences were found in some parameters 
at some stages of development, these can be attributed to the problems 
of assessing maturity, of differences in litter size and in some cases 
to the small number of animals studied. When each of the indices is 
examined in the two genotypes over the whole five week period, no 
consistent difference emerges. The two genotypes show near identical 
profiles despite large metabolic differences before and after birth. 
This result does not of course exclude changes in the more subtle, 
functional aspects of development or in all-important morphological 
events such as synapse formation. Nevertheless, in maternal PKU a 
thirtyf old increase in maternal phenylalanine concentration is 
sufficient to produce severe mental defect with accompanying features 
such as microcephaly suggesting severe impairment of cell growth or 
differentiation in virtually all cases (MacCready and Levy, 1972; 
Tourian and Sidbury, 1978). The twenty to thirty-fold increase in 
maternal plasma histidine concentrations in murine histidinaemia could 
therefore be expected to produce similar changes in the offspring. 
This is made more likely by the finding of a high foetal:maternal 
concentration ratio for histidine. Any metabolically induced brain 
damage in utero might also be accentuated by an average ten-fold 
increase in the histidine concentration of the litters during the 
postnatal growth spurt. Despite these factors, brain cell numbers 
and growth during the first five weeks after birth are essentially 
normal in histidinaemic mutants. The very high intrauterine histidine 
concentration (about 2°5 pmol/mml could perhaps lead to retardation of 
brain growth with postnatal recovery in the presence of a less extreme 
histidine elevation. There is no indication of this in the data. 
Also, as discussed in Chapter Ii., neuronal multiplication and morpho- 
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genesis are the predominant events occurring before birth, which 
do not usually recover from metabolic or toxic interference (see 
Altman et al., 1970).  In contrast, cell differentiation or histo- 
genesis which occurs to the greatest extent during the postnatal 
growth spurt, shows considerable powers of recovery. 
These results are consistent with the data on maternal histidin- 
aeimia, where the few reports available show offspring of normal 
intelligence. Possible reasons for the striking differences between 
PKU and histidinaemia with respect to intelligence include; (1) the 
two to three-fold higher plasma amino acid concentration in FEll, (2) 
differences in the ability of the two amino acids to interfere with 
processes such as transport or myelination discussed above; (3) differences 
in the concentrations or toxicity of their metabolites. The first 
possibility could be examined further in this mutant by a similar 
analysis of brain development in mutants raised on a 2 histidine 
supplemented diet. As far as the metabolites of histidine are concerned, 
they appear to be rapidly excreted both in utero and after birth, so that 
tissue concentrations are very low in molar terms (0.01 - 0o1ii). Although 
there are one or two examples of amino acids or their metabolites in- 
hibiting enzymes or processes in this concentration range, usually such 
effects are found at a concentration 1 or 2 orders of magnitude 
higher (Gaull et al., 1975).  The tissue concentration of phenyl- 
ketones in FEll has not been determined, but animal studies suggest 
that it is little more than 0.01 rnM (Edwards and Blau, 1972). 
If there is no major effect of histidinaeirtia on the overall 
growth and development of the mouse brain what if any, other aspects 
of brain function should be investigated? During the course of 
investigations into the penetrance of the balance defect, it was 
noticed that some 11* day embryos had abnormal hindbrain morphology 
(Kacser et al., 1979b). Since the hindbrain may induce the formation 
of the ear vesicle during embryogenesis (Deol, 1964a, b), it has 
been suggested that disturbance of this inductive effect in histidin- 
aeinia could distort inner ear development and cause the balance defect 
(Kacser et al., 1979b). The available evidence, while not sufficient 
to sustain this view, is not inconsistent with it. The experiments 
described in this thesis were carried out on a stock with only 7% 
penetrant balance defect, while the hindbrain abnormality was noted 
in a 73% penetrant (CAN) stock. If the hindbrain defect is confirmed, 
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it would be useful to extend the biochemical characterisation to 
embryonic brains in high and low penetrant stocks and to the hind- 
brains of mice taken after birth. One further observation may be 
relevant in this context. In the five years since the introduction 
of the his/his mutant in this laboratory, the penetrance of the balance 
defect has fallen from 80% to less than 10% (Kacser et al., 1979b). 
Bulfield and Kacser (1974) noted, at a time when the penetrance was 
still relatively high (> 50%), significant maternal effects in his/ 
his mice on litter size (33% reduction) and growth (measured by the 
three-week weight). The three-week weights were reduced by 34% 
in balance defective mice and by only 15% in behaviourally normal 
mice. In contrast, there is only a very small () effect on litter 
size and no effect on three-week weight in this study, at a time when 
the penetrance is only 7%. This might suggest that there is a relation- 
ship between the penetrance of the balance defect and growth impairment. 
Brain growth may be particularly important in this respect. The fall 
in penetrance is not due to a change in the plasma histidine concentration 
and so far no biochemical difference has emerged between high and low 
(Kacser et al. 1979b) 
penetrant stock. F\irter studies of brain growth in these stocks 
would therefore be useful. The dependence of the balance defect on 
the genetic background as well as the raised maternal histidine 
concentration also illustrates the general point that the effect of 
an aminoacidopathy will depend on the genetic as well as the environ-
mental background on which it occurs. Both factors are likely to 
contribute to the variable expressivity of human histidinaemia with 
regard to mental defect. 
The latter part of this thesis is concerned with the nature of 
the enzyme defect. The results of these experiments are less clear-
cut. The difference in histidase activity between wild-type and 
mutant does not appear to be due to stimulation or inhibition of 
histidase activity. Preliminary immunological studies suggest that 
the mutant is CRM negative. The striking difference in heat stability 
between crude mutant and wild-type liver extracts initially favoured 
a structural or processing locus mutation rather than a regulatory 
mutation affecting only the quantity of enzyme protein. This was 
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supported by studies on partially purified liver extracts, which 
led to the unexpected finding that two forms of histidase are 
present in wild-type extracts, only one of which is present in the 
mutant • The two forms differ markedly in their heat stability and 
sensitivity to ionic strength. While the possibility still exists 
that the two forms of histidase represent stable and unstable forms 
of a single enzyme (perhaps related to the state of aggregation), 
it seems more likely that they represent distinct isozyrnes, one of 
which is normally masked by the major, heat stable component. The 
low activity or instability of the minor component would result in 
its being destroyed or discarded at an early stage of most puification 
procedures, which is another reason for it not being previously recognised. 
The existence of distinct histidase isozynies is also suggested by 
the findings in the skin, where the early difference in activity 
between wild-type and mutant disappears completely at 15 days, 
suggesting that one component, that is present in both genotypes, 
is unaffected by mutation. If a low activity isozyme is uncovered 
by loss of the more active enzyme, what is the nature of the his locus 
mutation? This could be either a structural or regulatory locus 
mutation, resulting in the formation of little or no active enzyme. 
If it is a structural mutation, the low activity could arise from 
reduced catalytic function or instability and synthesis may also be 
diminished. A grossly abnormal structural gene product might lose 
its catalytic and antigenic properties or be rapidly degraded. Complete 
absence of the structural gene, due to a deletion, could also have 
occurred, in which case it would be hard to distinguish from a null 
regulatory mutant except by genetic mapping. A regulatory mutant 
could cause a complete absence of enzyme protein or a greatly diminished 
amount of normal enzyme. Analysis of the SN-3 extract of his/his 
liver would help to distinguish between these alternatives by showing 
whether or not it has the same properties as the wild-type SN-3 extract. 
Recently it has been suggested that niultilocus enzymes are very 
common in higher organisms and frequently show a marked degree of tissue 
differentiation in the expression of the different loci (Harris, 1 979). 
For example, lactate dehydrogenase is controlled by three loci (A,B,c), 
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two of which (A,B) are expressed in most tissues, but in a 
proportion varying from 10:1 in some tissues to 1:10 in others. 
Similarly, histidase may be controlled by two loci represented 
by the heat stable and heat labile components. The low, but 
measurable activity reported in many tissues in the guinea pig 
(Zannoni and La Du, 1 963) may represent a predominance of the 
heat labile isozyme (which may also act on other substrates), 
while the heat stable activity is predominant in the liver. This 
could be confirmed by comparing the heat stability of histidase 
in crude extracts from different tissues or by comparing the ratio 
of heat stable to heat labile forms in partially purified tissue 
extracts. 
Finally, these results do not suggest any obvious therapeutic 
approach to increasing mutant histidase activity, so that preliminary 
attempts to inject purified histidase in a stable form are under way. 
Although no clear answer to the genetic nature of the his locus 
mutation has emerged yet, the lack of any other histidase structural 
locus variant means that genetic mapping is not yet a feasible 
alternative approach. Further studies of SN-2 and SN-3 extracts in 
both genotypes may clarify the problem further. 
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APPENDIX 
Summary of Reported Cases of Histidinaeimia 
I 
Laboratory findings Clinical findings 
plasma histidase 
Reference 	Case Sex Age IQ speech Other 	 histidine urine activity 
defect (nig/lOOmi) histidine in skin 
Ghadiini et al. 1 F 13 yr 93 + frequent infections, temper 9°0 616 mg/24 hr absent 
1961a and tantrums, behaviourprob1 
1962 failed one year in school, 
had 5 years speech therapy 
and still did not speak 
clearly, hearing defect 
MacMillan 2 F 11 	yr normal - sister of case 1. Retarded 71 819 mg/24 hr absent 
1970 physical development 
Auerbach, et al. 3 F Liy,Lm 83 + small stature, history of 15°8 506 mg/24 hr absent 
1962 and 1966 seizures; elevated plasma 
alanine 
La Du et al.., L F 6 	yr normal + mirror writing 17.3 378 mg/24 hr absent 
1963 5 M 5 yr normal + brother of case 4 13•4 850 mg/24 hr absent 
Andrews et al., 6 F 5y.6m 85 + small stature elevated NB NB 
1962 7 F 7 	yr normal - sister of case 6 elevated NB NB 
Hudson et al., 8 M 8 yr retarded -I- seizures NB elevated NB 
1963 9 NB 1 	mo NB NR NB elevated NB 
Davies and 10 N 5 yr retarded - physical development below 9 312-578 mg/ NB 
Robinson 3rd percentile, episode of 24 hr 
1963 anaemia treated bytramfuion, 
febrile convulsions, 
frequent infections 











1 yr severely 
retarded 
F 3 y 	814 
N 3y,5rno 86 
Snyderman et 	11 
al., 1963; 
Berlow et al., 
1965; Kilhara 
et al.., 1968 
Shaw et al., 	12 
1963; Kilhara 
et al., 1968 
Gerritsen, 19; 13 




Holton, 19614, 	17 
1965; Holton 
et al., 19614 
Corner et. al., 
1968 
Clarence and 	18 
	
F 13 y 	514 
Bowman, 1966 
+ precocious puberty, hemi- 15 	709 mg/214 hr 
vertebrae, dislocated 
patella and genu valgwn, 
scoliosis, delayed devel- 
opmental milestones, int- 
ernal strabismus, poor 
muscular coordination, 




+ intention tremor, mild 14'9-55 	3140-680 mg/g 
progressive ataxia creat 
+ severe emotional problems 11 	NB 
+ very obese, dull exren 7.8-95 600 mg/24 hr 
hyperreflexia, failure to 
stand, failure to cry on 
painful stimuli, brain 
degeneration 
? delayed developmental 9.11 	570-61 7 mg/ 
milestones, dull express- 214 hr 
ion, sister of case 114 
NB small stature, retarded 503_15.0 	elevated 
growth, sister of case 14 
seizures, frequent inf-5..114 218 mg/214 hr 
ections, cerebral mal- 
development, postepileptic 
enc ephalop athy 
+ 	height and weight below 	11°2 	599 mg/214 hr absent 
3rd percentile, encorpresis 
F ilyr 65 
F 13 y 	50 
F 17 y 	76 





SM 	9 yr NB 
1 16 yr NB 
35 yr NR 
37 yr NB 
143 yr HR 
65 yr NR 
F 	8 yr retarded 
F 10 yr retarded 
F 1 yr mildly 
retarded 
history of stammering 




presence of pubic hair 
jaundice in early life, 
did not cry or react to 
sounds in early life, 
wt. below 3rd percentile, 
mild anaemia 
approx approx 238 	NB 
1)4 	ug/ml 
81-10.3 1495-590  mg/g 	NB 
creat. 
7 o 4 	771 mg/g 	NB 
creat. 
126-18•0 1409-2627 mg/ NB 
g creat. 
F 14y,8mo  retarded 
F 4y,8mo  retarded 
M 7y,5mo retarded 
F lOy,Snio retarded 
F 12 yr normal 
F 5 yr 	23 
F 	11 yr 	107 3)4 
7°91 	590 mg/g creat. NB 
838 3250 mg/gcieat. NB 
13.65 3840 mg/g creat. NB 
14°90 1216 mg/g creat . NB 
small stature, congenital 	8•2 	824 mg/24 hr absent 
hypoplas tic anaemia 
+ 	severe behaviour problem in 130817o1 elevated 
	absent 
earlier years, self-destruc-
tive, ht. 10th percentile, 
delayed motor development, 
hyperreflexia, seizures, E3 
dys rhythmic 
bad temper, short attention 85-126 elevated 
	absent 
span, failed one year in 
school, sister of case 33 
APPENDIX cont... 
Galamon and 	19 
Szulc-Kuberska, to 
1966 	 214 




Wadnian et al., 	28 
1971 	 29 
30 
31 
Gilman and 	32 
Howell, 1969 
Gatfield et al., 33 
1969 
APPENDIX cant... 
35 M 	6 yr 	88 	- 	bad temper, short 	174-180 elevated 	absent 
attention span, failed 
1 yr in school, encoiri, 
brother of case 33 
F 	19 ma 	97 	- 	sister of case 33 	11.6-14•9 elevated 	absent 
M 6y,9m 	92 + short stature, left 19.5 	5.10 gm/ absent 
esotropia, short 	 100 ml 
attention span, ab- 







38 F 8y, 6m 74 + 	abnormal EEG, visual irrit.or 10.1 685 mg/100  ml absent 
coordination impaired, 
sister of case 37 
39 F 12y9m 85 - 	abnormal EEG, sister 8.0 13°20 mg/ markedly 
of case 37 100 ml decreased 
40 F 37 	yr 83 + diabetic, niultinodular 123 8°90 mg/ absent 
goiter, enlarged liver, 100 ml 
iron deficiency, anaemia, 
reduced auditory reten- 
tion span, mother of 
case 37 
141 F 140 	yr normal - 	stuttering during child- 4'2 10°00 mg/ NR 
hood, aunt of case 37 100 ml 
142 F 1414 	yr NR - progressive deafness, 7°1 725 mg/ absent 
optic atrophy, abnormal 100 ml 
EEG, aunt of case 37 
143 1M NR NR(3) NR(3) 	2 aunts, 1 cousin of 2-14 350-5•75 NR(3) 
to145 2F case 37 mg/i 00 nil 
Baden et al., 	146 N 2 	ma NR - elevated elevated NR 
1969 




F 17 yr normal 
et a?., 1970 
Lott et a?., 49 M 5y,141n 
1970 50 M 8y,11m 
51 F 8y,7m 
Lyon & Ve&Le, 52 NB 6 d 
1970 53 NB 4  
Cain & Holton, 521 M 3y,3m 
1968 
Auerbach et a?., 55 F 7 ma 
1967 56 
57 
58 M 12 yr 
59 
60 
Kibel and 61 F 15 yr 
Levy, 1970 
Kierland et al., 62 N 6 yr 
1968 













NB single transplanted kidney; 218-6°2 elevated absent 
Cushing-like appearance 
- hypogainmaglobulinaemia 10 elevated NB 
- motor seizures, absence 9 elevated NB 
attacks, otitis media 
- tonsillar hypertrophy, 13°1 elevated NB 
hypospadias 
NB 10-20 430 mg/g creat. absent 
NB 20 NB absent 
NB grand mal seizures: anaemia NB NB absent 
with ndcrocytosis, hypo- 
chromia: delayed bone age: 
ht. & wt. on 10th percentile 
- normal clinically 156 NB absent 
- normal clinically 76 NB NB 
- normal clinically 9°1 NB NR 
- normal clinically 88 34•4mg/100nil NB 
- normal clinically 5°6 NB NB 
- normal clinically 46 23° 2mg/lOOm? NB 
NB abnormal EEG; arachnodactyly 14o2 elevated absent 
93 	NB some atopic dermatitis, ht. 	9°216 	elevated 
and wt. both below 3rd %ile. 
NB 	NB idiopathic thrombocytopenic 62-921 8 X controls 





Kiihara et al., 614 N 38 	yr retarded NB spastic diplegia 71-118 5 X normal - ery low 
1968 65 F 14 yr NB NB 278 very low 
66 N 20 	yr NB NB 128 very low 
Massengill & 67 M 3 	yr normal + generally healthy elevated elevated NB 
Smith, 1967 
Thaihammer et 68 newborn NB NB 8-21 elevated absent 
al., 	1971 69 newborn NB NB history of mental retardat- 6-15 elevated absent 
ion in the family 
70 newborn NB NB history of mental retardat- 6-18 elevated absent 
ion in the family 
Nevillé et al., 71 F 3 	yr 420 + gross developmental retard- 5.1 elevated very low 
1972 ation: frequent majorseiziir: (1tirg) or absent 
Whitfield and signs of mixed athetoid and 15 (<2%) 
Shepherd, 1970 spastic cerebral palsy (rantm) 
72 F 5y,6m 1114 - sister of case 714 60 (f) elevated very low 
clinically normal 12 	(r) or absent 
(<2%) 
73 N 12 	yr 35 + severely mentally retarded 7°5 	(f) elevated greatly 
with features of early- 15 (r) reduced 
onset infantile psychosis (15%) 
(autism) 
714 F 18 	yr 1114 - sister of case 76 6°2 	(f) elevated very low 
clinically normal 5°2 (r) or absent (3%) 
75 F 14y,6m <65 + severely subnormal with 14°C 	(f) elevated very low 
features of early infantile 10°C (r) (6%) 
psychosis (autism). 
Development probably normal 
until 2 years 
Neville et 76 F 28 	yr 100 - Infrequent major seizures 7°9 	(f) 390-720 mg/ very low 
al., 	1971 from age 16 yrs. 	Depressive  7-10(r) 214 hr or absent 
Neville et episodes. 	Immature person- (3%) 
al., 1972 ality 
	
+ 	apparently normal develop- 
ment till aged 2 yrs. Major 
seizures. Severely sub-
normal 
NB. 	epileptic. Brother of 
case 79 




- 	Marf an syndrome 
- 	Marf an syndrome, brother 








13°1 1490 mg/ 
9°2 2)4 hr 
12°1 3,090 mg/ 
10.3 2)4 hr 
126 112 mg/ 
2)4 hr 
M 	16 yr 80 
M 	27 yr 65 
M 	52 yr normal 
F 37 yr 105-115 
M 	17 yr normal 
M 	18 yr normal 








85 M 2 	yr 36 EEC showed hypsarrhythrnia, 12-14 
(DQ) infantile spasms 
86 F 7 	yr 77 + 	seizures, hyperactivity, 13 
learning problems 
87 M 6 	yr 60 + 	slow development, abnormal 13 
EEC 
88 M 13 	yr 90 - 6 
Neville et 
al., 1 971 
Lyon et al., 
1 97)4 
Stevens et 
al., 1 975 
Roberts and 
Ireland, 1978 
Hudson et al., 
13 
Duffner & 
Cohen, 1 975 
Kappelnian et 




Neville et 77 
	























Brown et al., 89 N 3 yr low 	+ seizures, unrelated encep- 8.5 increased NR 
1 977 halopathy, delayed bone age 
90 F 1 yr low 	NR seizures, unrelated encep- 11 increased NB 
halopathy 
91 F 10 yr 101 	- 7•5 increased about 
of normal 
Armstrong, 92 F NB normal 	- gave birth to 4 normal 10•6 1132 mg/ NP.. 
1 975 children 24 hr 
Rtenberg et 93 N 8 mo 35 abnormal EEG, moderate 2°1 NB NB 
a10, 1 974 diffuse cortical atrophy 
on air encephalogram 
Popldn et 94 NK 7 mo normal normal development on low 81 increased NP.. 
al., 1974 histidine diet 
Plchl et 95 M 14 yr 114 	+ hearing disability 6-8 1 195 umol/ NB 
al., 	1978 24 hr 
Kotsopoulos 96 M 10 yr NB 	+ normal development till aged 	9'2-109 )45)4 mg/ NB 
and Kutty, (autistic)2 yrs then developed infantile 24 hr 
1979 autism 
97 F 14 yr N 	- 83 NB. NB 
98 F 16 yr N - 9°5 NB NB 
99 F 40 yr N 	- mother of cases 96-98 87 NB NB 
Wad man et 100 M 11 yr 101 - abnormal EEG, seizures (perhaps 13°3 2018 mg/ NB 
al., 1973 related to perinatal hypo- g. creat. 
glycaemic brain damage) 
Levy et al., 101 12M 4-12 yr N 	- detected in neonatal screening 10 0 1 4•5-270 mniol/ NB 
1974 to 14F surveys to g. creat. 
126 173 
1 	N 11 yr 52 
2 	N 10 yr 47 
3 	F 6 yr 53 
Woody et al, 
1965 
APPENDIX 	cont 0.. 
Griffiths, 127 F 2 yr 108 - 	detected in neonatal screen- 1 3•2 increased Nit 
1973 128 F 1y,8m N - ing survey: developing norm- 9.3-12.21  increased NB 
129 F 2 yr N - ally on low histidine diet 18.6 increased NR 
130 M 2 yr N - 18.6-21.7 increased NB 
Beauvais et 131 F 2 yr 91 - 1224 76 very 
al., 	1971 low 
Rao et al., 132 N 8 yr 70 + 	consanguineous parents. 10 350-2400 Nit 
19714 Delayed development. mg/24 hr 
Frequent respiratory 
infections. 	Stunted growth 
Gehler and 133 N 13 yr mildly NB 	features of Marf an's syndrome 	increased increased NB 
Stopfkuchen, submrnal Delayed developmental mile- 
1977 stones. 
Holnigren et 1324 F 2 yr normal - 7°2 6830 pmol/ NB 
al.., 	19724 g. creat. 
135 F 12 yr normal - 11.o2 6970 1nnol/ Nit 
g. creat. 
136 M 23 yr 79 ± 	psychosis of unknown nature 24°8 6560 .unol/ Nit 
g. creat. 
ATYPICAL HISTIDINAEMIA 
+ 	abnormal ED. Sweat UA 	18-24°3 	500-2200 	present 
normal, urinary UA reduced mg/g. creat. 
+ 	abnormal EEG, seizures • 	1 -5-6-4 	500-2000 	present 
Sweat UA normal, urinary ing/g. creat. 
UA reduced 
+ 	abnormal EEG, seizures. 	124-324 	250-800 	present 
Sweat UA normal, urinary mg/g. creat. 
UA reduced 
HISTIDINURIA 
Sabater et al., 	M 	9 yr 	53 
1976 
2 M 11 yr 58 
Hoingren et 	3 	M 	normal 
al., 197)4 
renal tubular reabsorp- 0.94 2999-3143 	NE 
tion of histidine 40°1%. mg/24 hr 
Reduced intestinal hist- 
idine absorption. Urine 
negative for histidine 
metabolites 
renal tubular reabsorp- 0.47 151-3-202-7 	NB 
tion of histidine 52 8%. mg/24 hr 
Reduced intestinal hist- 
idine absorption. Urine 
-ye for histidine met- 
abolitesi  
developed niyoclonic sei- 1.4 2100 jnnol/ 	NE 
zures at age 13 years 24 hr 
APPENDIX 	cont... 
Kothari et L 	F 	8 yr 	83 
al., 1970 
5 F 10 yr 50 
Levy et al., 	6-7 NR 	NE 	NE 
1974 
	
+ 	behaviour problems, ab- 	14.5(nrrnL 40•6 mg/lOOnil NE 
normal EEG. Negative range 0.5 (normal range 
ferric chloride test in 	-5) 	iL - 19) 
urine. Increased sweat UA. 
+ 	normal EEG 	 17•6(n.r. 	NE 	 NE 
0°5-5) 
NE 	skin UA about 25%  of 	0°22-0"29 "mild 	NE 
normal 	 mm 	increase" 
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